BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369:1691-703. [PMID: 24131140 DOI: 10.1056/NEJMoa1304369] [Cited by in Crossref: 3143] [Cited by in F6Publishing: 1689] [Article Influence: 392.9] [Reference Citation Analysis]
Number Citing Articles
1 Hoverman JR. Rethinking clinical oncology drug research in an era of value-based cancer care: A role for chemotherapy pathways. Cancer Med 2020;9:5306-11. [PMID: 32524722 DOI: 10.1002/cam4.3193] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Johnson B, Vanderwalde A, Javadi N, Feldman R, Reddy SB. Molecular profiling of a case of advanced pancreatic cancer identifies an active and tolerable combination of targeted therapy with backbone chemotherapy. J Gastrointest Oncol 2016;7:E6-E12. [PMID: 27034805 DOI: 10.3978/j.issn.2078-6891.2015.091] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Liu X, Li C, Li J, Yu T, Zhou G, Cheng J, Li G, Zhou Y, Lou W, Wang X, Gong G, Liu L, Chen Y. Detection of CTCs in portal vein was associated with intrahepatic metastases and prognosis in patients with advanced pancreatic cancer. J Cancer. 2018;9:2038-2045. [PMID: 29896289 DOI: 10.7150/jca.23989] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 3.7] [Reference Citation Analysis]
4 Fogel EL, Shahda S, Sandrasegaran K, DeWitt J, Easler JJ, Agarwal DM, Eagleson M, Zyromski NJ, House MG, Ellsworth S, El Hajj I, O'Neil BH, Nakeeb A, Sherman S. A Multidisciplinary Approach to Pancreas Cancer in 2016: A Review. Am J Gastroenterol. 2017;112:537-554. [PMID: 28139655 DOI: 10.1038/ajg.2016.610] [Cited by in Crossref: 58] [Cited by in F6Publishing: 56] [Article Influence: 14.5] [Reference Citation Analysis]
5 Bhutani MS, Koduru P, Joshi V, Saxena P, Suzuki R, Irisawa A, Yamao K. The role of endoscopic ultrasound in pancreatic cancer screening. Endosc Ultrasound. 2016;5:8-16. [PMID: 26879161 DOI: 10.4103/2303-9027.175876] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 5.6] [Reference Citation Analysis]
6 Hanoun N, Gayral M, Pointreau A, Buscail L, Cordelier P. Initial Characterization of Integrase-Defective Lentiviral Vectors for Pancreatic Cancer Gene Therapy. Hum Gene Ther. 2016;27:184-192. [PMID: 26731312 DOI: 10.1089/hum.2015.151] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
7 Yin Z, Zhou Y, Hou B, Ma T, Yu M, Zhang C, Lu X, Jian Z. Revision of Surgical Margin under Frozen Section to Achieve R0 Status on Survival in Patients with Pancreatic Cancer. J Gastrointest Surg 2018;22:1565-75. [PMID: 29777452 DOI: 10.1007/s11605-018-3806-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
8 Parasido E, Avetian GS, Naeem A, Graham G, Pishvaian M, Glasgow E, Mudambi S, Lee Y, Ihemelandu C, Choudhry M, Peran I, Banerjee PP, Avantaggiati ML, Bryant K, Baldelli E, Pierobon M, Liotta L, Petricoin E, Fricke ST, Sebastian A, Cozzitorto J, Loots GG, Kumar D, Byers S, Londin E, DiFeo A, Narla G, Winter J, Brody JR, Rodriguez O, Albanese C. The Sustained Induction of c-MYC Drives Nab-Paclitaxel Resistance in Primary Pancreatic Ductal Carcinoma Cells. Mol Cancer Res 2019;17:1815-27. [PMID: 31164413 DOI: 10.1158/1541-7786.MCR-19-0191] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
9 Smith SJ, Li CM, Lingeman RG, Hickey RJ, Liu Y, Malkas LH, Raoof M. Molecular Targeting of Cancer-Associated PCNA Interactions in Pancreatic Ductal Adenocarcinoma Using a Cell-Penetrating Peptide. Mol Ther Oncolytics 2020;17:250-6. [PMID: 32368614 DOI: 10.1016/j.omto.2020.03.025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
10 Khan S, Ebeling MC, Chauhan N, Thompson PA, Gara RK, Ganju A, Yallapu MM, Behrman SW, Zhao H, Zafar N. Ormeloxifene suppresses desmoplasia and enhances sensitivity of gemcitabine in pancreatic cancer. Cancer Res. 2015;75:2292-2304. [PMID: 25840985 DOI: 10.1158/0008-5472.can-14-2397] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 7.8] [Reference Citation Analysis]
11 Saung MT, Zheng L. Current Standards of Chemotherapy for Pancreatic Cancer. Clin Ther 2017;39:2125-34. [PMID: 28939405 DOI: 10.1016/j.clinthera.2017.08.015] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 9.5] [Reference Citation Analysis]
12 Kozak GM, Epstein JD, Deshmukh SP, Scott BB, Keith SW, Lavu H, Yeo CJ, Winter JM. Common Hepatic Artery Abutment or Encasement Is an Adverse Prognostic Factor in Patients with Borderline and Unresectable Pancreatic Cancer. J Gastrointest Surg 2018;22:288-94. [PMID: 29139084 DOI: 10.1007/s11605-017-3595-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
13 Mehtala JG, Kulczar C, Lavan M, Knipp G, Wei A. Cys34-PEGylated Human Serum Albumin for Drug Binding and Delivery. Bioconjug Chem 2015;26:941-9. [PMID: 25918947 DOI: 10.1021/acs.bioconjchem.5b00143] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.7] [Reference Citation Analysis]
14 Wen CL, Huang K, Jiang LL, Lu XX, Dai YT, Shi MM, Tang XM, Wang QB, Zhang XD, Wang PH, Li HT, Ruan XX, Wang LW, Wang XJ, Wang Q, Lu W, Xiang XQ, Sun X, Xu YH, Lai LH, Zhan Q, Li HW, Peng CH, Chen J, Huang JY, Ye DY, Chen SJ, Chen Z, Li M, Fang Y, Shen BY, Zhou L. An allosteric PGAM1 inhibitor effectively suppresses pancreatic ductal adenocarcinoma. Proc Natl Acad Sci U S A 2019;116:23264-73. [PMID: 31662475 DOI: 10.1073/pnas.1914557116] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
15 Castle J, Kotopoulis S, Forsberg F. Sonoporation for Augmenting Chemotherapy of Pancreatic Ductal Adenocarcinoma. Methods Mol Biol 2020;2059:191-205. [PMID: 31435922 DOI: 10.1007/978-1-4939-9798-5_9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
16 Rapposelli IG, Zampiga V, Cangini I, Arcangeli V, Ravegnani M, Valgiusti M, Pini S, Tamberi S, Bartolini G, Passardi A, Martinelli G, Calistri D, Frassineti GL, Falcini F, Danesi R. Comprehensive analysis of DNA damage repair genes reveals pathogenic variants beyond BRCA and suggests the need for extensive genetic testing in pancreatic cancer. BMC Cancer 2021;21:611. [PMID: 34034685 DOI: 10.1186/s12885-021-08368-5] [Reference Citation Analysis]
17 Broekgaarden M, Rizvi I, Bulin AL, Petrovic L, Goldschmidt R, Massodi I, Celli JP, Hasan T. Neoadjuvant photodynamic therapy augments immediate and prolonged oxaliplatin efficacy in metastatic pancreatic cancer organoids. Oncotarget 2018;9:13009-22. [PMID: 29560127 DOI: 10.18632/oncotarget.24425] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
18 Mahalingam D, Goel S, Aparo S, Patel Arora S, Noronha N, Tran H, Chakrabarty R, Selvaggi G, Gutierrez A, Coffey M, Nawrocki ST, Nuovo G, Mita MM. A Phase II Study of Pelareorep (REOLYSIN®) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma. Cancers (Basel) 2018;10:E160. [PMID: 29799479 DOI: 10.3390/cancers10060160] [Cited by in Crossref: 50] [Cited by in F6Publishing: 41] [Article Influence: 16.7] [Reference Citation Analysis]
19 Sawada M, Kasuga A, Mie T, Furukawa T, Taniguchi T, Fukuda K, Yamada Y, Takeda T, Kanata R, Matsuyama M, Sasaki T, Ozaka M, Sasahira N. Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer. BMC Cancer 2020;20:449. [PMID: 32434547 DOI: 10.1186/s12885-020-06945-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 14.0] [Reference Citation Analysis]
20 Kim H, Morgan DE, Schexnailder P, Navari RM, Williams GR, Bart Rose J, Li Y, Paluri R. Accurate Therapeutic Response Assessment of Pancreatic Ductal Adenocarcinoma Using Quantitative Dynamic Contrast-Enhanced Magnetic Resonance Imaging With a Point-of-Care Perfusion Phantom: A Pilot Study. Invest Radiol 2019;54:16-22. [PMID: 30138218 DOI: 10.1097/RLI.0000000000000505] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
21 Lambert A, Schwarz L, Borbath I, Henry A, Van Laethem JL, Malka D, Ducreux M, Conroy T. An update on treatment options for pancreatic adenocarcinoma. Ther Adv Med Oncol 2019;11:1758835919875568. [PMID: 31598142 DOI: 10.1177/1758835919875568] [Cited by in Crossref: 46] [Cited by in F6Publishing: 51] [Article Influence: 23.0] [Reference Citation Analysis]
22 Innamarato P, Morse J, Mackay A, Asby S, Beatty M, Blauvelt J, Kidd S, Mullinax JE, Sarnaik AA, Pilon-Thomas S. Intralesional injection of rose bengal augments the efficacy of gemcitabine chemotherapy against pancreatic tumors. BMC Cancer 2021;21:756. [PMID: 34187428 DOI: 10.1186/s12885-021-08522-z] [Reference Citation Analysis]
23 Van Audenaerde JRM, De Waele J, Marcq E, Van Loenhout J, Lion E, Van den Bergh JMJ, Jesenofsky R, Masamune A, Roeyen G, Pauwels P, Lardon F, Peeters M, Smits ELJ. Interleukin-15 stimulates natural killer cell-mediated killing of both human pancreatic cancer and stellate cells. Oncotarget. 2017;8:56968-56979. [PMID: 28915646 DOI: 10.18632/oncotarget.18185] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 9.0] [Reference Citation Analysis]
24 Takano H, Nakamura T, Tsuchikawa T, Kushibiki T, Hontani K, Inoko K, Takahashi M, Sato S, Abe H, Takeuchi S, Sato N, Hiraoka K, Nishihara H, Shichinohe T, Hirano S. Inhibition of Eph receptor A4 by 2,5-dimethylpyrrolyl benzoic acid suppresses human pancreatic cancer growing orthotopically in nude mice. Oncotarget 2015;6:41063-76. [PMID: 26516928 DOI: 10.18632/oncotarget.5729] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
25 Wang K, Baldwin GS, Nikfarjam M, He H. p21-activated kinase signalling in pancreatic cancer: New insights into tumour biology and immune modulation. World J Gastroenterol 2018; 24(33): 3709-3723 [PMID: 30197477 DOI: 10.3748/wjg.v24.i33.3709] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
26 Chang CF, Huang PW, Chen JS, Chen YY, Lu CH, Chang PH, Hung YS, Chou WC. Prognostic Factors for Advanced Pancreatic Cancer Treated with Gemcitabine Plus S-1: Retrospective Analysis and Development of a Prognostic Model. Cancers (Basel) 2019;11:E57. [PMID: 30634387 DOI: 10.3390/cancers11010057] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
27 Satoi S, Yamamoto T, Yamaki S, Sakaguchi T, Sekimoto M. Surgical indication for and desirable outcomes of conversion surgery in patients with initially unresectable pancreatic ductal adenocarcinoma. Ann Gastroenterol Surg. 2020;4:6-13. [PMID: 32021953 DOI: 10.1002/ags3.12295] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
28 Dey J, Kerwin WS, Grenley MO, Casalini JR, Tretyak I, Ditzler SH, Thirstrup DJ, Frazier JP, Pierce DW, Carleton M, Klinghoffer RA. A Platform for Rapid, Quantitative Assessment of Multiple Drug Combinations Simultaneously in Solid Tumors In Vivo. PLoS One 2016;11:e0158617. [PMID: 27359113 DOI: 10.1371/journal.pone.0158617] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
29 Dodhiawala PB, Khurana N, Zhang D, Cheng Y, Li L, Wei Q, Seehra K, Jiang H, Grierson PM, Wang-Gillam A, Lim KH. TPL2 enforces RAS-induced inflammatory signaling and is activated by point mutations. J Clin Invest. 2020;130:4771-4790. [PMID: 32573499 DOI: 10.1172/jci137660] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
30 Oziel-Taieb S, Faure M, Gilabert M, Autret A, Turrini O, Moureau-Zabotto L, Giovannini M, Rousseau F, Raoul JL. Treatment of Pancreatic Adenocarcinoma in Elderly Patients over 75 Years of Age: A Retrospective Series of 129 Patients. J Gastrointest Cancer 2016;47:15-9. [PMID: 26545612 DOI: 10.1007/s12029-015-9774-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
31 Mizrahi JD, Rogers JE, Hess KR, Wolff RA, Varadhachary GR, Javle MM, Shroff RT, Ho L, Fogelman DR, Raghav KPS, Overman MJ, Pant S. Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older. Pancreatology 2020;20:501-4. [PMID: 31932214 DOI: 10.1016/j.pan.2020.01.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 15.0] [Reference Citation Analysis]
32 Iwai N, Okuda T, Sakagami J, Harada T, Ohara T, Taniguchi M, Sakai H, Oka K, Hara T, Tsuji T, Komaki T, Kagawa K, Yasuda H, Naito Y, Itoh Y. Neutrophil to lymphocyte ratio predicts prognosis in unresectable pancreatic cancer. Sci Rep 2020;10:18758. [PMID: 33127996 DOI: 10.1038/s41598-020-75745-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
33 Luheshi NM, Coates-Ulrichsen J, Harper J, Mullins S, Sulikowski MG, Martin P, Brown L, Lewis A, Davies G, Morrow M, Wilkinson RW. Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model. Oncotarget 2016;7:18508-20. [PMID: 26918344 DOI: 10.18632/oncotarget.7610] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 12.8] [Reference Citation Analysis]
34 Kaur K, Kozlowska AK, Topchyan P, Ko MW, Ohanian N, Chiang J, Cook J, Maung PO, Park SH, Cacalano N, Fang C, Jewett A. Probiotic-Treated Super-Charged NK Cells Efficiently Clear Poorly Differentiated Pancreatic Tumors in Hu-BLT Mice. Cancers (Basel) 2019;12:E63. [PMID: 31878338 DOI: 10.3390/cancers12010063] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
35 Mesmar F, Dai B, Ibrahim A, Hases L, Jafferali MH, Jose Augustine J, DiLorenzo S, Kang Y, Zhao Y, Wang J, Kim M, Lin CY, Berkenstam A, Fleming J, Williams C. Clinical candidate and genistein analogue AXP107-11 has chemoenhancing functions in pancreatic adenocarcinoma through G protein-coupled estrogen receptor signaling. Cancer Med 2019;8:7705-19. [PMID: 31568691 DOI: 10.1002/cam4.2581] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
36 Maggino L, Vollmer CM Jr. Recent Advances in Pancreatic Cancer Surgery. Curr Treat Options Gastroenterol 2017;15:520-37. [PMID: 28852967 DOI: 10.1007/s11938-017-0150-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
37 Liang S, Yang Z, Li D, Miao X, Yang L, Zou Q, Yuan Y. The Clinical and Pathological Significance of Nectin-2 and DDX3 Expression in Pancreatic Ductal Adenocarcinomas. Dis Markers 2015;2015:379568. [PMID: 26294807 DOI: 10.1155/2015/379568] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
38 Tekin C, Shi K, Daalhuisen JB, Ten Brink MS, Bijlsma MF, Spek CA. PAR1 signaling on tumor cells limits tumor growth by maintaining a mesenchymal phenotype in pancreatic cancer. Oncotarget 2018;9:32010-23. [PMID: 30174793 DOI: 10.18632/oncotarget.25880] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
39 Krzykawska-Serda M, Ho JC, Ware MJ, Law JJ, Newton JM, Nguyen L, Agha M, Curley SA, Corr SJ. Ultrasound Doppler as an Imaging Modality for Selection of Murine 4T1 Breast Tumors for Combination Radiofrequency Hyperthermia and Chemotherapy. Transl Oncol 2018;11:864-72. [PMID: 29763773 DOI: 10.1016/j.tranon.2018.04.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
40 Decoster C, Gilabert M, Autret A, Turrini O, Oziel-Taieb S, Poizat F, Giovannini M, Viens P, Iovanna J, Raoul JL. Heterogeneity of metastatic pancreatic adenocarcinoma: Lung metastasis show better prognosis than liver metastasis-a case control study. Oncotarget 2016;7:45649-55. [PMID: 27286454 DOI: 10.18632/oncotarget.9861] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
41 Pan Z, Li L, Fang Q, Zhang Y, Hu X, Qian Y, Huang P. Analysis of dynamic molecular networks for pancreatic ductal adenocarcinoma progression. Cancer Cell Int 2018;18:214. [PMID: 30598639 DOI: 10.1186/s12935-018-0718-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
42 Wysocka O, Kulbacka J, Saczko J. Adjuvant, neoadjuvant, and experimental regimens in overcoming pancreatic ductal adenocarcinoma. Prz Gastroenterol 2016;11:155-62. [PMID: 27713776 DOI: 10.5114/pg.2016.61438] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
43 Ge L, Pan B, Song F, Ma J, Zeraatkar D, Zhou J, Tian J. Comparing the diagnostic accuracy of five common tumour biomarkers and CA19-9 for pancreatic cancer: a protocol for a network meta-analysis of diagnostic test accuracy. BMJ Open 2017;7:e018175. [PMID: 29282264 DOI: 10.1136/bmjopen-2017-018175] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 4.8] [Reference Citation Analysis]
44 Ran D, Zhou J, Chai Z, Li J, Xie C, Mao J, Lu L, Zhang Y, Wu S, Zhan C, Lu W. All-stage precisional glioma targeted therapy enabled by a well-designed D-peptide. Theranostics 2020;10:4073-87. [PMID: 32226540 DOI: 10.7150/thno.41382] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
45 Hurwitz HI, Uppal N, Wagner SA, Bendell JC, Beck JT, Wade SM, Nemunaitis JJ, Stella PJ, Pipas JM, Wainberg ZA. Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed. J Clin Oncol. 2015;33:4039-4047. [PMID: 26351344 DOI: 10.1200/jco.2015.61] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
46 Granata V, Fusco R, Setola SV, Piccirillo M, Leongito M, Palaia R, Granata F, Lastoria S, Izzo F, Petrillo A. Early radiological assessment of locally advanced pancreatic cancer treated with electrochemotherapy. World J Gastroenterol 2017; 23(26): 4767-4778 [PMID: 28765698 DOI: 10.3748/wjg.v23.i26.4767] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
47 Tummers WS, Miller SE, Teraphongphom NT, Gomez A, Steinberg I, Huland DM, Hong S, Kothapalli SR, Hasan A, Ertsey R, Bonsing BA, Vahrmeijer AL, Swijnenburg RJ, Longacre TA, Fisher GA, Gambhir SS, Poultsides GA, Rosenthal EL. Intraoperative Pancreatic Cancer Detection using Tumor-Specific Multimodality Molecular Imaging. Ann Surg Oncol 2018;25:1880-8. [PMID: 29667116 DOI: 10.1245/s10434-018-6453-2] [Cited by in Crossref: 68] [Cited by in F6Publishing: 60] [Article Influence: 22.7] [Reference Citation Analysis]
48 Liu P, Ying Q, Liu H, Yu SQ, Bu LP, Shao L, Li XY. Curcumin enhances anti‑cancer efficacy of either gemcitabine or docetaxel on pancreatic cancer cells. Oncol Rep 2020;44:1393-402. [PMID: 32945513 DOI: 10.3892/or.2020.7713] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
49 Suzuki R, Takagi T, Hikichi T, Sugimoto M, Konno N, Asama H, Watanabe K, Nakamura J, Marubashi S, Ohira H. An observation study of the prognostic effect of waiting times in the management of pancreatic ductal adenocarcinoma. Oncol Lett 2019;17:587-93. [PMID: 30655805 DOI: 10.3892/ol.2018.9626] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
50 Fiorentini G, Sarti D, Casadei V, Milandri C, Dentico P, Mambrini A, Nani R, Fiorentini C, Guadagni S. Modulated Electro-Hyperthermia as Palliative Treatment for Pancreatic Cancer: A Retrospective Observational Study on 106 Patients.Integr Cancer Ther. 2019;18:1534735419878505. [PMID: 31561722 DOI: 10.1177/1534735419878505] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
51 Marchetti C, Zyner KG, Ohnmacht SA, Robson M, Haider SM, Morton JP, Marsico G, Vo T, Laughlin-Toth S, Ahmed AA, Di Vita G, Pazitna I, Gunaratnam M, Besser RJ, Andrade ACG, Diocou S, Pike JA, Tannahill D, Pedley RB, Evans TRJ, Wilson WD, Balasubramanian S, Neidle S. Targeting Multiple Effector Pathways in Pancreatic Ductal Adenocarcinoma with a G-Quadruplex-Binding Small Molecule. J Med Chem 2018;61:2500-17. [PMID: 29356532 DOI: 10.1021/acs.jmedchem.7b01781] [Cited by in Crossref: 62] [Cited by in F6Publishing: 57] [Article Influence: 20.7] [Reference Citation Analysis]
52 Tiffon C. Defining Parallels between the Salivary Glands and Pancreas to Better Understand Pancreatic Carcinogenesis. Biomedicines 2020;8:E178. [PMID: 32604970 DOI: 10.3390/biomedicines8060178] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 LaRocca CJ, Warner SG. A New Role for Vitamin D: The Enhancement of Oncolytic Viral Therapy in Pancreatic Cancer. Biomedicines 2018;6:E104. [PMID: 30400571 DOI: 10.3390/biomedicines6040104] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
54 Yang SH, Lu LC, Kao HF, Chen BB, Kuo TC, Kuo SH, Tien YW, Bai LY, Cheng AL, Yeh KH. Negative prognostic implications of splenomegaly in nivolumab-treated advanced or recurrent pancreatic adenocarcinoma. Oncoimmunology 2021;10:1973710. [PMID: 34595057 DOI: 10.1080/2162402X.2021.1973710] [Reference Citation Analysis]
55 Suzuki R, Takagi T, Hikichi T, Konno N, Sugimoto M, Watanabe KO, Nakamura J, Waragai Y, Kikuchi H, Takasumi M, Watanabe H, Ohira H. Derived neutrophil/lymphocyte ratio predicts gemcitabine therapy outcome in unresectable pancreatic cancer. Oncol Lett 2016;11:3441-5. [PMID: 27123132 DOI: 10.3892/ol.2016.4381] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 5.6] [Reference Citation Analysis]
56 Chawla SP, Bruckner H, Morse MA, Assudani N, Hall FL, Gordon EM. A Phase I-II Study Using Rexin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanced Pancreatic Cancer. Mol Ther Oncolytics 2019;12:56-67. [PMID: 30705966 DOI: 10.1016/j.omto.2018.12.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
57 Vreeland TJ, McAllister F, Javadi S, Prakash LR, Fogelman DR, Ho L, Varadhachary G, Aloia TA, Vauthey JN, Lee JE, Kim MP, Katz MHG, Tzeng CD. Benefit of Gemcitabine/Nab-Paclitaxel Rescue of Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma After Early Failure of FOLFIRINOX. Pancreas 2019;48:837-43. [PMID: 31210666 DOI: 10.1097/MPA.0000000000001345] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
58 Fanchon LM, Russell J, Pillarsetty N, O'Donoghue I, Gangangari K, Yu KH, Humm JL. Comparing the intra-tumoral distribution of Gemcitabine, 5-Fluorouracil, and Capecitabine in a murine model of pancreatic ductal adenocarcinoma. PLoS One 2020;15:e0231745. [PMID: 32298392 DOI: 10.1371/journal.pone.0231745] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
59 Aranda F, Buqué A, Bloy N, Castoldi F, Eggermont A, Cremer I, Fridman WH, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Adoptive cell transfer for oncological indications. Oncoimmunology 2015;4:e1046673. [PMID: 26451319 DOI: 10.1080/2162402X.2015.1046673] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
60 Hendifar A, Blais EM, Wolpin B, Subbiah V, Collisson E, Singh I, Cannon T, Shaw K, Petricoin EF 3rd, Klempner S, Lyons E, Wang-Gillam A, Pishvaian MJ, O'Reilly EM. Retrospective Case Series Analysis of RAF Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted and Standard Therapies. JCO Precis Oncol 2021;5:PO. [PMID: 34476331 DOI: 10.1200/PO.20.00494] [Reference Citation Analysis]
61 Bullock A, Stuart K, Jacobus S, Abrams T, Wadlow R, Goldstein M, Miksad R. Capecitabine and oxaliplatin as first and second line treatment for locally advanced and metastatic pancreatic ductal adenocarcinoma.J Gastrointest Oncol. 2017;8:945-952. [PMID: 29299353 DOI: 10.21037/jgo.2017.06.06] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
62 Zhao J, Zhao F, Shi Y, Deng Y, Hu X, Shen H. The efficacy of a new high intensity focused ultrasound therapy for locally advanced pancreatic cancer. J Cancer Res Clin Oncol 2017;143:2105-11. [PMID: 28620685 DOI: 10.1007/s00432-017-2459-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
63 Lao M, Zhang X, Ma T, Xu J, Yang H, Duan Y, Ying H, Zhang X, Guo C, Qiu J, Bai X, Liang T. Regulator of calcineurin 1 gene isoform 4 in pancreatic ductal adenocarcinoma regulates the progression of tumor cells. Oncogene 2021;40:3136-51. [PMID: 33824473 DOI: 10.1038/s41388-021-01763-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Hu X, Xiao Y, Sun J, Ji B, Luo S, Wu B, Zheng C, Wang P, Xu F, Cheng K, Hua H, Li D. New possible silver lining for pancreatic cancer therapy: Hydrogen sulfide and its donors. Acta Pharm Sin B 2021;11:1148-57. [PMID: 34094825 DOI: 10.1016/j.apsb.2020.10.019] [Reference Citation Analysis]
65 Awasthi N, Monahan S, Stefaniak A, Schwarz MA, Schwarz RE. Inhibition of the MEK/ERK pathway augments nab-paclitaxel-based chemotherapy effects in preclinical models of pancreatic cancer. Oncotarget 2018;9:5274-86. [PMID: 29435178 DOI: 10.18632/oncotarget.23684] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
66 Buc E, Orry D, Antomarchi O, Gagnière J, Da Ines D, Pezet D. Resection of pancreatic ductal adenocarcinoma with synchronous distant metastasis: is it worthwhile? World J Surg Oncol 2014;12:347. [PMID: 25407113 DOI: 10.1186/1477-7819-12-347] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
67 Kim M, Mun JG, Lee HJ, Son SR, Lee MJ, Kee JY. Inhibitory Effect of Oat Bran Ethanol Extract on Survival and Gemcitabine Resistance of Pancreatic Cancer Cells. Molecules 2019;24:E3829. [PMID: 31652886 DOI: 10.3390/molecules24213829] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Liu X, Lin P, Perrett I, Lin J, Liao YP, Chang CH, Jiang J, Wu N, Donahue T, Wainberg Z, Nel AE, Meng H. Tumor-penetrating peptide enhances transcytosis of silicasome-based chemotherapy for pancreatic cancer. J Clin Invest 2017;127:2007-18. [PMID: 28414297 DOI: 10.1172/JCI92284] [Cited by in Crossref: 97] [Cited by in F6Publishing: 44] [Article Influence: 24.3] [Reference Citation Analysis]
69 Du L, DeFoe M, Ruzinova MB, Olsen JR, Wang-Gillam A. Perioperative Therapy for Surgically Resectable Pancreatic Adenocarcinoma. Hematol Oncol Clin North Am 2015;29:717-26. [PMID: 26226906 DOI: 10.1016/j.hoc.2015.04.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
70 Mohelnikova-Duchonova B, Kocik M, Duchonova B, Brynychova V, Oliverius M, Hlavsa J, Honsova E, Mazanec J, Kala Z, Ojima I, Hughes DJ, Doherty JE, Murray HA, Crockard MA, Lemstrova R, Soucek P. Hedgehog pathway overexpression in pancreatic cancer is abrogated by new-generation taxoid SB-T-1216. Pharmacogenomics J 2017;17:452-60. [PMID: 27573236 DOI: 10.1038/tpj.2016.55] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
71 Li Q, Yan H, Liu W, Zhen H, Yang Y, Cao B. Efficacy and safety of gemcitabine-fluorouracil combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomized controlled trials. PLoS One 2014;9:e104346. [PMID: 25093849 DOI: 10.1371/journal.pone.0104346] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
72 Tanaka HY, Kano MR. Stromal barriers to nanomedicine penetration in the pancreatic tumor microenvironment. Cancer Sci 2018;109:2085-92. [PMID: 29737600 DOI: 10.1111/cas.13630] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 12.3] [Reference Citation Analysis]
73 Tehfe M, Dowden S, Kennecke H, El-Maraghi R, Lesperance B, Couture F, Letourneau R, Liu H, Romano A. nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial. Adv Ther 2016;33:747-59. [PMID: 27085323 DOI: 10.1007/s12325-016-0327-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
74 Fernandes GDS, Pereira A. Development of new therapies for metastatic pancreatic cancer: are they better than FOLFIRINOX? ESMO Open 2019;4:e000537. [PMID: 31354965 DOI: 10.1136/esmoopen-2019-000537] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
75 Scheithauer W, Putora PM, Grünberger B, Eisterer W, Wöll E, Prager G, Schaberl-Moser R, Greil R, Glatzer M. Patterns of care in metastatic pancreatic cancer: patient selection in clinical routine. Therap Adv Gastroenterol 2019;12:1756284819877635. [PMID: 31579123 DOI: 10.1177/1756284819877635] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
76 Rashid NU, Peng XL, Jin C, Moffitt RA, Volmar KE, Belt BA, Panni RZ, Nywening TM, Herrera SG, Moore KJ, Hennessey SG, Morrison AB, Kawalerski R, Nayyar A, Chang AE, Schmidt B, Kim HJ, Linehan DC, Yeh JJ. Purity Independent Subtyping of Tumors (PurIST), A Clinically Robust, Single-sample Classifier for Tumor Subtyping in Pancreatic Cancer. Clin Cancer Res 2020;26:82-92. [PMID: 31754050 DOI: 10.1158/1078-0432.CCR-19-1467] [Cited by in Crossref: 36] [Cited by in F6Publishing: 20] [Article Influence: 18.0] [Reference Citation Analysis]
77 Kipps E, Young K, Starling N. Liposomal irinotecan in gemcitabine-refractory metastatic pancreatic cancer: efficacy, safety and place in therapy. Ther Adv Med Oncol 2017;9:159-70. [PMID: 28344661 DOI: 10.1177/1758834016688816] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
78 Braiteh F, Patel MB, Parisi M, Ni Q, Park S, Faria C. Comparative effectiveness and resource utilization of nab-paclitaxel plus gemcitabine vs FOLFIRINOX or gemcitabine for the first-line treatment of metastatic pancreatic adenocarcinoma in a US community setting. Cancer Manag Res 2017;9:141-8. [PMID: 28461766 DOI: 10.2147/CMAR.S126073] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
79 Winograd R, Byrne KT, Evans RA, Odorizzi PM, Meyer AR, Bajor DL, Clendenin C, Stanger BZ, Furth EE, Wherry EJ, Vonderheide RH. Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma. Cancer Immunol Res. 2015;3:399-411. [PMID: 25678581 DOI: 10.1158/2326-6066.cir-14-0215] [Cited by in Crossref: 242] [Cited by in F6Publishing: 171] [Article Influence: 40.3] [Reference Citation Analysis]
80 de Jesus VHF, Camandaroba MPG, Calsavara VF, Riechelmann RP. Systematic review and meta-analysis of gemcitabine-based chemotherapy after FOLFIRINOX in advanced pancreatic cancer.Ther Adv Med Oncol. 2020;12:1758835920905408. [PMID: 32165927 DOI: 10.1177/1758835920905408] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
81 Yoo C, Shin SH, Kim KP, Jeong JH, Chang HM, Kang JH, Lee SS, Park DH, Song TJ, Seo DW, Lee SK, Kim MH, Park JH, Hwang DW, Song KB, Lee JH, Ryoo BY, Kim SC. Clinical Outcomes of Conversion Surgery after Neoadjuvant Chemotherapy in Patients with Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer: A Single-Center, Retrospective Analysis. Cancers (Basel). 2019;11. [PMID: 30813624 DOI: 10.3390/cancers11030278] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
82 Harris NLE, Vennin C, Conway JRW, Vine KL, Pinese M, Cowley MJ, Shearer RF, Lucas MC, Herrmann D, Allam AH, Pajic M, Morton JP;  Australian Pancreatic Cancer Genome Initiative; Biankin AV, Ranson M, Timpson P, Saunders DN. SerpinB2 regulates stromal remodelling and local invasion in pancreatic cancer. Oncogene. 2017;36:4288-4298. [PMID: 28346421 DOI: 10.1038/onc.2017.63] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 11.8] [Reference Citation Analysis]
83 Pusceddu S, Ghidini M, Torchio M, Corti F, Tomasello G, Niger M, Prinzi N, Nichetti F, Coinu A, Di Bartolomeo M, Cabiddu M, Passalacqua R, de Braud F, Petrelli F. Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis. Cancers (Basel). 2019;11. [PMID: 30959763 DOI: 10.3390/cancers11040484] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 14.5] [Reference Citation Analysis]
84 Whittle MC, Hingorani SR. Understanding Disease Biology and Informing the Management of Pancreas Cancer With Preclinical Model Systems. Cancer J 2017;23:326-32. [PMID: 29189328 DOI: 10.1097/PPO.0000000000000289] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
85 Latchana N, Davis L, Coburn NG, Mahar A, Liu Y, Hammad A, Kagedan D, Elmi M, Siddiqui M, Earle CC, Hallet J. Population-based study of the impact of surgical and adjuvant therapy at the same or a different institution on survival of patients with pancreatic adenocarcinoma. BJS Open 2019;3:85-94. [PMID: 30734019 DOI: 10.1002/bjs5.50115] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
86 Beutel AK, Schütte L, Scheible J, Roger E, Müller M, Perkhofer L, Kestler AMTU, Kraus JM, Kestler HA, Barth TFE, Lemke J, Kornmann M, Ettrich TJ, Gout J, Seufferlein T, Kleger A. A Prospective Feasibility Trial to Challenge Patient-Derived Pancreatic Cancer Organoids in Predicting Treatment Response. Cancers (Basel) 2021;13:2539. [PMID: 34064221 DOI: 10.3390/cancers13112539] [Reference Citation Analysis]
87 Broekgaarden M, Anbil S, Bulin AL, Obaid G, Mai Z, Baglo Y, Rizvi I, Hasan T. Modulation of redox metabolism negates cancer-associated fibroblasts-induced treatment resistance in a heterotypic 3D culture platform of pancreatic cancer. Biomaterials 2019;222:119421. [PMID: 31494503 DOI: 10.1016/j.biomaterials.2019.119421] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 12.0] [Reference Citation Analysis]
88 Massey AE, Sikander M, Chauhan N, Kumari S, Setua S, Shetty AB, Mandil H, Kashyap VK, Khan S, Jaggi M, Yallapu MM, Hafeez BB, Chauhan SC. Next-generation paclitaxel-nanoparticle formulation for pancreatic cancer treatment. Nanomedicine 2019;20:102027. [PMID: 31170509 DOI: 10.1016/j.nano.2019.102027] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
89 Domen A, Quatannens D, Zanivan S, Deben C, Van Audenaerde J, Smits E, Wouters A, Lardon F, Roeyen G, Verhoeven Y, Janssens A, Vandamme T, van Dam P, Peeters M, Prenen H. Cancer-Associated Fibroblasts as a Common Orchestrator of Therapy Resistance in Lung and Pancreatic Cancer. Cancers (Basel) 2021;13:987. [PMID: 33673405 DOI: 10.3390/cancers13050987] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
90 Yoo C, Im HS, Kim KP, Oh DY, Lee KH, Chon HJ, Kim JH, Kang M, Kim I, Lee GJ, Oh SY, Choi Y, Choi HJ, Kim ST, Park JO, Ryoo BY. Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/Leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group. Ther Adv Med Oncol. 2019;11:1758835919871126. [PMID: 31489036 DOI: 10.1177/1758835919871126] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
91 Chen K, Qian W, Li J, Jiang Z, Cheng L, Yan B, Cao J, Sun L, Zhou C, Lei M, Duan W, Ma J, Ma Q, Ma Z. Loss of AMPK activation promotes the invasion and metastasis of pancreatic cancer through an HSF1-dependent pathway. Mol Oncol 2017;11:1475-92. [PMID: 28783244 DOI: 10.1002/1878-0261.12116] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 9.0] [Reference Citation Analysis]
92 O'Kane GM, Ladak F, Gallinger S. Advances in the management of pancreatic ductal adenocarcinoma. CMAJ 2021;193:E844-51. [PMID: 34099468 DOI: 10.1503/cmaj.201450] [Reference Citation Analysis]
93 Hsueh CT, Selim JH, Tsai JY, Hsueh CT. Nanovectors for anti-cancer drug delivery in the treatment of advanced pancreatic adenocarcinoma. World J Gastroenterol 2016; 22(31): 7080-7090 [PMID: 27610018 DOI: 10.3748/wjg.v22.i31.7080] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
94 Fenocchio E, Filippi R, Lombardi P, Quarà V, Milanesio M, Aimar G, Leone F, Aglietta M. Is There a Standard Adjuvant Therapy for Resected Pancreatic Cancer? Cancers (Basel) 2019;11:E1547. [PMID: 31614884 DOI: 10.3390/cancers11101547] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
95 Orlandi A, Calegari MA, Martini M, Cocomazzi A, Bagalà C, Indellicati G, Zurlo V, Basso M, Cassano A, Larocca LM, Barone C. Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse. Clin Transl Oncol 2016;18:988-95. [PMID: 26742940 DOI: 10.1007/s12094-015-1471-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
96 Arru C, De Miglio MR, Cossu A, Muroni MR, Carru C, Zinellu A, Paliogiannis P. Durvalumab Plus Tremelimumab in Solid Tumors: A Systematic Review. Adv Ther 2021;38:3674-93. [PMID: 34105088 DOI: 10.1007/s12325-021-01796-6] [Reference Citation Analysis]
97 Hann A, Bohle W, Egger J, Zoller W. Feasibility of alternating induction and maintenance chemotherapy in pancreatic cancer. Sci Rep 2017;7:41549. [PMID: 28139684 DOI: 10.1038/srep41549] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
98 Zhang H, Zeng J, Tan Y, Lu L, Sun C, Liang Y, Zou H, Yang X, Tan Y. Subgroup analysis reveals molecular heterogeneity and provides potential precise treatment for pancreatic cancers. Onco Targets Ther 2018;11:5811-9. [PMID: 30254473 DOI: 10.2147/OTT.S163139] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
99 Tran NH, Sahai V, Griffith KA, Nathan H, Kaza R, Cuneo KC, Shi J, Kim E, Sonnenday CJ, Cho CS, Lawrence TS, Zalupski MM. Phase 2 Trial of Neoadjuvant FOLFIRINOX and Intensity Modulated Radiation Therapy Concurrent With Fixed-Dose Rate-Gemcitabine in Patients With Borderline Resectable Pancreatic Cancer. Int J Radiat Oncol Biol Phys 2020;106:124-33. [PMID: 31494181 DOI: 10.1016/j.ijrobp.2019.08.057] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
100 Peng JS, Mino J, Monteiro R, Morris-Stiff G, Ali NS, Wey J, El-Hayek KM, Walsh RM, Chalikonda S. Diagnostic Laparoscopy Prior to Neoadjuvant Therapy in Pancreatic Cancer Is High Yield: an Analysis of Outcomes and Costs. J Gastrointest Surg 2017;21:1420-7. [PMID: 28597320 DOI: 10.1007/s11605-017-3470-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
101 Ng K, Hendifar A, Starodub A, Chaves J, Yang Y, Koh B, Barbie D, Hahn WC, Fuchs CS. Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma. Invest New Drugs 2019;37:159-65. [PMID: 30105668 DOI: 10.1007/s10637-018-0650-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
102 Soni KS, Thomas D, Caffrey T, Mehla K, Lei F, O'Connell KA, Sagar S, Lele SM, Hollingsworth MA, Radhakrishnan P, Bronich TK. A Polymeric Nanogel-Based Treatment Regimen for Enhanced Efficacy and Sequential Administration of Synergistic Drug Combination in Pancreatic Cancer. J Pharmacol Exp Ther 2019;370:894-901. [PMID: 30683666 DOI: 10.1124/jpet.118.255372] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
103 Ueno M, Li CP, Ikeda M, Ishii H, Mizuno N, Yamaguchi T, Ioka T, Oh DY, Ichikawa W, Okusaka T, Matsuyama Y, Arai D, Chen LT, Park YS, Furuse J. A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placebo. Cancer Chemother Pharmacol 2017;80:307-15. [PMID: 28634650 DOI: 10.1007/s00280-017-3351-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
104 Okada KI, Kawai M, Hirono S, Kojima F, Tanioka K, Terada M, Miyazawa M, Kitahata Y, Iwahashi Y, Ueno M, Hayami S, Murata SI, Shimokawa T, Yamaue H. Diffusion-weighted MRI predicts the histologic response for neoadjuvant therapy in patients with pancreatic cancer: a prospective study (DIFFERENT trial). Langenbecks Arch Surg. 2020;405:23-33. [PMID: 31993737 DOI: 10.1007/s00423-020-01857-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
105 Sarabi M, Mais L, Oussaid N, Desseigne F, Guibert P, De La Fouchardiere C. Use of gemcitabine as a second-line treatment following chemotherapy with folfirinox for metastatic pancreatic adenocarcinoma. Oncol Lett. 2017;13:4917-4924. [PMID: 28599496 DOI: 10.3892/ol.2017.6061] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
106 Duan Z, Chinn D, Tu MJ, Zhang QY, Huynh J, Chen J, Mack P, Yu AM, Kim EJ. Novel Synergistic Combination of Mitotic Arrest and Promotion of Apoptosis for Treatment of Pancreatic Adenocarcinoma. Transl Oncol 2019;12:683-92. [PMID: 30844579 DOI: 10.1016/j.tranon.2019.01.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
107 Huang J, Qian W, Wang L, Wu H, Zhou H, Wang AY, Chen H, Yang L, Mao H. Functionalized milk-protein-coated magnetic nanoparticles for MRI-monitored targeted therapy of pancreatic cancer. Int J Nanomedicine 2016;11:3087-99. [PMID: 27462153 DOI: 10.2147/IJN.S92722] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
108 Aiello NM, Bajor DL, Norgard RJ, Sahmoud A, Bhagwat N, Pham MN, Cornish TC, Iacobuzio-Donahue CA, Vonderheide RH, Stanger BZ. Metastatic progression is associated with dynamic changes in the local microenvironment. Nat Commun 2016;7:12819. [PMID: 27628423 DOI: 10.1038/ncomms12819] [Cited by in Crossref: 71] [Cited by in F6Publishing: 64] [Article Influence: 14.2] [Reference Citation Analysis]
109 Bruera G, Massacese S, Candria S, Galvano A, Manetta R, Giordano AV, Carducci S, Di Sibio A, Ciacco E, Russo A, Ricevuto E; Oncology Network ASL1 Abruzzo, Italy. Real life triplet FIr/FOx chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma patients: recommended schedule for expected activity and safety and phase II study. Oncotarget 2018;9:31861-76. [PMID: 30159128 DOI: 10.18632/oncotarget.25870] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
110 Oyasiji T, Ma WW. Novel adjuvant therapies for pancreatic adenocarcinoma. J Gastrointest Oncol 2015;6:430-5. [PMID: 26261729 DOI: 10.3978/j.issn.2078-6891.2015.031] [Reference Citation Analysis]
111 Wang Y, Lakoma A, Zogopoulos G. Building towards Precision Oncology for Pancreatic Cancer: Real-World Challenges and Opportunities. Genes (Basel) 2020;11:E1098. [PMID: 32967105 DOI: 10.3390/genes11091098] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
112 Muzumdar MD, Chen PY, Dorans KJ, Chung KM, Bhutkar A, Hong E, Noll EM, Sprick MR, Trumpp A, Jacks T. Survival of pancreatic cancer cells lacking KRAS function. Nat Commun 2017;8:1090. [PMID: 29061961 DOI: 10.1038/s41467-017-00942-5] [Cited by in Crossref: 70] [Cited by in F6Publishing: 68] [Article Influence: 17.5] [Reference Citation Analysis]
113 Pan Y, Rhea P, Tan L, Cartwright C, Lee HJ, Ravoori MK, Addington C, Gagea M, Kundra V, Kim SJ, Newman RA, Yang P. PBI-05204, a supercritical CO₂ extract of Nerium oleander, inhibits growth of human pancreatic cancer via targeting the PI3K/mTOR pathway. Invest New Drugs 2015;33:271-9. [PMID: 25476893 DOI: 10.1007/s10637-014-0190-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
114 Takahashi R, Ijichi H, Sano M, Miyabayashi K, Mohri D, Kim J, Kimura G, Nakatsuka T, Fujiwara H, Yamamoto K, Kudo Y, Tanaka Y, Tateishi K, Nakai Y, Morishita Y, Soma K, Takeda N, Moses HL, Isayama H, Koike K. Soluble VCAM-1 promotes gemcitabine resistance via macrophage infiltration and predicts therapeutic response in pancreatic cancer. Sci Rep 2020;10:21194. [PMID: 33273652 DOI: 10.1038/s41598-020-78320-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
115 Kruger S, Legenstein ML, Rösgen V, Haas M, Modest DP, Westphalen CB, Ormanns S, Kirchner T, Heinemann V, Holdenrieder S, Boeck S. Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer. Oncoimmunology 2017;6:e1310358. [PMID: 28638732 DOI: 10.1080/2162402X.2017.1310358] [Cited by in Crossref: 59] [Cited by in F6Publishing: 42] [Article Influence: 14.8] [Reference Citation Analysis]
116 Brunner M, Wu Z, Krautz C, Pilarsky C, Grützmann R, Weber GF. Current Clinical Strategies of Pancreatic Cancer Treatment and Open Molecular Questions. Int J Mol Sci 2019;20:E4543. [PMID: 31540286 DOI: 10.3390/ijms20184543] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 9.5] [Reference Citation Analysis]
117 Tomlinson B, Lin TY, Dall'Era M, Pan CX. Nanotechnology in bladder cancer: current state of development and clinical practice. Nanomedicine (Lond) 2015;10:1189-201. [PMID: 25929573 DOI: 10.2217/nnm.14.212] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
118 Deng J, Yang H, Haak VM, Yang J, Kipper FC, Barksdale C, Hwang SH, Gartung A, Bielenberg DR, Subbian S, Ho KK, Ye X, Fan D, Sun Y, Hammock BD, Panigrahy D. Eicosanoid regulation of debris-stimulated metastasis. Proc Natl Acad Sci U S A 2021;118:e2107771118. [PMID: 34607951 DOI: 10.1073/pnas.2107771118] [Reference Citation Analysis]
119 Jiang J, Yu C, Guo X, Zhang H, Tian S, Cai K, He Z, Sun C. G Protein-Coupled Receptor GPR87 Promotes the Expansion of PDA Stem Cells through Activating JAK2/STAT3. Mol Ther Oncolytics 2020;17:384-93. [PMID: 32405536 DOI: 10.1016/j.omto.2020.01.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
120 Chandra V, McAllister F. Therapeutic potential of microbial modulation in pancreatic cancer. Gut 2021:gutjnl-2019-319807. [PMID: 33906958 DOI: 10.1136/gutjnl-2019-319807] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
121 Kumar Das Majumdar S, Kumar Muduly D, Mishra S, Mohapatra CRR, Bunger D, Khan MA. Management of primary squamous cell carcinoma of the pancreas with a nanosomal paclitaxel lipid suspension-based regimen: A case report. Mol Clin Oncol 2019;10:430-4. [PMID: 30931112 DOI: 10.3892/mco.2019.1814] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
122 Zechner D, Bürtin F, Amme J, Lindner T, Radecke T, Hadlich S, Kühn JP, Vollmar B. Characterization of novel carcinoma cell lines for the analysis of therapeutical strategies fighting pancreatic cancer. Cell Biosci 2015;5:51. [PMID: 26322225 DOI: 10.1186/s13578-015-0038-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
123 Li YF, Zhang C, Zhou S, He M, Zhang H, Chen N, Li F, Luan X, Pai M, Yuan H, Sun D, Li Y. Species difference in paclitaxel disposition correlated with poor pharmacological efficacy translation from mice to humans. Clin Pharmacol 2018;10:165-74. [PMID: 30519122 DOI: 10.2147/CPAA.S185449] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
124 Chevalier H, Vienot A, Lièvre A, Edeline J, El Hajbi F, Peugniez C, Vernerey D, Meurisse A, Hammel P, Neuzillet C, Borg C, Turpin A. FOLFIRINOX De-Escalation in Advanced Pancreatic Cancer: A Multicenter Real-Life Study.Oncologist. 2020;25:e1701-e1710. [PMID: 32886823 DOI: 10.1634/theoncologist.2020-0577] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
125 Gujral TS, Kirschner MW. Hippo pathway mediates resistance to cytotoxic drugs. Proc Natl Acad Sci U S A 2017;114:E3729-38. [PMID: 28416665 DOI: 10.1073/pnas.1703096114] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 8.3] [Reference Citation Analysis]
126 El-Deiry WS, Vijayvergia N, Xiu J, Scicchitano A, Lim B, Yee NS, Harvey HA, Gatalica Z, Reddy S. Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites. Cancer Biol Ther 2015;16:1726-37. [PMID: 26553611 DOI: 10.1080/15384047.2015.1113356] [Cited by in Crossref: 46] [Cited by in F6Publishing: 53] [Article Influence: 9.2] [Reference Citation Analysis]
127 Kikuchi Y, Nishikawa Y, Amanuma M, Kishimoto Y, Takuma K, Wakayama M, Shibuya K, Okano N, Shimada H, Igarashi Y. Successful treatment of advanced pancreatic leiomyosarcoma treated with gemcitabine plus nab-paclitaxel: a case report and literature review. Int Cancer Conf J 2021;10:63-7. [PMID: 33489704 DOI: 10.1007/s13691-020-00452-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
128 Houghton PJ, Kurmasheva RT, Kolb EA, Gorlick R, Maris JM, Wu J, Tong Z, Arnold MA, Chatterjee M, Williams TM, Smith MA. Initial testing (stage 1) of the tubulin binding agent nanoparticle albumin-bound (nab) paclitaxel (Abraxane(®)) by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer 2015;62:1214-21. [PMID: 25809532 DOI: 10.1002/pbc.25474] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
129 Fan X, Zhang X, Shen J, Zhao H, Yu X, Chen Y, Zhuang Z, Deng X, Feng H, Wang Y, Peng L. Decreased TUSC3 Promotes Pancreatic Cancer Proliferation, Invasion and Metastasis. PLoS One 2016;11:e0149028. [PMID: 26871953 DOI: 10.1371/journal.pone.0149028] [Cited by in Crossref: 14] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
130 Mitragotri S, Burke PA, Langer R. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat Rev Drug Discov. 2014;13:655-672. [PMID: 25103255 DOI: 10.1038/nrd4363] [Cited by in Crossref: 868] [Cited by in F6Publishing: 776] [Article Influence: 124.0] [Reference Citation Analysis]
131 Narayanan V, Weekes CD. Molecular therapeutics in pancreas cancer. World J Gastrointest Oncol 2016; 8(4): 366-379 [PMID: 27096032 DOI: 10.4251/wjgo.v8.i4.366] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
132 Wong SK, Gondara L, Renouf DJ, Lim HJ, Loree JM, Davies JM, Gill S. Impact of surveillance among patients with resected pancreatic cancer following adjuvant chemotherapy. J Gastrointest Oncol 2021;12:446-54. [PMID: 34012638 DOI: 10.21037/jgo-20-422] [Reference Citation Analysis]
133 Ding L, Madamsetty VS, Kiers S, Alekhina O, Ugolkov A, Dube J, Zhang Y, Zhang JS, Wang E, Dutta SK, Schmitt DM, Giles FJ, Kozikowski AP, Mazar AP, Mukhopadhyay D, Billadeau DD. Glycogen Synthase Kinase-3 Inhibition Sensitizes Pancreatic Cancer Cells to Chemotherapy by Abrogating the TopBP1/ATR-Mediated DNA Damage Response. Clin Cancer Res 2019;25:6452-62. [PMID: 31533931 DOI: 10.1158/1078-0432.CCR-19-0799] [Cited by in F6Publishing: 14] [Reference Citation Analysis]
134 An N, Zheng B. MiR-203a-3p Inhibits Pancreatic Cancer Cell Proliferation, EMT, and Apoptosis by Regulating SLUG. Technol Cancer Res Treat 2020;19:1533033819898729. [PMID: 32301392 DOI: 10.1177/1533033819898729] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
135 Du L, Che Z, Wang-Gillam A. Promising therapeutics of gastrointestinal cancers in clinical trials. J Gastrointest Oncol 2017;8:524-33. [PMID: 28736639 DOI: 10.21037/jgo.2017.01.08] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
136 Miller AL, Garcia PL, Fehling SC, Gamblin TL, Vance RB, Council LN, Chen D, Yang ES, van Waardenburg RCAM, Yoon KJ. The BET Inhibitor JQ1 Augments the Antitumor Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer. Cancers (Basel) 2021;13:3470. [PMID: 34298684 DOI: 10.3390/cancers13143470] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
137 Leigh N, Solomon D, Pletcher E, Labow DM, Magge DR, Sarpel U, Golas BJ. Is cytoreductive surgery and hyperthermic intraperitoneal chemotherapy indicated in hepatobiliary malignancies? World J Surg Oncol 2020;18:124. [PMID: 32527272 DOI: 10.1186/s12957-020-01898-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
138 Shirai Y, Saito N, Uwagawa T, Shiba H, Horiuchi T, Iwase R, Haruki K, Ohashi T, Yanaga K. Pomalidomide promotes chemosensitization of pancreatic cancer by inhibition of NF-κB. Oncotarget 2018;9:15292-301. [PMID: 29632644 DOI: 10.18632/oncotarget.24577] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
139 Catanese S, Pentheroudakis G, Douillard JY, Lordick F. ESMO Management and treatment adapted recommendations in the COVID-19 era: Pancreatic Cancer. ESMO Open. 2020;5. [PMID: 32423899 DOI: 10.1136/esmoopen-2020-000804] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 13.0] [Reference Citation Analysis]
140 Hosein AN, Brekken RA, Maitra A. Pancreatic cancer stroma: an update on therapeutic targeting strategies. Nat Rev Gastroenterol Hepatol 2020;17:487-505. [PMID: 32393771 DOI: 10.1038/s41575-020-0300-1] [Cited by in Crossref: 75] [Cited by in F6Publishing: 79] [Article Influence: 75.0] [Reference Citation Analysis]
141 Farge D, Bournet B, Conroy T, Vicaut E, Rak J, Zogoulous G, Barkun J, Ouaissi M, Buscail L, Frere C. Primary Thromboprophylaxis in Pancreatic Cancer Patients: Why Clinical Practice Guidelines Should Be Implemented. Cancers (Basel). 2020;12. [PMID: 32155940 DOI: 10.3390/cancers12030618] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
142 Hagiwara Y, Ohashi Y, Okusaka T, Ueno H, Ioka T, Boku N, Egawa S, Hatori T, Furuse J, Mizumoto K, Ohkawa S, Yamaguchi T, Yamao K, Funakoshi A, Cheng AL, Kihara K, Sato A, Tanaka M. Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study. ESMO Open 2017;2:e000151. [PMID: 28761731 DOI: 10.1136/esmoopen-2016-000151] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
143 Yuan C, Qian ZR, Babic A, Morales-Oyarvide V, Rubinson DA, Kraft P, Ng K, Bao Y, Giovannucci EL, Ogino S, Stampfer MJ, Gaziano JM, Sesso HD, Buring JE, Cochrane BB, Chlebowski RT, Snetselaar LG, Manson JE, Fuchs CS, Wolpin BM. Prediagnostic Plasma 25-Hydroxyvitamin D and Pancreatic Cancer Survival. J Clin Oncol. 2016;34:2899-2905. [PMID: 27325858 DOI: 10.1200/jco.2015.66.3005] [Cited by in Crossref: 30] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
144 Hang J, Xue P, Yang H, Li S, Chen D, Zhu L, Huang W, Ren S, Zhu Y, Wang L. Pretreatment C-reactive protein to albumin ratio for predicting overall survival in advanced pancreatic cancer patients. Sci Rep 2017;7:2993. [PMID: 28592881 DOI: 10.1038/s41598-017-03153-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
145 Desai AM, Lichtman SM. Systemic therapy of non-colorectal gastrointestinal malignancies in the elderly. Cancer Biol Med. 2015;12:284-291. [PMID: 26779365 DOI: 10.7497/j.issn.2095-3941.2015.0078] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
146 Uwagawa T, Yanaga K. Effect of NF-κB inhibition on chemoresistance in biliary-pancreatic cancer. Surg Today 2015;45:1481-8. [PMID: 25673034 DOI: 10.1007/s00595-015-1129-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
147 Chen Q, Yuan H, Shi GD, Wu Y, Liu DF, Lin YT, Chen L, Ge WL, Jiang K, Miao Y. Association between NR5A2 and the risk of pancreatic cancer, especially among Caucasians: a meta-analysis of case-control studies. Onco Targets Ther 2018;11:2709-23. [PMID: 29785120 DOI: 10.2147/OTT.S157759] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
148 Liu X, Jiang J, Nel AE, Meng H. Major effect of transcytosis on nano drug delivery to pancreatic cancer. Mol Cell Oncol 2017;4:e1335273. [PMID: 28868347 DOI: 10.1080/23723556.2017.1335273] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
149 Samanta K, Setua S, Kumari S, Jaggi M, Yallapu MM, Chauhan SC. Gemcitabine Combination Nano Therapies for Pancreatic Cancer. Pharmaceutics. 2019;11. [PMID: 31689930 DOI: 10.3390/pharmaceutics11110574] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 10.5] [Reference Citation Analysis]
150 Lelond S, Ward J, Lambert PJ, Kim CA. Symptom Burden of Patients with Advanced Pancreas Cancer (APC): A Provincial Cancer Institute Observational Study. Curr Oncol 2021;28:2789-800. [PMID: 34436010 DOI: 10.3390/curroncol28040244] [Reference Citation Analysis]
151 Eng JW, Mace TA, Sharma R, Twum DYF, Peng P, Gibbs JF, Pitoniak R, Reed CB, Abrams SI, Repasky EA, Hylander BL. Pancreatic cancer stem cells in patient pancreatic xenografts are sensitive to drozitumab, an agonistic antibody against DR5. J Immunother Cancer 2016;4:33. [PMID: 27330806 DOI: 10.1186/s40425-016-0136-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
152 Wang W, Zhang T, Zhao W, Xu L, Yang Y, Liao Q, Zhao Y. A Single Talent Immunogenic Membrane Antigen and Novel Prognostic Predictor: voltage-dependent anion channel 1 (VDAC1) in Pancreatic Cancer. Sci Rep 2016;6:33648. [PMID: 27659305 DOI: 10.1038/srep33648] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
153 Mejia I, Bodapati S, Chen KT, Díaz B. Pancreatic Adenocarcinoma Invasiveness and the Tumor Microenvironment: From Biology to Clinical Trials. Biomedicines 2020;8:E401. [PMID: 33050151 DOI: 10.3390/biomedicines8100401] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
154 van Straten D, Mashayekhi V, de Bruijn HS, Oliveira S, Robinson DJ. Oncologic Photodynamic Therapy: Basic Principles, Current Clinical Status and Future Directions. Cancers (Basel) 2017;9:E19. [PMID: 28218708 DOI: 10.3390/cancers9020019] [Cited by in Crossref: 355] [Cited by in F6Publishing: 295] [Article Influence: 88.8] [Reference Citation Analysis]
155 Kim HW, Lee JC, Paik KH, Lee YS, Hwang JH, Kim J. Initial Metastatic Site as a Prognostic Factor in Patients With Stage IV Pancreatic Ductal Adenocarcinoma. Medicine (Baltimore) 2015;94:e1012. [PMID: 26107667 DOI: 10.1097/MD.0000000000001012] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
156 Wang Y, Camateros P, Cheung WY. A Real-World Comparison of FOLFIRINOX, Gemcitabine Plus nab-Paclitaxel, and Gemcitabine in Advanced Pancreatic Cancers. J Gastrointest Cancer. 2019;50:62-68. [PMID: 29143916 DOI: 10.1007/s12029-017-0028-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 10.5] [Reference Citation Analysis]
157 Vilimas T, Wang AQ, Patnaik S, Hughes EA, Singleton MD, Knotts Z, Li D, Frankowski K, Schlomer JJ, Guerin TM, Springer S, Drennan C, Dextras C, Wang C, Gilbert D, Southall N, Ferrer M, Huang S, Kozlov S, Marugan J, Xu X, Rudloff U. Pharmacokinetic evaluation of the PNC disassembler metarrestin in wild-type and Pdx1-Cre;LSL-KrasG12D/+;Tp53R172H/+ (KPC) mice, a genetically engineered model of pancreatic cancer. Cancer Chemother Pharmacol 2018;82:1067-80. [PMID: 30306263 DOI: 10.1007/s00280-018-3699-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
158 Han SY, Kim DU, Seol YM, Kim S, Lee NK, Hong SB, Seo HI. First-line chemotherapy in very elderly patients with metastatic pancreatic cancer: Gemcitabine monotherapy vs combination chemotherapy. World J Clin Cases 2020; 8(18): 4022-4033 [PMID: 33024759 DOI: 10.12998/wjcc.v8.i18.4022] [Cited by in CrossRef: 2] [Article Influence: 2.0] [Reference Citation Analysis]
159 Hurwitz HI, Uppal N, Wagner SA, Bendell JC, Beck JT, Wade SM 3rd, Nemunaitis JJ, Stella PJ, Pipas JM, Wainberg ZA, Manges R, Garrett WM, Hunter DS, Clark J, Leopold L, Sandor V, Levy RS. Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed. J Clin Oncol. 2015;33:4039-4047. [PMID: 26351344 DOI: 10.1200/jco.2015.61.4578] [Cited by in Crossref: 155] [Cited by in F6Publishing: 90] [Article Influence: 25.8] [Reference Citation Analysis]
160 Yoshida M, Miyasaka Y, Ohuchida K, Okumura T, Zheng B, Torata N, Fujita H, Nabae T, Manabe T, Shimamoto M, Ohtsuka T, Mizumoto K, Nakamura M. Calpain inhibitor calpeptin suppresses pancreatic cancer by disrupting cancer-stromal interactions in a mouse xenograft model. Cancer Sci 2016;107:1443-52. [PMID: 27487486 DOI: 10.1111/cas.13024] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
161 Wishart G, Gupta P, Schettino G, Nisbet A, Velliou E. 3d tissue models as tools for radiotherapy screening for pancreatic cancer. Br J Radiol 2021;94:20201397. [PMID: 33684308 DOI: 10.1259/bjr.20201397] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
162 Awasthi N, Hinz S, Brekken RA, Schwarz MA, Schwarz RE. Nintedanib, a triple angiokinase inhibitor, enhances cytotoxic therapy response in pancreatic cancer. Cancer Lett. 2015;358:59-66. [PMID: 25527450 DOI: 10.1016/j.canlet.2014.12.027] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.9] [Reference Citation Analysis]
163 Kunjachan S, Kotb S, Pola R, Pechar M, Kumar R, Singh B, Gremse F, Taleeli R, Trichard F, Motto-Ros V, Sancey L, Detappe A, Yasmin-Karim S, Protti A, Shanmugam I, Ireland T, Etrych T, Sridhar S, Tillement O, Makrigiorgos M, Berbeco RI. Selective Priming of Tumor Blood Vessels by Radiation Therapy Enhances Nanodrug Delivery. Sci Rep 2019;9:15844. [PMID: 31676822 DOI: 10.1038/s41598-019-50538-w] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
164 Chan SL, Chan ST, Chan EH, He ZX. Systemic treatment for inoperable pancreatic adenocarcinoma: review and update. Chin J Cancer 2014;33:267-76. [PMID: 24472302 DOI: 10.5732/cjc.013.10134] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
165 Buwenge M, Cellini F, Silvestris N, Cilla S, Deodato F, Macchia G, Mattiucci GC, Valentini V, Morganti AG. Robotic radiosurgery in pancreatic cancer: A systematic review. World J Gastroenterol 2015; 21(31): 9420-9429 [PMID: 26309369 DOI: 10.3748/wjg.v21.i31.9420] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
166 Martinelli P, Carrillo-de Santa Pau E, Cox T, Sainz B Jr, Dusetti N, Greenhalf W, Rinaldi L, Costello E, Ghaneh P, Malats N, Büchler M, Pajic M, Biankin AV, Iovanna J, Neoptolemos J, Real FX. GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer. Gut 2017;66:1665-76. [PMID: 27325420 DOI: 10.1136/gutjnl-2015-311256] [Cited by in Crossref: 106] [Cited by in F6Publishing: 92] [Article Influence: 21.2] [Reference Citation Analysis]
167 Adiseshaiah PP, Crist RM, Hook SS, McNeil SE. Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer. Nat Rev Clin Oncol 2016;13:750-65. [PMID: 27531700 DOI: 10.1038/nrclinonc.2016.119] [Cited by in Crossref: 115] [Cited by in F6Publishing: 113] [Article Influence: 23.0] [Reference Citation Analysis]
168 Hakim N, Patel R, Devoe C, Saif MW. Why HALO 301 Failed and Implications for Treatment of Pancreatic Cancer. Pancreas (Fairfax) 2019;3:e1-4. [PMID: 32030361 DOI: 10.17140/POJ-3-e010] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 12.5] [Reference Citation Analysis]
169 van Mackelenbergh MG, Stroes CI, Spijker R, van Eijck CHJ, Wilmink JW, Bijlsma MF, van Laarhoven HWM. Clinical Trials Targeting the Stroma in Pancreatic Cancer: A Systematic Review and Meta-Analysis. Cancers (Basel). 2019;11. [PMID: 31035512 DOI: 10.3390/cancers11050588] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 10.5] [Reference Citation Analysis]
170 Kumar K, DeCant BT, Grippo PJ, Hwang RF, Bentrem DJ, Ebine K, Munshi HG. BET inhibitors block pancreatic stellate cell collagen I production and attenuate fibrosis in vivo. JCI Insight 2017;2:e88032. [PMID: 28194432 DOI: 10.1172/jci.insight.88032] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 7.8] [Reference Citation Analysis]
171 Chang CY, Lin CC. Hydrogel Models with Stiffness Gradients for Interrogating Pancreatic Cancer Cell Fate. Bioengineering (Basel) 2021;8:37. [PMID: 33805737 DOI: 10.3390/bioengineering8030037] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
172 Vaziri-Gohar A, Zarei M, Brody JR, Winter JM. Metabolic Dependencies in Pancreatic Cancer. Front Oncol. 2018;8:617. [PMID: 30631752 DOI: 10.3389/fonc.2018.00617] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 9.3] [Reference Citation Analysis]
173 Rouanet M, Lebrin M, Gross F, Bournet B, Cordelier P, Buscail L. Gene Therapy for Pancreatic Cancer: Specificity, Issues and Hopes. Int J Mol Sci 2017;18:E1231. [PMID: 28594388 DOI: 10.3390/ijms18061231] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
174 Papapanagiotou A, Sgourakis G, Karkoulias K, Raptis D, Parkin E, Brotzakis P, Panchal S, Papavassiliou AG. Osteonectin as a screening marker for pancreatic cancer: A prospective study. J Int Med Res. 2018;46:2769-2779. [PMID: 29756486 DOI: 10.1177/0300060518772413] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
175 Noll EM, Eisen C, Stenzinger A, Espinet E, Muckenhuber A, Klein C, Vogel V, Klaus B, Nadler W, Rösli C, Lutz C, Kulke M, Engelhardt J, Zickgraf FM, Espinosa O, Schlesner M, Jiang X, Kopp-Schneider A, Neuhaus P, Bahra M, Sinn BV, Eils R, Giese NA, Hackert T, Strobel O, Werner J, Büchler MW, Weichert W, Trumpp A, Sprick MR. CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma. Nat Med 2016;22:278-87. [PMID: 26855150 DOI: 10.1038/nm.4038] [Cited by in Crossref: 127] [Cited by in F6Publishing: 105] [Article Influence: 25.4] [Reference Citation Analysis]
176 Xin X, Kumar V, Lin F, Kumar V, Bhattarai R, Bhatt VR, Tan C, Mahato RI. Redox-responsive nanoplatform for codelivery of miR-519c and gemcitabine for pancreatic cancer therapy. Sci Adv 2020;6:eabd6764. [PMID: 33177098 DOI: 10.1126/sciadv.abd6764] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
177 Akce M, Zaidi MY, Waller EK, El-Rayes BF, Lesinski GB. The Potential of CAR T Cell Therapy in Pancreatic Cancer. Front Immunol. 2018;9:2166. [PMID: 30319627 DOI: 10.3389/fimmu.2018.02166] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 12.7] [Reference Citation Analysis]
178 Von Hoff DD, Cridebring D, Tian OY, Han H, Bhore R, Franco T, Ondovik MS, Louis CU. Analysis of the Role of Plasma 25-Hydroxyvitamin D Levels in Survival Outcomes in Patients from the Phase III MPACT Trial of Metastatic Pancreatic Cancer. Oncologist 2021;26:e704-9. [PMID: 33345430 DOI: 10.1002/onco.13645] [Reference Citation Analysis]
179 Okada KI, Kawai M, Hirono S, Miyazawa M, Kitahata Y, Kobayashi R, Ueno M, Hayami S, Shimokawa T, Yamaue H. Impact of Ninjin'Yoeito on Fatigue in Patients Receiving Nab-Paclitaxel Plus Gemcitabine Therapy: A Prospective, Single-Arm, Phase II Open Label, Nonrandomized, Historically-Controlled Study. Curr Ther Res Clin Exp 2020;93:100605. [PMID: 33014206 DOI: 10.1016/j.curtheres.2020.100605] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
180 Thibodeau S, Voutsadakis IA. FOLFIRINOX Chemotherapy in Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis of Retrospective and Phase II Studies. J Clin Med 2018;7:E7. [PMID: 29300345 DOI: 10.3390/jcm7010007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 6.7] [Reference Citation Analysis]
181 Desai NV, Sliesoraitis S, Hughes SJ, Trevino JG, Zlotecki RA, Ivey AM, George TJ Jr. Multidisciplinary neoadjuvant management for potentially curable pancreatic cancer. Cancer Med 2015;4:1224-39. [PMID: 25766842 DOI: 10.1002/cam4.444] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
182 Mitsunaga S, Kasamatsu E, Machii K. Incidence and frequency of cancer cachexia during chemotherapy for advanced pancreatic ductal adenocarcinoma. Support Care Cancer 2020;28:5271-9. [PMID: 32103356 DOI: 10.1007/s00520-020-05346-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
183 Chen PY, Muzumdar MD, Dorans KJ, Robbins R, Bhutkar A, Del Rosario A, Mertins P, Qiao J, Schafer AC, Gertler F, Carr S, Jacks T. Adaptive and Reversible Resistance to Kras Inhibition in Pancreatic Cancer Cells. Cancer Res 2018;78:985-1002. [PMID: 29279356 DOI: 10.1158/0008-5472.CAN-17-2129] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 5.5] [Reference Citation Analysis]
184 Yokota T, Takano S, Yoshitomi H, Kagawa S, Furukawa K, Takayashiki T, Kuboki S, Suzuki D, Sakai N, Nojima H, Mishima T, Nakadai E, Ohtsuka M. Successful treatment of a locally advanced unresectable pancreatic cancer patient with interstitial pneumonitis by conversion surgery following gemcitabine plus nab-paclitaxel chemotherapy: A case report. Mol Clin Oncol 2019;10:419-24. [PMID: 30931110 DOI: 10.3892/mco.2019.1807] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
185 McCarroll J, Teo J, Boyer C, Goldstein D, Kavallaris M, Phillips PA. Potential applications of nanotechnology for the diagnosis and treatment of pancreatic cancer. Front Physiol 2014;5:2. [PMID: 24478715 DOI: 10.3389/fphys.2014.00002] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 4.6] [Reference Citation Analysis]
186 Li T, Liu X, Xu B, Wu W, Zang Y, Li J, Wei L, Qian Y, Xu H, Xie M, Wang Q, Wang L. SKA1 regulates actin cytoskeleton remodelling via activating Cdc42 and influences the migration of pancreatic ductal adenocarcinoma cells. Cell Prolif 2020;53:e12799. [PMID: 32232899 DOI: 10.1111/cpr.12799] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
187 Liu Q, Liao Q, Zhao Y. Chemotherapy and tumor microenvironment of pancreatic cancer. Cancer Cell Int 2017;17:68. [PMID: 28694739 DOI: 10.1186/s12935-017-0437-3] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 11.0] [Reference Citation Analysis]
188 Khurana N, Dodhiawala PB, Bulle A, Lim KH. Deciphering the Role of Innate Immune NF-ĸB Pathway in Pancreatic Cancer. Cancers (Basel) 2020;12:E2675. [PMID: 32961746 DOI: 10.3390/cancers12092675] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
189 Wu W, Wu Q, Hong X, Zhou L, Zhang J, You L, Wang W, Wu H, Dai H, Zhao Y. Catechol-O-methyltransferase, a new target for pancreatic cancer therapy. Cancer Sci 2015;106:576-83. [PMID: 25711924 DOI: 10.1111/cas.12648] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
190 Parkin A, Man J, Timpson P, Pajic M. Targeting the complexity of Src signalling in the tumour microenvironment of pancreatic cancer: from mechanism to therapy. FEBS J 2019;286:3510-39. [PMID: 31330086 DOI: 10.1111/febs.15011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
191 van der Geest LGM, van Eijck CHJ, Groot Koerkamp B, Lemmens VEPP, Busch OR, Vissers PAJ, Wilmink JW, Besselink MG; Dutch Pancreatic Cancer Group. Trends in treatment and survival of patients with nonresected, nonmetastatic pancreatic cancer: A population-based study. Cancer Med 2018;7:4943-51. [PMID: 30188015 DOI: 10.1002/cam4.1750] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
192 Laquente B, Lopez-Martin J, Richards D, Illerhaus G, Chang DZ, Kim G, Stella P, Richel D, Szcylik C, Cascinu S, Frassineti GL, Ciuleanu T, Hurt K, Hynes S, Lin J, Lin AB, Von Hoff D, Calvo E. A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients. BMC Cancer 2017;17:137. [PMID: 28202004 DOI: 10.1186/s12885-017-3131-x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
193 Sahlin M, Bauden MP, Andersson R, Ansari D. Radioimmunotherapy--a potential novel tool for pancreatic cancer therapy? Tumour Biol 2015;36:4053-62. [PMID: 25926382 DOI: 10.1007/s13277-015-3479-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
194 Ishido K, Hakamada K, Kimura N, Miura T, Wakiya T. Essential updates 2018/2019: Current topics in the surgical treatment of pancreatic ductal adenocarcinoma. Ann Gastroenterol Surg 2021;5:7-23. [PMID: 33532676 DOI: 10.1002/ags3.12379] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
195 Yang Y, Sun Y, Wang H, Li H, Zhang M, Zhou L, Meng X, Wu Y, Liu P, Liu X, Zhang J, Tan X. MicroRNA-221 induces autophagy through suppressing HDAC6 expression and promoting apoptosis in pancreatic cancer. Oncol Lett 2018;16:7295-301. [PMID: 30546469 DOI: 10.3892/ol.2018.9513] [Cited by in Crossref: 4] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
196 Goel G, Sun W. Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future. J Hematol Oncol. 2015;8:44. [PMID: 25935754 DOI: 10.1186/s13045-015-0141-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
197 Strippoli A, Rossi S, Martini M, Basso M, D'Argento E, Schinzari G, Barile R, Cassano A, Barone C. ERCC1 expression affects outcome in metastatic pancreatic carcinoma treated with FOLFIRINOX: A single institution analysis. Oncotarget 2016;7:35159-68. [PMID: 27147577 DOI: 10.18632/oncotarget.9063] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
198 Barrett MT, Deiotte R, Lenkiewicz E, Malasi S, Holley T, Evers L, Posner RG, Jones T, Han H, Sausen M, Velculescu VE, Drebin J, O'Dwyer P, Jameson G, Ramanathan RK, Von Hoff DD. Clinical study of genomic drivers in pancreatic ductal adenocarcinoma. Br J Cancer 2017;117:572-82. [PMID: 28720843 DOI: 10.1038/bjc.2017.209] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
199 Jain R, Vijayvergia N, Devarajan K, Lewis B, Denlinger CS, Cohen SJ, Dotan E. Chemotherapy use and survival in older adults with metastatic pancreatic cancer in the combination therapy era. J Geriatr Oncol 2020;11:640-6. [PMID: 31917116 DOI: 10.1016/j.jgo.2019.12.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
200 Park I, Choi SJ, Kim YS, Ahn HK, Hong J, Sym SJ, Park J, Cho EK, Lee JH, Shin YJ, Shin DB. Prognostic Factors for Risk Stratification of Patients with Recurrent or Metastatic Pancreatic Adenocarcinoma Who Were Treated with Gemcitabine-Based Chemotherapy. Cancer Res Treat 2016;48:1264-73. [PMID: 27034148 DOI: 10.4143/crt.2015.250] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 4.4] [Reference Citation Analysis]
201 Chen C, Wang W, Wang W, Wang Y, Yu Z, Li Y. Locally advanced pancreatic carcinoma with jaundice: the benefit of a sequential treatment with stenting followed by CT-guided 125I seeds implantation. Eur Radiol 2021;31:6500-10. [PMID: 33630162 DOI: 10.1007/s00330-021-07764-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
202 Miao L, Li J, Liu Q, Feng R, Das M, Lin CM, Goodwin TJ, Dorosheva O, Liu R, Huang L. Transient and Local Expression of Chemokine and Immune Checkpoint Traps To Treat Pancreatic Cancer. ACS Nano 2017;11:8690-706. [PMID: 28809532 DOI: 10.1021/acsnano.7b01786] [Cited by in Crossref: 74] [Cited by in F6Publishing: 70] [Article Influence: 18.5] [Reference Citation Analysis]
203 Škubník J, Pavlíčková V, Ruml T, Rimpelová S. Current Perspectives on Taxanes: Focus on Their Bioactivity, Delivery and Combination Therapy. Plants (Basel) 2021;10:569. [PMID: 33802861 DOI: 10.3390/plants10030569] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
204 Pimienta M, Edderkaoui M, Wang R, Pandol S. The Potential for Circulating Tumor Cells in Pancreatic Cancer Management. Front Physiol 2017;8:381. [PMID: 28626429 DOI: 10.3389/fphys.2017.00381] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
205 Nabavizadeh A, Payen T, Iuga AC, Sagalovskiy IR, Desrouilleres D, Saharkhiz N, Palermo CF, Sastra SA, Oberstein PE, Rosario V, Kluger MD, Schrope BA, Chabot JA, Olive KP, Konofagou EE. Noninvasive Young's modulus visualization of fibrosis progression and delineation of pancreatic ductal adenocarcinoma (PDAC) tumors using Harmonic Motion Elastography (HME) in vivo. Theranostics 2020;10:4614-26. [PMID: 32292518 DOI: 10.7150/thno.37965] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
206 Meng H, Nel AE. Use of nano engineered approaches to overcome the stromal barrier in pancreatic cancer. Adv Drug Deliv Rev 2018;130:50-7. [PMID: 29958925 DOI: 10.1016/j.addr.2018.06.014] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 13.3] [Reference Citation Analysis]
207 Chung MJ, Kang H, Kim HG, Hyun JJ, Lee JK, Lee KH, Noh MH, Kang DH, Lee SH, Bang S, Pancreatobiliary Cancer Study Group of Korean Society of Gastrointestinal Cancer. Multicenter phase II trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer. World J Gastrointest Oncol 2018; 10(12): 505-515 [PMID: 30595804 DOI: 10.4251/wjgo.v10.i12.505] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 10] [Article Influence: 5.3] [Reference Citation Analysis]
208 Ozaki T, Yu M, Yin D, Sun D, Zhu Y, Bu Y, Sang M. Impact of RUNX2 on drug-resistant human pancreatic cancer cells with p53 mutations. BMC Cancer 2018;18:309. [PMID: 29558908 DOI: 10.1186/s12885-018-4217-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
209 Mikulic D, Mrzljak A. Borderline resectable pancreatic cancer and vascular resections in the era of neoadjuvant therapy. World J Clin Cases 2021; 9(20): 5398-5407 [PMID: 34307593 DOI: 10.12998/wjcc.v9.i20.5398] [Reference Citation Analysis]
210 Gillson J, Ramaswamy Y, Singh G, Gorfe AA, Pavlakis N, Samra J, Mittal A, Sahni S. Small Molecule KRAS Inhibitors: The Future for Targeted Pancreatic Cancer Therapy? Cancers (Basel). 2020;12. [PMID: 32456277 DOI: 10.3390/cancers12051341] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
211 Taniuchi K, Yawata T, Tsuboi M, Ueba T, Saibara T. Efficient delivery of small interfering RNAs targeting particular mRNAs into pancreatic cancer cells inhibits invasiveness and metastasis of pancreatic tumors. Oncotarget 2019;10:2869-86. [PMID: 31080558 DOI: 10.18632/oncotarget.26880] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
212 Bittoni A, Santoni M, Lanese A, Pellei C, Andrikou K, Stefano C. Neoadjuvant therapy in pancreatic cancer: an emerging strategy. Gastroenterol Res Pract 2014;2014:183852. [PMID: 25101123 DOI: 10.1155/2014/183852] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
213 Court CM, Ankeny JS, Sho S, Winograd P, Hou S, Song M, Wainberg ZA, Girgis MD, Graeber TG, Agopian VG, Tseng HR, Tomlinson JS. Circulating Tumor Cells Predict Occult Metastatic Disease and Prognosis in Pancreatic Cancer. Ann Surg Oncol. 2018;25:1000-1008. [PMID: 29442211 DOI: 10.1245/s10434-017-6290-8] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 12.7] [Reference Citation Analysis]
214 Lonardo E, Cioffi M, Sancho P, Crusz S, Heeschen C. Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies. J Vis Exp 2015;:e52801. [PMID: 26132091 DOI: 10.3791/52801] [Cited by in Crossref: 5] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
215 Ueno M, Nagashima F, Ueno H, Ikeda M, Ohkawa S, Mizuno N, Ioka T, Omuro Y, Nakajima TE, Furuse J. Phase I/II Study: Experience with the Late Onset of Acute Pancreatitis after the Start of Chemotherapy with Gemcitabine Plus nab-Paclitaxel for Metastatic Pancreatic Cancer. Intern Med 2019;58:2957-62. [PMID: 31243233 DOI: 10.2169/internalmedicine.2362-18] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
216 Gong J, Muñoz AR, Pingali S, Payton-Stewart F, Chan DE, Freeman JW, Ghosh R, Kumar AP. Downregulation of STAT3/NF-κB potentiates gemcitabine activity in pancreatic cancer cells. Mol Carcinog 2017;56:402-11. [PMID: 27208550 DOI: 10.1002/mc.22503] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
217 Babiker HM, Karass M, Recio-Boiles A, Chandana SR, McBride A, Mahadevan D. Everolimus for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC). Expert Opin Investig Drugs 2019;28:583-92. [PMID: 31215251 DOI: 10.1080/13543784.2019.1632289] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
218 Chen K, Qian W, Jiang Z, Cheng L, Li J, Sun L, Zhou C, Gao L, Lei M, Yan B, Cao J, Duan W, Ma Q. Metformin suppresses cancer initiation and progression in genetic mouse models of pancreatic cancer. Mol Cancer 2017;16:131. [PMID: 28738823 DOI: 10.1186/s12943-017-0701-0] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 11.5] [Reference Citation Analysis]
219 Ueda A, Sakai N, Yoshitomi H, Furukawa K, Takayashiki T, Kuboki S, Takano S, Suzuki D, Kagawa S, Mishima T, Nakadai E, Miyazaki M, Ohtsuka M. Is hepatic artery coil embolization useful in distal pancreatectomy with en bloc celiac axis resection for locally advanced pancreatic cancer? World J Surg Oncol 2019;17:124. [PMID: 31315628 DOI: 10.1186/s12957-019-1667-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
220 Pant S, Martin LK, Geyer S, Wei L, Van Loon K, Sommovilla N, Zalupski M, Iyer R, Fogelman D, Ko AH. Treatment-related Hypertension as a Pharmacodynamic Biomarker for the Efficacy of Bevacizumab in Advanced Pancreas Cancer: A Pooled Analysis of 4 Prospective Trials of Gemcitabine-based Therapy With Bevacizumab. Am J Clin Oncol. 2014;Epub ahead of print. [PMID: 25068471 DOI: 10.1097/coc.0000000000000108] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
221 Muranaka T, Kuwatani M, Komatsu Y, Sawada K, Nakatsumi H, Kawamoto Y, Yuki S, Kubota Y, Kubo K, Kawahata S. Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer. J Gastrointest Oncol. 2017;8:566-571. [PMID: 28736643 DOI: 10.21037/jgo.2017.02.02] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 9.0] [Reference Citation Analysis]
222 Liu X, Jiang J, Meng H. Transcytosis - An effective targeting strategy that is complementary to "EPR effect" for pancreatic cancer nano drug delivery. Theranostics 2019;9:8018-25. [PMID: 31754378 DOI: 10.7150/thno.38587] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 17.0] [Reference Citation Analysis]
223 Patel H, Okamura R, Fanta P, Patel C, Lanman RB, Raymond VM, Kato S, Kurzrock R. Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer. J Hematol Oncol. 2019;12:130. [PMID: 31801585 DOI: 10.1186/s13045-019-0824-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 10.0] [Reference Citation Analysis]
224 Woods N, Trevino J, Coppola D, Chellappan S, Yang S, Padmanabhan J. Fendiline inhibits proliferation and invasion of pancreatic cancer cells by interfering with ADAM10 activation and β-catenin signaling. Oncotarget 2015;6:35931-48. [PMID: 26440150 DOI: 10.18632/oncotarget.5933] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 4.6] [Reference Citation Analysis]
225 Whatcott CJ, Han H, Von Hoff DD. Orchestrating the Tumor Microenvironment to Improve Survival for Patients With Pancreatic Cancer: Normalization, Not Destruction. Cancer J. 2015;21:299-306. [PMID: 26222082 DOI: 10.1097/ppo.0000000000000140] [Cited by in Crossref: 45] [Cited by in F6Publishing: 33] [Article Influence: 9.0] [Reference Citation Analysis]
226 Isherwood J, Arshad A, Chung WY, Runau F, Cooke J, Pollard C, Howells L, Fishwick J, Thompson J, Metcalfe M, Steward W, Dennison A. Myeloid derived suppressor cells are reduced and T regulatory cells stabilised in patients with advanced pancreatic cancer treated with gemcitabine and intravenous omega 3. Ann Transl Med 2020;8:172. [PMID: 32309319 DOI: 10.21037/atm.2020.02.02] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
227 Veenstra VL, Damhofer H, Waasdorp C, van Rijssen LB, van de Vijver MJ, Dijk F, Wilmink HW, Besselink MG, Busch OR, Chang DK, Bailey PJ, Biankin AV, Kocher HM, Medema JP, Li JS, Jiang R, Pierce DW, van Laarhoven HWM, Bijlsma MF. ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy. Oncogenesis 2018;7:87. [PMID: 30442938 DOI: 10.1038/s41389-018-0096-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
228 Nie D, Lai G, An G, Wu Z, Lei S, Li J, Cao J. Individualized Prediction of Survival Benefits of Pancreatectomy Plus Chemotherapy in Patients With Simultaneous Metastatic Pancreatic Cancer. Front Oncol 2021;11:719253. [PMID: 34604055 DOI: 10.3389/fonc.2021.719253] [Reference Citation Analysis]
229 Poh AR, Ernst M. Tumor-Associated Macrophages in Pancreatic Ductal Adenocarcinoma: Therapeutic Opportunities and Clinical Challenges. Cancers (Basel) 2021;13:2860. [PMID: 34201127 DOI: 10.3390/cancers13122860] [Reference Citation Analysis]
230 Xu X, Zong K, Wang X, Dou D, Lv P, Zhang Z, Li H. miR-30d suppresses proliferation and invasiveness of pancreatic cancer by targeting the SOX4/PI3K-AKT axis and predicts poor outcome. Cell Death Dis 2021;12:350. [PMID: 33824274 DOI: 10.1038/s41419-021-03576-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
231 Sultan M, Nearing JT, Brown JM, Huynh TT, Cruickshank BM, Lamoureaux E, Vidovic D, Dahn ML, Fernando W, Coyle KM, Giacomantonio CA, Langille MGI, Marcato P. An in vivo genome-wide shRNA screen identifies BCL6 as a targetable biomarker of paclitaxel resistance in breast cancer. Mol Oncol 2021;15:2046-64. [PMID: 33932086 DOI: 10.1002/1878-0261.12964] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
232 Hua J, Shi S, Liang D, Liang C, Meng Q, Zhang B, Ni Q, Xu J, Yu X. Current status and dilemma of second-line treatment in advanced pancreatic cancer: is there a silver lining? Onco Targets Ther 2018;11:4591-608. [PMID: 30122951 DOI: 10.2147/OTT.S166405] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
233 Ormanns S, Siveke JT, Heinemann V, Haas M, Sipos B, Schlitter AM, Esposito I, Jung A, Laubender RP, Kruger S, Vehling-Kaiser U, Winkelmann C, Fischer von Weikersthal L, Clemens MR, Gauler TC, Märten A, Geissler M, Greten TF, Kirchner T, Boeck S. pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104. BMC Cancer 2014;14:624. [PMID: 25164437 DOI: 10.1186/1471-2407-14-624] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
234 Smigiel JM, Parameswaran N, Jackson MW. Targeting Pancreatic Cancer Cell Plasticity: The Latest in Therapeutics. Cancers (Basel) 2018;10:E14. [PMID: 29320425 DOI: 10.3390/cancers10010014] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
235 De Jesus-Acosta A, Laheru D, Maitra A, Arcaroli J, Rudek MA, Dasari A, Blatchford PJ, Quackenbush K, Messersmith W. A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma. Invest New Drugs. 2014;32:739-745. [PMID: 24668033 DOI: 10.1007/s10637-014-0083-8] [Cited by in Crossref: 70] [Cited by in F6Publishing: 65] [Article Influence: 10.0] [Reference Citation Analysis]
236 Pandey V, Storz P. Targeting the tumor microenvironment in pancreatic ductal adenocarcinoma. Expert Rev Anticancer Ther 2019;19:473-82. [PMID: 31148495 DOI: 10.1080/14737140.2019.1622417] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
237 Sahin IH, Geyer AI, Kelly DW, O'Reilly EM. Gemcitabine-Related Pneumonitis in Pancreas Adenocarcinoma--An Infrequent Event: Elucidation of Risk Factors and Management Implications. Clin Colorectal Cancer 2016;15:24-31. [PMID: 26395520 DOI: 10.1016/j.clcc.2015.08.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
238 Goodwin A, Pak K, Sanchez J, Laczek J, Matulonis R. Signet Ring Cell Carcinoma of the Ampulla of Vater Presenting With Bone Marrow Carcinomatosis. ACG Case Rep J 2021;8:e00592. [PMID: 34079841 DOI: 10.14309/crj.0000000000000592] [Reference Citation Analysis]
239 Glassman DC, Palmaira RL, Covington CM, Desai AM, Ku GY, Li J, Harding JJ, Varghese AM, O'Reilly EM, Yu KH. Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience. BMC Cancer 2018;18:693. [PMID: 29945562 DOI: 10.1186/s12885-018-4605-1] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 8.7] [Reference Citation Analysis]
240 Padhi P, Narula A, Balog A, Christou A. Use of molecular studies for treatment of metastatic pleomorphic large cell pancreatic cancers-a novel strategy. J Gastrointest Oncol 2016;7:E17-21. [PMID: 27034802 DOI: 10.3978/j.issn.2078-6891.2015.118] [Reference Citation Analysis]
241 Polireddy K, Chen Q. Cancer of the Pancreas: Molecular Pathways and Current Advancement in Treatment. J Cancer 2016;7:1497-514. [PMID: 27471566 DOI: 10.7150/jca.14922] [Cited by in Crossref: 35] [Cited by in F6Publishing: 41] [Article Influence: 7.0] [Reference Citation Analysis]
242 Ostapoff KT, Gabriel E, Attwood K, Kuvshinoff BW, Nurkin SJ, Hochwald SN. Does adjuvant therapy improve overall survival for stage IA/B pancreatic adenocarcinoma? HPB (Oxford) 2017;19:587-94. [PMID: 28433254 DOI: 10.1016/j.hpb.2017.03.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
243 Kim TH, Lee WJ, Woo SM, Oh ES, Youn SH, Jang HY, Han SS, Park SJ, Suh YG, Moon SH, Kim SS, Kim DY. Efficacy and feasibility of proton beam radiotherapy using the simultaneous integrated boost technique for locally advanced pancreatic cancer. Sci Rep 2020;10:21712. [PMID: 33303947 DOI: 10.1038/s41598-020-78875-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
244 Hayasaki A, Isaji S, Kishiwada M, Fujii T, Iizawa Y, Kato H, Tanemura A, Murata Y, Azumi Y, Kuriyama N, Mizuno S, Usui M, Sakurai H. Survival Analysis in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Chemoradiotherapy Followed by Surgery According to the International Consensus on the 2017 Definition of Borderline Resectable Cancer. Cancers (Basel) 2018;10:E65. [PMID: 29510561 DOI: 10.3390/cancers10030065] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
245 Nelson SR, Walsh N. Genetic Alterations Featuring Biological Models to Tailor Clinical Management of Pancreatic Cancer Patients. Cancers (Basel) 2020;12:E1233. [PMID: 32423157 DOI: 10.3390/cancers12051233] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
246 Ghosn M, Ibrahim T, Assi T, El Rassy E, Kourie HR, Kattan J. Dilemma of first line regimens in metastatic pancreatic adenocarcinoma. World J Gastroenterol 2016; 22(46): 10124-10130 [PMID: 28028360 DOI: 10.3748/wjg.v22.i46.10124] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
247 Mirlekar B, Michaud D, Searcy R, Greene K, Pylayeva-Gupta Y. IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer. Cancer Immunol Res 2018;6:1014-24. [PMID: 29980536 DOI: 10.1158/2326-6066.CIR-17-0710] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 7.3] [Reference Citation Analysis]
248 Salem AF, Gambini L, Udompholkul P, Baggio C, Pellecchia M. Therapeutic Targeting of Pancreatic Cancer via EphA2 Dimeric Agonistic Agents. Pharmaceuticals (Basel) 2020;13:E90. [PMID: 32397624 DOI: 10.3390/ph13050090] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
249 Chauhan N, Kruse A, Newby H, Jaggi M, Yallapu MM, Chauhan SC. Pluronic Polymer-Based Ormeloxifene Nanoformulations Induce Superior Anticancer Effects in Pancreatic Cancer Cells. ACS Omega 2020;5:1147-56. [PMID: 31984272 DOI: 10.1021/acsomega.9b03382] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
250 Yamamoto KN, Nakamura A, Liu LL, Stein S, Tramontano AC, Kartoun U, Shimizu T, Inoue Y, Asakuma M, Haeno H, Kong CY, Uchiyama K, Gonen M, Hur C, Michor F. Computational modeling of pancreatic cancer patients receiving FOLFIRINOX and gemcitabine-based therapies identifies optimum intervention strategies. PLoS One 2019;14:e0215409. [PMID: 31026288 DOI: 10.1371/journal.pone.0215409] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
251 Gao S, Zhu X, Shi X, Cao K, Bian Y, Jiang H, Wang K, Guo S, Zhang H, Jin G. Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: study protocol of a prospective, randomized phase II trial (BRPCNCC-1). Radiat Oncol 2019;14:52. [PMID: 30917842 DOI: 10.1186/s13014-019-1254-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
252 毛永欢, 喻春钊. 胰腺癌多学科综合治疗的现状及困境. 世界华人消化杂志 2015; 23(36): 5750-5759 [DOI: 10.11569/wcjd.v23.i36.5750] [Reference Citation Analysis]
253 Manzur A, Oluwasanmi A, Moss D, Curtis A, Hoskins C. Nanotechnologies in Pancreatic Cancer Therapy. Pharmaceutics 2017;9:E39. [PMID: 28946666 DOI: 10.3390/pharmaceutics9040039] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
254 Desbuissons G, Izzedine H, Bardier A, Dubreuil O, Vaillant JC, Frochot V, Mercadal L. Oxalate nephropathy is a major cause of kidney injury in surgically treated pancreatic adenocarcinoma patients. Clin Kidney J 2019;12:821-8. [PMID: 31807294 DOI: 10.1093/ckj/sfz015] [Reference Citation Analysis]
255 Kleeff J, Stöß C, Yip V, Knoefel WT. [Resection for advanced pancreatic cancer following multimodal therapy]. Chirurg 2016;87:406-12. [PMID: 27138271 DOI: 10.1007/s00104-016-0184-3] [Reference Citation Analysis]
256 Dallos MC, Eisenberger AB, Bates SE. Prevention of Venous Thromboembolism in Pancreatic Cancer: Breaking Down a Complex Clinical Dilemma. Oncologist 2020;25:132-9. [PMID: 32043768 DOI: 10.1634/theoncologist.2019-0264] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
257 Perri G, Prakash LR, Katz MHG. Response to Preoperative Therapy in Localized Pancreatic Cancer. Front Oncol 2020;10:516. [PMID: 32351893 DOI: 10.3389/fonc.2020.00516] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
258 Chiramel J, Backen AC, Pihlak R, Lamarca A, Frizziero M, Tariq NU, Hubner RA, Valle JW, Amir E, McNamara MG. Targeting the Epidermal Growth Factor Receptor in Addition to Chemotherapy in Patients with Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis. Int J Mol Sci 2017;18:E909. [PMID: 28445400 DOI: 10.3390/ijms18050909] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
259 Pishvaian MJ, Joseph Bender R, Matrisian LM, Rahib L, Hendifar A, Hoos WA, Mikhail S, Chung V, Picozzi V, Heartwell C. A pilot study evaluating concordance between blood-based and patient-matched tumor molecular testing within pancreatic cancer patients participating in the Know Your Tumor (KYT) initiative. Oncotarget. 2016;8:83446-83456. [PMID: 29137355 DOI: 10.18632/oncotarget.13225] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 7.6] [Reference Citation Analysis]
260 Kieler M, Unseld M, Bianconi D, Scheithauer W, Prager GW. A real-world analysis of second-line treatment options in pancreatic cancer: liposomal-irinotecan plus 5-fluorouracil and folinic acid. Ther Adv Med Oncol. 2019;11:1758835919853196. [PMID: 31360237 DOI: 10.1177/1758835919853196] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
261 Conway JR, Herrmann D, Evans TJ, Morton JP, Timpson P. Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine. Gut 2019;68:742-58. [PMID: 30396902 DOI: 10.1136/gutjnl-2018-316822] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
262 Martín AJ, Alfonso PG, Rupérez AB, Jiménez MM. Nab-paclitaxel plus gemcitabine as first-line palliative chemotherapy in a patient with metastatic pancreatic cancer with Eastern Cooperative Oncology Group performance status of 2. Oncol Lett 2016;12:727-30. [PMID: 27347207 DOI: 10.3892/ol.2016.4667] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
263 Costa Neves M, Giakoustidis A, Stamp G, Gaya A, Mudan S. Extended Survival after Complete Pathological Response in Metastatic Pancreatic Ductal Adenocarcinoma Following Induction Chemotherapy, Chemoradiotherapy, and a Novel Immunotherapy Agent, IMM-101. Cureus 2015;7:e435. [PMID: 26870619 DOI: 10.7759/cureus.435] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
264 Di Franco G, Usai A, Funel N, Palmeri M, Montesanti IER, Bianchini M, Gianardi D, Furbetta N, Guadagni S, Vasile E, Falcone A, Pollina LE, Raffa V, Morelli L. Use of zebrafish embryos as avatar of patients with pancreatic cancer: A new xenotransplantation model towards personalized medicine. World J Gastroenterol 2020; 26(21): 2792-2809 [PMID: 32550755 DOI: 10.3748/wjg.v26.i21.2792] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
265 Sorber R, Teper Y, Abisoye-Ogunniyan A, Waterfall JJ, Davis S, Killian JK, Pineda M, Ray S, McCord MR, Pflicke H, Burkett SS, Meltzer PS, Rudloff U. Whole Genome Sequencing of Newly Established Pancreatic Cancer Lines Identifies Novel Somatic Mutation (c.2587G>A) in Axon Guidance Receptor Plexin A1 as Enhancer of Proliferation and Invasion. PLoS One 2016;11:e0149833. [PMID: 26962861 DOI: 10.1371/journal.pone.0149833] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
266 Wang B, Fan P, Zhao J, Wu H, Jin X, Wu H. FBP1 loss contributes to BET inhibitors resistance by undermining c-Myc expression in pancreatic ductal adenocarcinoma. J Exp Clin Cancer Res 2018;37:224. [PMID: 30201002 DOI: 10.1186/s13046-018-0888-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
267 Jia Y, Gu D, Wan J, Yu B, Zhang X, Chiorean EG, Wang Y, Xie J. The role of GLI-SOX2 signaling axis for gemcitabine resistance in pancreatic cancer. Oncogene 2019;38:1764-77. [PMID: 30382189 DOI: 10.1038/s41388-018-0553-0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 8.0] [Reference Citation Analysis]
268 Cardin DB, Goff LW, Chan E, Whisenant JG, Dan Ayers G, Takebe N, Arlinghaus LR, Yankeelov TE, Berlin J, Merchant N. Dual Src and EGFR inhibition in combination with gemcitabine in advanced pancreatic cancer: phase I results : A phase I clinical trial. Invest New Drugs 2018;36:442-50. [PMID: 28990119 DOI: 10.1007/s10637-017-0519-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
269 Hassanzadeh C, Rudra S, Bommireddy A, Hawkins WG, Wang-Gillam A, Fields RC, Cai B, Park J, Green O, Roach M, Henke L, Kim H. Ablative Five-Fraction Stereotactic Body Radiation Therapy for Inoperable Pancreatic Cancer Using Online MR-Guided Adaptation. Adv Radiat Oncol 2021;6:100506. [PMID: 33665480 DOI: 10.1016/j.adro.2020.06.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
270 Chen Y, Gu J, Yin M, Wang C, Chen D, Yang L, Chen X, Lin Z, Du J, Cui S, Ma C, Luo H. Safety and efficacy of S1 monotherapy or combined with nab-paclitaxel in advanced elderly pancreatic cancer patients: A meta-analysis. Medicine (Baltimore) 2021;100:e26342. [PMID: 34160399 DOI: 10.1097/MD.0000000000026342] [Reference Citation Analysis]
271 Corty RW, Langworthy BW, Fine JP, Buse JB, Sanoff HK, Lund JL. Antibacterial Use Is Associated with an Increased Risk of Hematologic and Gastrointestinal Adverse Events in Patients Treated with Gemcitabine for Stage IV Pancreatic Cancer. Oncologist 2020;25:579-84. [PMID: 32181968 DOI: 10.1634/theoncologist.2019-0570] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
272 Li Y, Li X, Tip P, Zhang L. Use of a novel herbal medicine in a 75-year-old woman with multi-metastatic pancreatic cancer: A case report and review of the literature. Oncol Lett 2015;10:263-7. [PMID: 26171011 DOI: 10.3892/ol.2015.3237] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
273 Alvarez R, Musteanu M, Garcia-Garcia E, Lopez-Casas PP, Megias D, Guerra C, Muñoz M, Quijano Y, Cubillo A, Rodriguez-Pascual J, Plaza C, de Vicente E, Prados S, Tabernero S, Barbacid M, Lopez-Rios F, Hidalgo M. Reply: 'Comments on Stromal disrupting effects of nab-paclitaxel in pancreatic cancer'. Br J Cancer 2014;111:1677-8. [PMID: 24642623 DOI: 10.1038/bjc.2014.129] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
274 Khan MA, Srivastava SK, Zubair H, Patel GK, Arora S, Khushman M, Carter JE, Gorman GS, Singh S, Singh AP. Co-targeting of CXCR4 and hedgehog pathways disrupts tumor-stromal crosstalk and improves chemotherapeutic efficacy in pancreatic cancer. J Biol Chem 2020;295:8413-24. [PMID: 32358063 DOI: 10.1074/jbc.RA119.011748] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 11.0] [Reference Citation Analysis]
275 Huang PW, Chang CF, Hung CY, Hsueh SW, Chang PH, Yeh KY, Chen JS, Chen YY, Lu CH, Hung YS, Chou WC. Validation and application of a prognostic model for patients with advanced pancreatic cancer receiving palliative chemotherapy. Cancer Med 2019;8:5554-63. [PMID: 31385456 DOI: 10.1002/cam4.2483] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
276 Chiorean EG, Cheung WY, Giordano G, Kim G, Al-Batran SE. Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in advanced pancreatic cancer: a systematic review. Ther Adv Med Oncol. 2019;11:1758835919850367. [PMID: 31205510 DOI: 10.1177/1758835919850367] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 9.5] [Reference Citation Analysis]
277 Cartwright TH, Parisi M, Espirito JL, Wilson TW, Pelletier C, Patel M, Babiker HM. Clinical Outcomes with First-Line Chemotherapy in a Large Retrospective Study of Patients with Metastatic Pancreatic Cancer Treated in a US Community Oncology Setting. Drugs Real World Outcomes 2018;5:149-59. [PMID: 29946913 DOI: 10.1007/s40801-018-0137-x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 7.3] [Reference Citation Analysis]
278 Kruger S, Schirle K, Haas M, Crispin A, Schirra J, Mayerle J, D'Haese JG, Kunz WG, Ricke J, Ormanns S, Kirchner T, Kobold S, Ilmer M, Gebauer L, Westphalen CB, von Bergwelt-Baildon M, Werner J, Heinemann V, Boeck S. Prolonged time to treatment initiation in advanced pancreatic cancer patients has no major effect on treatment outcome: a retrospective cohort study controlled for lead time bias and waiting time paradox. J Cancer Res Clin Oncol 2020;146:391-9. [PMID: 31642961 DOI: 10.1007/s00432-019-03061-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
279 Scheithauer W, Kornek G, Prager G, Stranzl N, Laengle F, Schindl M, Friedl J, Klech J, Roethlin S, Zielinski C. Phase II trial of capecitabine plus nab-paclitaxel in patients with metastatic pancreatic adenocarcinoma. J Gastrointest Oncol. 2016;7:234-238. [PMID: 27034791 DOI: 10.3978/j.issn.2078-6891.2015.107] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
280 Das S, Berlin J, Cardin D. Harnessing the Immune System in Pancreatic Cancer. Curr Treat Options Oncol 2018;19:48. [PMID: 30128712 DOI: 10.1007/s11864-018-0566-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
281 Martin-Perez E, Domínguez-Muñoz JE, Botella-Romero F, Cerezo L, Matute Teresa F, Serrano T, Vera R. Multidisciplinary consensus statement on the clinical management of patients with pancreatic cancer. Clin Transl Oncol 2020;22:1963-75. [PMID: 32318964 DOI: 10.1007/s12094-020-02350-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
282 Crippa S, Cirocchi R, Weiss MJ, Partelli S, Reni M, Wolfgang CL, Hackert T, Falconi M. A systematic review of surgical resection of liver-only synchronous metastases from pancreatic cancer in the era of multiagent chemotherapy. Updates Surg 2020;72:39-45. [PMID: 31997233 DOI: 10.1007/s13304-020-00710-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
283 Peng C, Xu B, Xiao J, Zhou C, Li X, Shi H, Qiang W, Wang T, Zhao J, Liu F, Li G, Li H, Chen C, Shi L. Hepatic Artery Infusion of Floxuridine in Combination With Systemic Chemotherapy for Pancreatic Cancer Liver Metastasis: A Propensity Score-Matched Analysis in Two Centers. Front Oncol 2021;11:652426. [PMID: 33996572 DOI: 10.3389/fonc.2021.652426] [Reference Citation Analysis]
284 Krepline AN, Bliss L, Geurts J, Akinola I, Christians KK, George B, Ritch PS, Hall WA, Erickson BA, Evans DB, Tsai S. Role of Molecular Profiling of Pancreatic Cancer After Neoadjuvant Therapy: Does it Change Practice? J Gastrointest Surg 2020;24:235-42. [DOI: 10.1007/s11605-019-04423-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
285 Brar G, Blais EM, Joseph Bender R, Brody JR, Sohal D, Madhavan S, Picozzi VJ, Hendifar AE, Chung VM, Halverson D, Mikhail S, Matrisian LM, Rahib L, Petricoin E, Pishvaian MJ. Multi-omic molecular comparison of primary versus metastatic pancreatic tumours. Br J Cancer 2019;121:264-70. [PMID: 31292535 DOI: 10.1038/s41416-019-0507-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
286 Liu S, Qin Z, Xu J, Zeng J, Chen J, Niu L, Xu M. Irreversible electroporation combined with chemotherapy for unresectable pancreatic carcinoma: a prospective cohort study. Onco Targets Ther. 2019;12:1341-1350. [PMID: 30863100 DOI: 10.2147/ott.s186721] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
287 Coveler AL, Ko AH, Catenacci DV, Von Hoff D, Becerra C, Whiting NC, Yang J, Wolpin B. A phase 1 clinical trial of ASG-5ME, a novel drug-antibody conjugate targeting SLC44A4, in patients with advanced pancreatic and gastric cancers. Invest New Drugs 2016;34:319-28. [PMID: 26994014 DOI: 10.1007/s10637-016-0343-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
288 Burtness B, Powell M, Catalano P, Berlin J, Liles DK, Chapman AE, Mitchell E, Benson AB. Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study. Am J Clin Oncol 2016;39:340-5. [PMID: 24685886 DOI: 10.1097/COC.0000000000000068] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 3.8] [Reference Citation Analysis]
289 Froeling FEM, Casolino R, Pea A, Biankin AV, Chang DK. Molecular Subtyping and Precision Medicine for Pancreatic Cancer. J Clin Med 2021;10:E149. [PMID: 33406790 DOI: 10.3390/jcm10010149] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
290 El-Behaedi S, Landsman R, Rudloff M, Kolyvas E, Albalawy R, Zhang X, Bera T, Collins K, Kozlov S, Alewine C. Protein Synthesis Inhibition Activity of Mesothelin Targeting Immunotoxin LMB-100 Decreases Concentrations of Oncogenic Signaling Molecules and Secreted Growth Factors. Toxins (Basel) 2018;10:E447. [PMID: 30384408 DOI: 10.3390/toxins10110447] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
291 Wong CH, Li YJ, Chen YC. Therapeutic potential of targeting acinar cell reprogramming in pancreatic cancer. World J Gastroenterol 2016; 22(31): 7046-7057 [PMID: 27610015 DOI: 10.3748/wjg.v22.i31.7046] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
292 Vera R, Dotor E, Feliu J, González E, Laquente B, Macarulla T, Martínez E, Maurel J, Salgado M, Manzano JL. SEOM Clinical Guideline for the treatment of pancreatic cancer (2016). Clin Transl Oncol 2016;18:1172-8. [PMID: 27896637 DOI: 10.1007/s12094-016-1586-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
293 Sinn M, Bahra M, Denecke T, Travis S, Pelzer U, Riess H. Perioperative treatment options in resectable pancreatic cancer - how to improve long-term survival. World J Gastrointest Oncol 2016; 8(3): 248-257 [PMID: 26989460 DOI: 10.4251/wjgo.v8.i3.248] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
294 Du J, Gu J, Li J. Mechanisms of drug resistance of pancreatic ductal adenocarcinoma at different levels. Biosci Rep 2020;40:BSR20200401. [PMID: 32677676 DOI: 10.1042/BSR20200401] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
295 Wu AA, Bever KM, Ho WJ, Fertig EJ, Niu N, Zheng L, Parkinson RM, Durham JN, Onners B, Ferguson AK, Wilt C, Ko AH, Wang-Gillam A, Laheru DA, Anders RA, Thompson ED, Sugar EA, Jaffee EM, Le DT. A Phase II Study of Allogeneic GM-CSF-Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer. Clin Cancer Res. 2020;26:5129-5139. [PMID: 32591464 DOI: 10.1158/1078-0432.ccr-20-1025] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 13.0] [Reference Citation Analysis]
296 Cui J, Yang H, Liu J, Chen D, Hu J, Zhang H, Wang Y, Han T, Mao T, Jiao F, Biskup E, Pan Y, Liu M, Wang L. A phase I study of the safety and activity of K-001 in patients with advanced pancreatic ductal adenocarcinoma. BMC Cancer 2021;21:672. [PMID: 34098895 DOI: 10.1186/s12885-021-08375-6] [Reference Citation Analysis]
297 Yoon KA, Woo SM, Kim YH, Kong SY, Lee MK, Han SS, Kim TH, Lee WJ, Park SJ. Comprehensive Cancer Panel Sequencing Defines Genetic Diversity and Changes in the Mutational Characteristics of Pancreatic Cancer Patients Receiving Neoadjuvant Treatment. Gut Liver. 2019;. [PMID: 30970447 DOI: 10.5009/gnl18355] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
298 Hao J, Yang X, Ding XL, Guo LM, Zhu CH, Ji W, Zhou T, Wu XZ. Paeoniflorin Potentiates the Inhibitory Effects of Erlotinib in Pancreatic Cancer Cell Lines by Reducing ErbB3 Phosphorylation. Sci Rep 2016;6:32809. [PMID: 27609096 DOI: 10.1038/srep32809] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
299 Tiriac H, Plenker D, Baker LA, Tuveson DA. Organoid models for translational pancreatic cancer research. Curr Opin Genet Dev 2019;54:7-11. [PMID: 30844513 DOI: 10.1016/j.gde.2019.02.003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 11.5] [Reference Citation Analysis]
300 Sasaki Y, Hamada K, Kaneta T, Takahashi T, Kubota Y, Ishida H, Ichikawa W. Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer? Cancer Sci 2015;106:1100. [PMID: 26268893 DOI: 10.1111/cas.12708] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
301 Perez VM, Kearney JF, Yeh JJ. The PDAC Extracellular Matrix: A Review of the ECM Protein Composition, Tumor Cell Interaction, and Therapeutic Strategies. Front Oncol 2021;11:751311. [PMID: 34692532 DOI: 10.3389/fonc.2021.751311] [Reference Citation Analysis]
302 Bazou D, Maimon N, Gruionu G, Grahovac J, Seano G, Liu H, Evans CL, Munn LL. Vascular beds maintain pancreatic tumour explants for ex vivo drug screening. J Tissue Eng Regen Med 2018;12:e318-22. [PMID: 28568605 DOI: 10.1002/term.2481] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
303 Akhoundova Sanoyan D, Reiner CS, Papageorgiou P, Siebenhüner AR. Sequential Treatment of Metastatic Adenocarcinoma of the Pancreatic Duct with Liver Metastasis Following the NAPOLI-1 Study Protocol with nal-Irinotecan plus 5-FU in the Second Line. Case Rep Oncol 2020;13:79-84. [PMID: 32110224 DOI: 10.1159/000504471] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
304 Aprile G, Rihawi K, De Carlo E, Sonis ST. Treatment-related gastrointestinal toxicities and advanced colorectal or pancreatic cancer: A critical update. World J Gastroenterol 2015; 21(41): 11793-11803 [PMID: 26557003 DOI: 10.3748/wjg.v21.i41.11793] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
305 Miyasaka Y, Ohtsuka T, Eguchi S, Inomata M, Nishihara K, Shinchi H, Okuda K, Baba H, Nagano H, Ueki T, Noshiro H, Nakamura M; Kyushu study group of treatment for pancreatobiliary cancer. Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel Regimen for Borderline Resectable Pancreatic Cancer with Arterial Involvement: A Prospective Multicenter Single-Arm Phase II Study Protocol. Int J Surg Protoc 2021;25:55-60. [PMID: 34013145 DOI: 10.29337/ijsp.142] [Reference Citation Analysis]
306 Wu Y, Feng J, Hu W, Luo Q. A randomized placebo-controlled clinical study of <i>nab</i>-paclitaxel as second-line chemotherapy for patients with advanced non-small cell lung cancer in China. Biosci Rep. 2017;37. [PMID: 28356484 DOI: 10.1042/bsr20170020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
307 Luo D, Digiovanni MG, Wei R, Lacomb JF, Williams JL, Rigas B, Mackenzie GG. Phospho-valproic acid (MDC-1112) reduces pancreatic cancer growth in patient-derived tumor xenografts and KPC mice: enhanced efficacy when combined with gemcitabine. Carcinogenesis 2020;41:927-39. [PMID: 31584613 DOI: 10.1093/carcin/bgz170] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
308 Zhang X, Detering L, Sultan D, Luehmann H, Li L, Heo GS, Zhang X, Lou L, Grierson PM, Greco S, Ruzinova M, Laforest R, Dehdashti F, Lim KH, Liu Y. CC Chemokine Receptor 2-Targeting Copper Nanoparticles for Positron Emission Tomography-Guided Delivery of Gemcitabine for Pancreatic Ductal Adenocarcinoma. ACS Nano 2021;15:1186-98. [PMID: 33406361 DOI: 10.1021/acsnano.0c08185] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
309 Schneitler S, Kröpil P, Riemer J, Antoch G, Knoefel WT, Häussinger D, Graf D. Metastasized pancreatic carcinoma with neoadjuvant FOLFIRINOX therapy and R0 resection. World J Gastroenterol 2015; 21(20): 6384-6390 [PMID: 26034375 DOI: 10.3748/wjg.v21.i20.6384] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
310 Sen S, Kato S, Agarwal R, Piha-Paul S, Hess K, Karp D, Janku F, Fu S, Naing A, Pant S, Falchook G, Tang C, Wu X, Ye Y, Tsimberidou A, Subbiah V, Kurzrock R, Byers L, Westin S, Lim J, Bean S, Bass A, Nguyen L, Meric-Bernstam F, Hong D. Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers. Br J Cancer 2018;118:1419-24. [PMID: 29695765 DOI: 10.1038/s41416-018-0068-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
311 Sohal DP, Mangu PB, Khorana AA, Shah MA, Philip PA, O'Reilly EM, Uronis HE, Ramanathan RK, Crane CH, Engebretson A, Ruggiero JT, Copur MS, Lau M, Urba S, Laheru D. Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34:2784-2796. [PMID: 27247222 DOI: 10.1200/jco.2016.67.1412] [Cited by in Crossref: 166] [Cited by in F6Publishing: 90] [Article Influence: 33.2] [Reference Citation Analysis]
312 Zhong J, Patel K, Switchenko J, Cassidy RJ, Hall WA, Gillespie T, Patel PR, Kooby D, Landry J. Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radiation. Cancer. 2017;123:3486-3493. [PMID: 28493288 DOI: 10.1002/cncr.30706] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 12.5] [Reference Citation Analysis]
313 Hruban RH, Klimstra DS. Adenocarcinoma of the pancreas. Semin Diagn Pathol 2014;31:443-51. [PMID: 25441308 DOI: 10.1053/j.semdp.2014.08.004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
314 Hue JJ, Bingmer K, Sugumar K, Markt SC, Rothermel LD, Hardacre JM, Ammori JB, Winter JM, Ocuin LM. Immunotherapy Is Associated with a Survival Benefit in Patients Receiving Chemotherapy for Metastatic Pancreatic Cancer. J Pancreat Cancer 2021;7:31-8. [PMID: 33937617 DOI: 10.1089/pancan.2021.0003] [Reference Citation Analysis]
315 Gayral M, Lulka H, Hanoun N, Biollay C, Sèlves J, Vignolle-Vidoni A, Berthommé H, Trempat P, Epstein AL, Buscail L, Béjot JL, Cordelier P. Targeted oncolytic herpes simplex virus type 1 eradicates experimental pancreatic tumors. Hum Gene Ther 2015;26:104-13. [PMID: 25423447 DOI: 10.1089/hum.2014.072] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
316 Pelzer U, Sinn M, Stieler J, Riess H. [Multimodal treatment of pancreatic cancer]. Internist (Berl). 2014;55:31-36. [PMID: 24399472 DOI: 10.1007/s00108-013-3316-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
317 Chiorean EG, Von Hoff D, Wan Y, Margunato-Debay S, Botteman M, Goldstein D. Performance status dynamics during treatment with nab-paclitaxel plus gemcitabine versus gemcitabine alone for metastatic pancreatic cancer. Cancer Manag Res 2018;10:1389-96. [PMID: 29910636 DOI: 10.2147/CMAR.S163475] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
318 Kang S, Lee S, Park S. iRGD Peptide as a Tumor-Penetrating Enhancer for Tumor-Targeted Drug Delivery. Polymers (Basel) 2020;12:E1906. [PMID: 32847045 DOI: 10.3390/polym12091906] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
319 Timmer FEF, Geboers B, Nieuwenhuizen S, Schouten EAC, Dijkstra M, de Vries JJJ, van den Tol MP, Meijerink MR, Scheffer HJ. Locoregional Treatment of Metastatic Pancreatic Cancer Utilizing Resection, Ablation and Embolization: A Systematic Review. Cancers (Basel) 2021;13:1608. [PMID: 33807220 DOI: 10.3390/cancers13071608] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
320 Yoneda A, Minomi K, Tamura Y. Heat shock protein 47 confers chemoresistance on pancreatic cancer cells by interacting with calreticulin and IRE1α. Cancer Sci 2021;112:2803-20. [PMID: 34109710 DOI: 10.1111/cas.14976] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
321 Parkin A, Man J, Chou A, Nagrial AM, Samra J, Gill AJ, Timpson P, Pajic M. The Evolving Understanding of the Molecular and Therapeutic Landscape of Pancreatic Ductal Adenocarcinoma. Diseases 2018;6:E103. [PMID: 30428574 DOI: 10.3390/diseases6040103] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
322 Haj Mohammad N, Bernards N, Besselink MG, Busch OR, Wilmink JW, Creemers GJ, De Hingh IH, Lemmens VE, van Laarhoven HW. Volume matters in the systemic treatment of metastatic pancreatic cancer: a population-based study in the Netherlands. J Cancer Res Clin Oncol 2016;142:1353-60. [PMID: 26995276 DOI: 10.1007/s00432-016-2140-5] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 5.4] [Reference Citation Analysis]
323 Kyrochristos ID, Glantzounis GK, Ziogas DE, Gizas I, Schizas D, Lykoudis EG, Felekouras E, Machairas A, Katsios C, Liakakos T, Cho WC, Roukos DH. From Clinical Standards to Translating Next-Generation Sequencing Research into Patient Care Improvement for Hepatobiliary and Pancreatic Cancers. Int J Mol Sci 2017;18:E180. [PMID: 28106782 DOI: 10.3390/ijms18010180] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
324 Wu AA, Jaffee E, Lee V. Current Status of Immunotherapies for Treating Pancreatic Cancer. Curr Oncol Rep 2019;21:60. [PMID: 31101991 DOI: 10.1007/s11912-019-0811-5] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 11.5] [Reference Citation Analysis]
325 Nelson BS, Lin L, Kremer DM, Sousa CM, Cotta-Ramusino C, Myers A, Ramos J, Gao T, Kovalenko I, Wilder-Romans K, Dresser J, Davis M, Lee HJ, Nwosu ZC, Campit S, Mashadova O, Nicolay BN, Tolstyka ZP, Halbrook CJ, Chandrasekaran S, Asara JM, Crawford HC, Cantley LC, Kimmelman AC, Wahl DR, Lyssiotis CA. Tissue of origin dictates GOT1 dependence and confers synthetic lethality to radiotherapy. Cancer Metab 2020;8:1. [PMID: 31908776 DOI: 10.1186/s40170-019-0202-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 12.0] [Reference Citation Analysis]
326 Braghiroli MI, de Celis Ferrari AC, Pfiffer TE, Alex AK, Nebuloni D, Carneiro AS, Caparelli F, Senna L, Lobo J, Hoff PM, Riechelmann RP. Phase II trial of metformin and paclitaxel for patients with gemcitabine-refractory advanced adenocarcinoma of the pancreas. Ecancermedicalscience. 2015;9:563. [PMID: 26316884 DOI: 10.3332/ecancer.2015.563] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 4.3] [Reference Citation Analysis]
327 Borazanci E, Pishvaian MJ, Nemunaitis J, Weekes C, Huang J, Rajakumaraswamy N. A Phase Ib Study of Single-Agent Idelalisib Followed by Idelalisib in Combination with Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Oncologist 2020;25:e1604-13. [PMID: 32356383 DOI: 10.1634/theoncologist.2020-0321] [Reference Citation Analysis]
328 Javadrashid D, Baghbanzadeh A, Derakhshani A, Leone P, Silvestris N, Racanelli V, Solimando AG, Baradaran B. Pancreatic Cancer Signaling Pathways, Genetic Alterations, and Tumor Microenvironment: The Barriers Affecting the Method of Treatment. Biomedicines 2021;9:373. [PMID: 33918146 DOI: 10.3390/biomedicines9040373] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
329 Roth MT, Cardin DB, Berlin JD. Recent advances in the treatment of pancreatic cancer. F1000Res. 2020;9. [PMID: 32148767 DOI: 10.12688/f1000research.21981.1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
330 Nakai Y, Chang KJ. EUS-guided fine-needle injection for pancreatic cancer: back to the future. Gastrointest Endosc 2020;92:1053-4. [PMID: 33160487 DOI: 10.1016/j.gie.2020.06.025] [Reference Citation Analysis]
331 Furuse J. Paradigm Shifting of Systemic Chemotherapy for Unresectable Pancreatic Cancer in Japan. J Clin Med 2019;8:E1170. [PMID: 31382681 DOI: 10.3390/jcm8081170] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
332 Haller SD, Monaco ML, Essani K. The Present Status of Immuno-Oncolytic Viruses in the Treatment of Pancreatic Cancer. Viruses. 2020;12. [PMID: 33213031 DOI: 10.3390/v12111318] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
333 Chllamma MK, Cook N, Dhani NC, Giby K, Dodd A, Wang L, Hedley DW, Moore MJ, Knox JJ. FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience. Br J Cancer. 2016;115:649-654. [PMID: 27467054 DOI: 10.1038/bjc.2016.222] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
334 Di Marco M, Grassi E, Durante S, Vecchiarelli S, Palloni A, Macchini M, Casadei R, Ricci C, Panzacchi R, Santini D, Biasco G. State of the art biological therapies in pancreatic cancer. World J Gastrointest Oncol 2016; 8(1): 55-66 [PMID: 26798437 DOI: 10.4251/wjgo.v8.i1.55] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
335 Ramanathan RK, Weiss GJ, Posner RG, Rajeshkumar NV, Jameson G, Aziz M, Hoering A, Bolejack V, Maitra A, Fulk M, Stites EC, Hlavacek WS, Gatalica Z, Xiu J, Hidalgo M, Von Hoff DD, Barrett MT. A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients. J Gastrointest Oncol 2017;8:925-35. [PMID: 29299351 DOI: 10.21037/jgo.2017.09.05] [Reference Citation Analysis]
336 Tao Z, Muzumdar MD, Detappe A, Huang X, Xu ES, Yu Y, Mouhieddine TH, Song H, Jacks T, Ghoroghchian PP. Differences in Nanoparticle Uptake in Transplanted and Autochthonous Models of Pancreatic Cancer. Nano Lett 2018;18:2195-208. [PMID: 29533667 DOI: 10.1021/acs.nanolett.7b04043] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
337 Roger E, Gout J, Arnold F, Beutel AK, Müller M, Abaei A, Barth TFE, Rasche V, Seufferlein T, Perkhofer L, Kleger A. Maintenance Therapy for ATM-Deficient Pancreatic Cancer by Multiple DNA Damage Response Interferences after Platinum-Based Chemotherapy. Cells 2020;9:E2110. [PMID: 32948057 DOI: 10.3390/cells9092110] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
338 Guo F, Li J, Qi Y, Hou J, Chen H, Jiang SW. HE4 overexpression decreases pancreatic cancer Capan-1 cell sensitivity to paclitaxel via cell cycle regulation. Cancer Cell Int 2020;20:163. [PMID: 32435154 DOI: 10.1186/s12935-020-01248-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
339 Boone BA, Bahary N, Zureikat AH, Moser AJ, Normolle DP, Wu WC, Singhi AD, Bao P, Bartlett DL, Liotta LA, Espina V, Loughran P, Lotze MT, Zeh HJ. Safety and Biologic Response of Pre-operative Autophagy Inhibition in Combination with Gemcitabine in Patients with Pancreatic Adenocarcinoma. Ann Surg Oncol. 2015;22:4402-4410. [PMID: 25905586 DOI: 10.1245/s10434-015-4566-4] [Cited by in Crossref: 108] [Cited by in F6Publishing: 104] [Article Influence: 18.0] [Reference Citation Analysis]
340 Brunetto E, De Monte L, Balzano G, Camisa B, Laino V, Riba M, Heltai S, Bianchi M, Bordignon C, Falconi M, Bondanza A, Doglioni C, Protti MP. The IL-1/IL-1 receptor axis and tumor cell released inflammasome adaptor ASC are key regulators of TSLP secretion by cancer associated fibroblasts in pancreatic cancer. J Immunother Cancer 2019;7:45. [PMID: 30760333 DOI: 10.1186/s40425-019-0521-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 10.0] [Reference Citation Analysis]
341 Kandimalla R, Tomihara H, Banwait JK, Yamamura K, Singh G, Baba H, Goel A. A 15-Gene Immune, Stromal, and Proliferation Gene Signature that Significantly Associates with Poor Survival in Patients with Pancreatic Ductal Adenocarcinoma. Clin Cancer Res 2020;26:3641-8. [PMID: 32234757 DOI: 10.1158/1078-0432.CCR-19-4044] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
342 Park SJ, Kim H, Shin K, Lee MA, Hong TH. Oral chemotherapy for second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer. World J Gastrointest Oncol 2019; 11(11): 1021-1030 [PMID: 31798782 DOI: 10.4251/wjgo.v11.i11.1021] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
343 Tramontano AC, Chen Y, Watson TR, Eckel A, Sheehan DF, Peters MLB, Pandharipande PV, Hur C, Kong CY. Pancreatic cancer treatment costs, including patient liability, by phase of care and treatment modality, 2000-2013. Medicine (Baltimore) 2019;98:e18082. [PMID: 31804317 DOI: 10.1097/MD.0000000000018082] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
344 Sunami Y, Böker V, Kleeff J. Targeting and Reprograming Cancer-Associated Fibroblasts and the Tumor Microenvironment in Pancreatic Cancer. Cancers (Basel) 2021;13:697. [PMID: 33572223 DOI: 10.3390/cancers13040697] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
345 Moik F, van Es N, Posch F, Di Nisio M, Fuereder T, Preusser M, Pabinger I, Ay C. Gemcitabine and Platinum-Based Agents for the Prediction of Cancer-Associated Venous Thromboembolism: Results from the Vienna Cancer and Thrombosis Study. Cancers (Basel) 2020;12:E2493. [PMID: 32899157 DOI: 10.3390/cancers12092493] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
346 Nigri J, Gironella M, Bressy C, Vila-Navarro E, Roques J, Lac S, Bontemps C, Kozaczyk C, Cros J, Pietrasz D, Maréchal R, Van Laethem JL, Iovanna J, Bachet JB, Folch-Puy E, Tomasini R. PAP/REG3A favors perineural invasion in pancreatic adenocarcinoma and serves as a prognostic marker. Cell Mol Life Sci 2017;74:4231-43. [PMID: 28656348 DOI: 10.1007/s00018-017-2579-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
347 Beglyarova N, Banina E, Zhou Y, Mukhamadeeva R, Andrianov G, Bobrov E, Lysenko E, Skobeleva N, Gabitova L, Restifo D, Pressman M, Serebriiskii IG, Hoffman JP, Paz K, Behrens D, Khazak V, Jablonski SA, Golemis EA, Weiner LM, Astsaturov I. Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3-MYC Interactions as a Target in Pancreatic Cancer. Clin Cancer Res 2016;22:6153-63. [PMID: 27384421 DOI: 10.1158/1078-0432.CCR-16-0149] [Cited by in Crossref: 39] [Cited by in F6Publishing: 21] [Article Influence: 7.8] [Reference Citation Analysis]
348 Ghosn M, Kourie HR, Tabchi S. Gastrointestinal cancers in the era of theranostics: Updates and future perspectives. World J Gastroenterol 2015; 21(28): 8473-8477 [PMID: 26229391 DOI: 10.3748/wjg.v21.i28.8473] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
349 Kokkinos J, Sharbeen G, Haghighi KS, Ignacio RMC, Kopecky C, Gonzales-Aloy E, Youkhana J, Timpson P, Pereira BA, Ritchie S, Pandzic E, Boyer C, Davis TP, Butler LM, Goldstein D, McCarroll JA, Phillips PA. Ex vivo culture of intact human patient derived pancreatic tumour tissue. Sci Rep 2021;11:1944. [PMID: 33479301 DOI: 10.1038/s41598-021-81299-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
350 McCormick KA, Coveler AL, Rossi GR, Vahanian NN, Link C, Chiorean EG. Pancreatic cancer: Update on immunotherapies and algenpantucel-L. Hum Vaccin Immunother 2016;12:563-75. [PMID: 26619245 DOI: 10.1080/21645515.2015.1093264] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
351 Polireddy K, Dong R, Reed G, Yu J, Chen P, Williamson S, Violet PC, Pessetto Z, Godwin AK, Fan F, Levine M, Drisko JA, Chen Q. High Dose Parenteral Ascorbate Inhibited Pancreatic Cancer Growth and Metastasis: Mechanisms and a Phase I/IIa study. Sci Rep 2017;7:17188. [PMID: 29215048 DOI: 10.1038/s41598-017-17568-8] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 11.8] [Reference Citation Analysis]
352 Hagiwara Y, Yamada S, Isozaki Y, Takiyama H, Shinoto M, Kawashiro S, Bhattacharyya T, Nemoto K, Tsuji H. Efficacy and feasibility of re-irradiation using carbon ions for pancreatic cancer that recurs after carbon-ion radiotherapy. Clin Transl Radiat Oncol 2021;26:24-9. [PMID: 33294643 DOI: 10.1016/j.ctro.2020.10.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
353 Karamouzis MV, Athanasiadis I, Samelis G, Vallilas C, Bokas A, Nikolaidi A, Dimitriadou A, Sarantis P, Pistamaltzian N, Schizas D, Papalampros A, Felekouras E, Dimitroulis D, Antoniou E, Sotiropoulos G, Papakotoulas P. The Impact of Thromboprophylaxis on the Survival of Patients with Advanced Pancreatic Cancer. The Pancreatic Cancer and Tinzaparin (PaCT) Study. Cancers (Basel) 2021;13:2884. [PMID: 34207591 DOI: 10.3390/cancers13122884] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
354 Chen N, Brachmann C, Liu X, Pierce DW, Dey J, Kerwin WS, Li Y, Zhou S, Hou S, Carleton M. Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration. Cancer Chemother Pharmacol. 2015;76:699-712. [PMID: 26231955 DOI: 10.1007/s00280-015-2833-5] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 8.5] [Reference Citation Analysis]
355 Janky R, Binda MM, Allemeersch J, Van den Broeck A, Govaere O, Swinnen JV, Roskams T, Aerts S, Topal B. Prognostic relevance of molecular subtypes and master regulators in pancreatic ductal adenocarcinoma. BMC Cancer 2016;16:632. [PMID: 27520560 DOI: 10.1186/s12885-016-2540-6] [Cited by in Crossref: 58] [Cited by in F6Publishing: 55] [Article Influence: 11.6] [Reference Citation Analysis]
356 Yu KH, Ricigliano M, McCarthy B, Chou JF, Capanu M, Cooper B, Bartlett A, Covington C, Lowery MA, O'Reilly EM. Circulating Tumor and Invasive Cell Gene Expression Profile Predicts Treatment Response and Survival in Pancreatic Adenocarcinoma. Cancers (Basel) 2018;10:E467. [PMID: 30477242 DOI: 10.3390/cancers10120467] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
357 Heestand GM, Kurzrock R. Molecular landscape of pancreatic cancer: implications for current clinical trials. Oncotarget 2015;6:4553-61. [PMID: 25714017 DOI: 10.18632/oncotarget.2972] [Cited by in Crossref: 51] [Cited by in F6Publishing: 50] [Article Influence: 10.2] [Reference Citation Analysis]
358 Heinrich S, Lang H. Neoadjuvant Therapy of Pancreatic Cancer: Definitions and Benefits. Int J Mol Sci 2017;18:E1622. [PMID: 28933761 DOI: 10.3390/ijms18081622] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 6.8] [Reference Citation Analysis]
359 Han B, Kim BJ, Kim HS, Choi DR, Shim BY, Lee KH, Kim JW, Kim JH, Song H, Kim JH, Park CK, Lee JW, Kim MJ, Zang DY. A phase II study of gemcitabine, erlotinib and S-1 in patients with advanced pancreatic cancer. J Cancer 2021;12:912-7. [PMID: 33403047 DOI: 10.7150/jca.50514] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
360 White MN, Dotan E, Catalano PJ, Cardin DB, Berlin JD. Advanced pancreatic cancer clinical trials: The continued underrepresentation of older patients. J Geriatr Oncol 2019;10:540-6. [PMID: 30573201 DOI: 10.1016/j.jgo.2018.11.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
361 Pan CH, Otsuka Y, Sridharan B, Woo M, Leiton CV, Babu S, Torrente Gonçalves M, Kawalerski RR, K Bai JD, Chang DK, Biankin AV, Scampavia L, Spicer T, Escobar-Hoyos LF, Shroyer KR. An unbiased high-throughput drug screen reveals a potential therapeutic vulnerability in the most lethal molecular subtype of pancreatic cancer. Mol Oncol 2020;14:1800-16. [PMID: 32533886 DOI: 10.1002/1878-0261.12743] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
362 Brody JR, Dixon DA. Complex HuR function in pancreatic cancer cells. Wiley Interdiscip Rev RNA 2018;9:e1469. [PMID: 29452455 DOI: 10.1002/wrna.1469] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
363 Gu D, Lin H, Zhang X, Fan Q, Chen S, Shahda S, Liu Y, Sun J, Xie J. Simultaneous Inhibition of MEK and Hh Signaling Reduces Pancreatic Cancer Metastasis. Cancers (Basel) 2018;10:E403. [PMID: 30373214 DOI: 10.3390/cancers10110403] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
364 Madamsetty VS, Pal K, Dutta SK, Wang E, Mukhopadhyay D. Targeted Dual Intervention-Oriented Drug-Encapsulated (DIODE) Nanoformulations for Improved Treatment of Pancreatic Cancer. Cancers (Basel) 2020;12:E1189. [PMID: 32397114 DOI: 10.3390/cancers12051189] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
365 Kolyvas E, Rudloff M, Poruchynsky M, Landsman R, Hollevoet K, Venzon D, Alewine C. Mesothelin-targeted immunotoxin RG7787 has synergistic anti-tumor activity when combined with taxanes. Oncotarget 2017;8:9189-99. [PMID: 27999204 DOI: 10.18632/oncotarget.13984] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
366 De Vlieghere E, Verset L, Demetter P, Bracke M, De Wever O. Cancer-associated fibroblasts as target and tool in cancer therapeutics and diagnostics. Virchows Arch. 2015;467:367-382. [PMID: 26259962 DOI: 10.1007/s00428-015-1818-4] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 4.7] [Reference Citation Analysis]
367 Catalano M, Conca R, Petrioli R, Ramello M, Roviello G. FOLFOX vs FOLFIRI as Second-line of Therapy After Progression to Gemcitabine/Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer. Cancer Manag Res. 2020;12:10271-10278. [PMID: 33116881 DOI: 10.2147/cmar.s267393] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
368 Maggino L, Malleo G, Marchegiani G, Viviani E, Nessi C, Ciprani D, Esposito A, Landoni L, Casetti L, Tuveri M, Paiella S, Casciani F, Sereni E, Binco A, Bonamini D, Secchettin E, Auriemma A, Merz V, Simionato F, Zecchetto C, D'Onofrio M, Melisi D, Bassi C, Salvia R. Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma. JAMA Surg 2019;154:932-42. [PMID: 31339530 DOI: 10.1001/jamasurg.2019.2277] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 36.0] [Reference Citation Analysis]
369 Sahin IH, Elias H, Chou JF, Capanu M, O'Reilly EM. Pancreatic adenocarcinoma: insights into patterns of recurrence and disease behavior. BMC Cancer 2018;18:769. [PMID: 30055578 DOI: 10.1186/s12885-018-4679-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
370 Porter CE, Waddell JA, Solimando DA Jr. nab-Paclitaxel Plus Gemcitabine Regimen for Pancreatic Cancer. Hosp Pharm 2014;49:18-22. [PMID: 24421558 DOI: 10.1310/hpj4901-18] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
371 Ahmad G, Mackenzie GG, Egan J, Amiji MM. DHA-SBT-1214 Taxoid Nanoemulsion and Anti-PD-L1 Antibody Combination Therapy Enhances Antitumor Efficacy in a Syngeneic Pancreatic Adenocarcinoma Model. Mol Cancer Ther 2019;18:1961-72. [PMID: 31439714 DOI: 10.1158/1535-7163.MCT-18-1046] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
372 Mavros MN, Coburn NG, Davis LE, Mahar AL, Liu Y, Beyfuss K, Myrehaug S, Earle CC, Hallet J. Low rates of specialized cancer consultation and cancer-directed therapy for noncurable pancreatic adenocarcinoma: a population-based analysis. CMAJ 2019;191:E574-80. [PMID: 31133604 DOI: 10.1503/cmaj.190211] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
373 Bauer TM, Patel MR, Forero-Torres A, George TJ Jr, Assad A, Du Y, Hurwitz H. A Phase Ib study of ruxolitinib + gemcitabine ± nab-paclitaxel in patients with advanced solid tumors. Onco Targets Ther 2018;11:2399-407. [PMID: 29750040 DOI: 10.2147/OTT.S157331] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
374 Ko AH, LoConte N, Tempero MA, Walker EJ, Kate Kelley R, Lewis S, Chang WC, Kantoff E, Vannier MW, Catenacci DV, Venook AP, Kindler HL. A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. Pancreas. 2016;45:370-375. [PMID: 26390428 DOI: 10.1097/mpa.0000000000000458] [Cited by in Crossref: 103] [Cited by in F6Publishing: 71] [Article Influence: 20.6] [Reference Citation Analysis]
375 Bobrov E, Skobeleva N, Restifo D, Beglyarova N, Cai KQ, Handorf E, Campbell K, Proia DA, Khazak V, Golemis EA, Astsaturov I. Targeted delivery of chemotherapy using HSP90 inhibitor drug conjugates is highly active against pancreatic cancer models. Oncotarget 2017;8:4399-409. [PMID: 27779106 DOI: 10.18632/oncotarget.12642] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
376 Pham TND, Shields MA, Spaulding C, Principe DR, Li B, Underwood PW, Trevino JG, Bentrem DJ, Munshi HG. Preclinical Models of Pancreatic Ductal Adenocarcinoma and Their Utility in Immunotherapy Studies. Cancers (Basel) 2021;13:440. [PMID: 33503832 DOI: 10.3390/cancers13030440] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
377 Argentiero A, Calabrese A, Solimando AG, Notaristefano A, Panarelli MMG, Brunetti O. Bone metastasis as primary presentation of pancreatic ductal adenocarcinoma: A case report and literature review. Clin Case Rep 2019;7:1972-6. [PMID: 31624620 DOI: 10.1002/ccr3.2412] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
378 Awasthi N, Scire E, Monahan S, Grojean M, Zhang E, Schwarz MA, Schwarz RE. Augmentation of response to nab-paclitaxel by inhibition of insulin-like growth factor (IGF) signaling in preclinical pancreatic cancer models. Oncotarget. 2016;7:46988-47001. [PMID: 27127884 DOI: 10.18632/oncotarget.9029] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
379 Meng H, Wang M, Liu H, Liu X, Situ A, Wu B, Ji Z, Chang CH, Nel AE. Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice. ACS Nano. 2015;9:3540-3557. [PMID: 25776964 DOI: 10.1021/acsnano.5b00510] [Cited by in Crossref: 254] [Cited by in F6Publishing: 231] [Article Influence: 42.3] [Reference Citation Analysis]
380 Dardare J, Witz A, Merlin JL, Bochnakian A, Toussaint P, Gilson P, Harlé A. Epithelial to Mesenchymal Transition in Patients with Pancreatic Ductal Adenocarcinoma: State-of-the-Art and Therapeutic Opportunities. Pharmaceuticals (Basel) 2021;14:740. [PMID: 34451837 DOI: 10.3390/ph14080740] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
381 Berger AK, Haag GM, Ehmann M, Byl A, Jäger D, Springfeld C. Palliative chemotherapy for pancreatic adenocarcinoma: a retrospective cohort analysis of efficacy and toxicity of the FOLFIRINOX regimen focusing on the older patient. BMC Gastroenterol 2017;17:143. [PMID: 29207968 DOI: 10.1186/s12876-017-0709-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
382 Neesse A, Krug S, Gress TM, Tuveson DA, Michl P. Emerging concepts in pancreatic cancer medicine: targeting the tumor stroma. Onco Targets Ther. 2013;7:33-43. [PMID: 24379681 DOI: 10.2147/ott.s38111] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 5.1] [Reference Citation Analysis]
383 Sheahan AV, Biankin AV, Parish CR, Khachigian LM. Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: a systematic review. Oncotarget 2018;9:21613-27. [PMID: 29765563 DOI: 10.18632/oncotarget.25085] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 8.7] [Reference Citation Analysis]
384 Yin ZZ, Zhao ZM, Tang WB, Jiang N, Zhang KD, Song YY, Wang Y, Li CG, Gao YX, Liu R. Adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for resected pancreatic ductal adenocarcinoma: A single center experience in China. World J Clin Cases 2020; 8(13): 2778-2786 [PMID: 32742988 DOI: 10.12998/wjcc.v8.i13.2778] [Reference Citation Analysis]
385 Singh RR, O'Reilly EM. New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma. Drugs 2020;80:647-69. [PMID: 32306207 DOI: 10.1007/s40265-020-01304-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 16.0] [Reference Citation Analysis]
386 Hajda J, Lehmann M, Krebs O, Kieser M, Geletneky K, Jäger D, Dahm M, Huber B, Schöning T, Sedlaczek O, Stenzinger A, Halama N, Daniel V, Leuchs B, Angelova A, Rommelaere J, Engeland CE, Springfeld C, Ungerechts G. A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer: ParvOryx02 protocol.BMC Cancer. 2017;17:576. [PMID: 28851316 DOI: 10.1186/s12885-017-3604-y] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
387 Awad S, Alkashash AM, Amin M, Baker SJ, Rose JB. Biochemical Predictors of Response to Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. Front Oncol 2020;10:620. [PMID: 32477933 DOI: 10.3389/fonc.2020.00620] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
388 Riechelmann RP, Peixoto RD, Fernandes GDS, Weschenfelder RF, Prolla G, Filho DR, Andrade AC, Crosara M, Rego JFM, Gansl RC, Coimbra F, Aguiar S Jr, Carvalho E, Hoff PM, Coutinho AK. Evidence-based recommendations for gastrointestinal cancers during the COVID-19 pandemic by the Brazilian Gastrointestinal Tumours Group. Ecancermedicalscience 2020;14:1048. [PMID: 32565901 DOI: 10.3332/ecancer.2020.1048] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
389 Chou A, Froio D, Nagrial AM, Parkin A, Murphy KJ, Chin VT, Wohl D, Steinmann A, Stark R, Drury A, Walters SN, Vennin C, Burgess A, Pinese M, Chantrill LA, Cowley MJ, Molloy TJ, Waddell N, Johns A, Grimmond SM, Chang DK, Biankin AV, Sansom OJ, Morton JP, Grey ST, Cox TR, Turchini J, Samra J, Clarke SJ, Timpson P, Gill AJ, Pajic M; Australian Pancreatic Cancer Genome Initiative (APGI). Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer. Gut 2018;67:2142-55. [PMID: 29080858 DOI: 10.1136/gutjnl-2017-315144] [Cited by in Crossref: 61] [Cited by in F6Publishing: 61] [Article Influence: 15.3] [Reference Citation Analysis]
390 Ormanns S, Haas M, Baechmann S, Altendorf-Hofmann A, Remold A, Quietzsch D, Clemens MR, Bentz M, Geissler M, Lambertz H, Kruger S, Kirchner T, Heinemann V, Boeck S. Impact of SPARC expression on outcome in patients with advanced pancreatic cancer not receiving nab-paclitaxel: a pooled analysis from prospective clinical and translational trials. Br J Cancer. 2016;115:1520-1529. [PMID: 27802454 DOI: 10.1038/bjc.2016.355] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
391 Pan P, Skaer C, Yu J, Zhao H, Ren H, Oshima K, Wang LS. Berries and other natural products in the pancreatic cancer chemoprevention in human clinical trials. J Berry Res 2017;7:147-61. [PMID: 29367867 DOI: 10.3233/JBR-170159] [Cited by in Crossref: 33] [Cited by in F6Publishing: 13] [Article Influence: 8.3] [Reference Citation Analysis]
392 Hegewisch-Becker S, Aldaoud A, Wolf T, Krammer-Steiner B, Linde H, Scheiner-Sparna R, Hamm D, Jänicke M, Marschner N; TPK-Group (Tumour Registry Pancreatic Cancer). Results from the prospective German TPK clinical cohort study: Treatment algorithms and survival of 1,174 patients with locally advanced, inoperable, or metastatic pancreatic ductal adenocarcinoma. Int J Cancer 2019;144:981-90. [PMID: 30006989 DOI: 10.1002/ijc.31751] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
393 Ahmad IM, Dafferner AJ, O'Connell KA, Mehla K, Britigan BE, Hollingsworth MA, Abdalla MY. Heme Oxygenase-1 Inhibition Potentiates the Effects of Nab-Paclitaxel-Gemcitabine and Modulates the Tumor Microenvironment in Pancreatic Ductal Adenocarcinoma. Cancers (Basel) 2021;13:2264. [PMID: 34066839 DOI: 10.3390/cancers13092264] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
394 Zhao L, Liu Y, Zhao F, Jin Y, Feng J, Geng R, Sun J, Kang L, Yu L, Wei Y. Inhibition of Cholesterol Esterification Enzyme Enhances the Potency of Human Chimeric Antigen Receptor T Cells against Pancreatic Carcinoma. Mol Ther Oncolytics 2020;16:262-71. [PMID: 32181327 DOI: 10.1016/j.omto.2020.01.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
395 Fru PN, Nweke EE, Mthimkhulu N, Mvango S, Nel M, Pilcher LA, Balogun M. Anti-Cancer and Immunomodulatory Activity of a Polyethylene Glycol-Betulinic Acid Conjugate on Pancreatic Cancer Cells. Life (Basel) 2021;11:462. [PMID: 34063891 DOI: 10.3390/life11060462] [Reference Citation Analysis]
396 Stotz M, Szkandera J, Seidel J, Stojakovic T, Samonigg H, Reitz D, Gary T, Kornprat P, Schaberl-Moser R, Hoefler G, Gerger A, Pichler M. Evaluation of uric acid as a prognostic blood-based marker in a large cohort of pancreatic cancer patients. PLoS One. 2014;9:e104730. [PMID: 25133546 DOI: 10.1371/journal.pone.0104730] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 4.1] [Reference Citation Analysis]
397 Gu M, Gao Y, Chang P. KRAS Mutation Dictates the Cancer Immune Environment in Pancreatic Ductal Adenocarcinoma and Other Adenocarcinomas. Cancers (Basel) 2021;13:2429. [PMID: 34069772 DOI: 10.3390/cancers13102429] [Reference Citation Analysis]
398 Moningi S, Abi Jaoude J, Kouzy R, Lin D, Nguyen ND, Garcia Garcia CJ, Phan JL, Avila S, Smani D, Cazacu IM, Singh BS, Smith GL, Holliday EB, Koay EJ, Das P, Bhutani MS, Herman JM, Minsky BD, Koong AC, Taniguchi CM. Impact of Fiducial Marker Placement Before Stereotactic Body Radiation Therapy on Clinical Outcomes in Patients With Pancreatic Cancer. Adv Radiat Oncol 2021;6:100621. [PMID: 33912734 DOI: 10.1016/j.adro.2020.11.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
399 Nakamura T, Katagiri T, Sato S, Kushibiki T, Hontani K, Tsuchikawa T, Hirano S, Nakamura Y. Overexpression of C16orf74 is involved in aggressive pancreatic cancers. Oncotarget 2017;8:50460-75. [PMID: 28881575 DOI: 10.18632/oncotarget.10912] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
400 Garrido-Laguna I, Tometich D, Hu N, Ying J, Geiersbach K, Whisenant J, Wang K, Ross JS, Sharma S. N of 1 case reports of exceptional responders accrued from pancreatic cancer patients enrolled in first-in-man studies from 2002 through 2012. Oncoscience 2015;2:285-93. [PMID: 25897431 DOI: 10.18632/oncoscience.141] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
401 Ma YT, Leonard SM, Gordon N, Anderton J, James C, Huen D, Woodman CB, Palmer DH. Use of a genome-wide haploid genetic screen to identify treatment predicting factors: a proof-of-principle study in pancreatic cancer. Oncotarget 2017;8:63635-45. [PMID: 28969017 DOI: 10.18632/oncotarget.18879] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
402 Leca J, Martinez S, Lac S, Nigri J, Secq V, Rubis M, Bressy C, Sergé A, Lavaut MN, Dusetti N, Loncle C, Roques J, Pietrasz D, Bousquet C, Garcia S, Granjeaud S, Ouaissi M, Bachet JB, Brun C, Iovanna JL, Zimmermann P, Vasseur S, Tomasini R. Cancer-associated fibroblast-derived annexin A6+ extracellular vesicles support pancreatic cancer aggressiveness. J Clin Invest 2016;126:4140-56. [PMID: 27701147 DOI: 10.1172/JCI87734] [Cited by in Crossref: 107] [Cited by in F6Publishing: 75] [Article Influence: 21.4] [Reference Citation Analysis]
403 Kao CT, Aziz M, Kasi A. Pathological complete response in pancreatic adenocarcinoma with FOLFIRINOX. BMJ Case Rep 2018;2018:bcr-2018-225621. [PMID: 30173133 DOI: 10.1136/bcr-2018-225621] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
404 Valero V 3rd, Saunders TJ, He J, Weiss MJ, Cameron JL, Dholakia A, Wild AT, Shin EJ, Khashab MA, O'Broin-Lennon AM, Ali SZ, Laheru D, Hruban RH, Iacobuzio-Donahue CA, Herman JM, Wolfgang CL. Reliable Detection of Somatic Mutations in Fine Needle Aspirates of Pancreatic Cancer With Next-generation Sequencing: Implications for Surgical Management. Ann Surg 2016;263:153-61. [PMID: 26020105 DOI: 10.1097/SLA.0000000000001156] [Cited by in Crossref: 32] [Cited by in F6Publishing: 16] [Article Influence: 6.4] [Reference Citation Analysis]
405 Das S, Shapiro B, Vucic EA, Vogt S, Bar-Sagi D. Tumor Cell-Derived IL1β Promotes Desmoplasia and Immune Suppression in Pancreatic Cancer. Cancer Res 2020;80:1088-101. [PMID: 31915130 DOI: 10.1158/0008-5472.CAN-19-2080] [Cited by in Crossref: 41] [Cited by in F6Publishing: 31] [Article Influence: 41.0] [Reference Citation Analysis]
406 Yu X, Di Y, Xie C, Song Y, He H, Li H, Pu X, Lu W, Fu D, Jin C. An in vitro and in vivo study of gemcitabine-loaded albumin nanoparticles in a pancreatic cancer cell line. Int J Nanomedicine 2015;10:6825-34. [PMID: 26586944 DOI: 10.2147/IJN.S93835] [Cited by in Crossref: 35] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
407 Au M, Emeto TI, Power J, Vangaveti VN, Lai HC. Emerging Therapeutic Potential of Nanoparticles in Pancreatic Cancer: A Systematic Review of Clinical Trials. Biomedicines 2016;4:E20. [PMID: 28536387 DOI: 10.3390/biomedicines4030020] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
408 Kang BW, Chau I. Emerging agents for metastatic pancreatic cancer: spotlight on early phase clinical trials. Expert Opin Investig Drugs 2021;:1-19. [PMID: 34727804 DOI: 10.1080/13543784.2021.1995354] [Reference Citation Analysis]
409 Bossé D, Ng T, Ahmad C, Alfakeeh A, Alruzug I, Biagi J, Brierley J, Chaudhury P, Cleary S, Colwell B, Cripps C, Dawson LA, Dorreen M, Ferland E, Galiatsatos P, Girard S, Gray S, Halwani F, Kopek N, Mahmud A, Martel G, Robillard L, Samson B, Seal M, Siddiqui J, Sideris L, Snow S, Thirwell M, Vickers M, Goodwin R, Goel R, Hsu T, Tsvetkova E, Ward B, Asmis T. Eastern Canadian Gastrointestinal Cancer Consensus Conference 2016. Curr Oncol 2016;23:e605-14. [PMID: 28050151 DOI: 10.3747/co.23.3394] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
410 Wang Z, Liu Y, Li R, Shang Y, Zhang Y, Zhao L, Li W, Yang Y, Zhang X, Yang T, Nie C, Han F, Luo S, Gao Q, Song Y. Autologous cytokine-induced killer cell transfusion increases overall survival in advanced pancreatic cancer. J Hematol Oncol. 2016;9:6. [PMID: 26842696 DOI: 10.1186/s13045-016-0237-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
411 Dohopolski MJ, Glaser SM, Vargo JA, Balasubramani GK, Beriwal S. Stereotactic body radiotherapy for locally-advanced unresectable pancreatic cancer-patterns of care and overall survival. J Gastrointest Oncol 2017;8:766-77. [PMID: 29184680 DOI: 10.21037/jgo.2017.08.04] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
412 Geerdes EE, Sideras K, Aziz MH, van Eijck CH, Bruno MJ, Sprengers D, Boor PPC, Kwekkeboom J. Cancer Cell B7-H3 Expression Is More Prevalent in the Pancreato-Biliary Subtype of Ampullary Cancer Than in Pancreatic Cancer. Front Oncol 2021;11:615691. [PMID: 33996541 DOI: 10.3389/fonc.2021.615691] [Reference Citation Analysis]
413 Zhu X, Shen X, Qu J, Straubinger RM, Jusko WJ. Proteomic Analysis of Combined Gemcitabine and Birinapant in Pancreatic Cancer Cells. Front Pharmacol 2018;9:84. [PMID: 29520231 DOI: 10.3389/fphar.2018.00084] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
414 Li Y, Sarkar FH. MicroRNA Targeted Therapeutic Approach for Pancreatic Cancer. Int J Biol Sci. 2016;12:326-337. [PMID: 26929739 DOI: 10.7150/ijbs.15017] [Cited by in Crossref: 43] [Cited by in F6Publishing: 48] [Article Influence: 8.6] [Reference Citation Analysis]
415 Malgerud L, Lindberg J, Wirta V, Gustafsson-Liljefors M, Karimi M, Moro CF, Stecker K, Picker A, Huelsewig C, Stein M, Bohnert R, Del Chiaro M, Haas SL, Heuchel RL, Permert J, Maeurer MJ, Brock S, Verbeke CS, Engstrand L, Jackson DB, Grönberg H, Löhr JM. Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer. Mol Oncol 2017;11:1413-29. [PMID: 28675654 DOI: 10.1002/1878-0261.12108] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
416 Principe DR, Narbutis M, Kumar S, Park A, Viswakarma N, Dorman MJ, Kamath SD, Grippo PJ, Fishel ML, Hwang RF, Thummuri D, Underwood PW, Munshi HG, Trevino JG, Rana A. Long-Term Gemcitabine Treatment Reshapes the Pancreatic Tumor Microenvironment and Sensitizes Murine Carcinoma to Combination Immunotherapy. Cancer Res 2020;80:3101-15. [PMID: 32238357 DOI: 10.1158/0008-5472.CAN-19-2959] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 26.0] [Reference Citation Analysis]
417 Krishnamoorthy M, Lenehan JG, Burton JP, Maleki Vareki S. Immunomodulation in Pancreatic Cancer. Cancers (Basel) 2020;12:E3340. [PMID: 33198059 DOI: 10.3390/cancers12113340] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
418 Wode K, Hök Nordberg J, Kienle GS, Elander NO, Bernhardson BM, Sunde B, Sharp L, Henriksson R, Fransson P. Efficacy of mistletoe extract as a complement to standard treatment in advanced pancreatic cancer: study protocol for a multicentre, parallel group, double-blind, randomised, placebo-controlled clinical trial (MISTRAL). Trials 2020;21:783. [PMID: 32917288 DOI: 10.1186/s13063-020-04581-y] [Reference Citation Analysis]
419 Li D, Mullinax JE, Aiken T, Xin H, Wiegand G, Anderson A, Thorgeirsson S, Avital I, Rudloff U. Loss of PDPK1 abrogates resistance to gemcitabine in label-retaining pancreatic cancer cells. BMC Cancer 2018;18:772. [PMID: 30064387 DOI: 10.1186/s12885-018-4690-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
420 Pratt M, Glassman SJ. Complete response of refractory mycosis fungoides to treatment of pancreatic cancer with combination gemcitabine and nab-paclitaxel: A possible new regimen for the treatment of advanced cutaneous T-cell lymphoma. JAAD Case Rep 2020;6:581-3. [PMID: 32685643 DOI: 10.1016/j.jdcr.2020.05.013] [Reference Citation Analysis]
421 Ferrara B, Pignatelli C, Cossutta M, Citro A, Courty J, Piemonti L. The Extracellular Matrix in Pancreatic Cancer: Description of a Complex Network and Promising Therapeutic Options. Cancers (Basel) 2021;13:4442. [PMID: 34503252 DOI: 10.3390/cancers13174442] [Reference Citation Analysis]
422 García-Reyes B, Kretz AL, Ruff JP, von Karstedt S, Hillenbrand A, Knippschild U, Henne-Bruns D, Lemke J. The Emerging Role of Cyclin-Dependent Kinases (CDKs) in Pancreatic Ductal Adenocarcinoma. Int J Mol Sci 2018;19:E3219. [PMID: 30340359 DOI: 10.3390/ijms19103219] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 6.7] [Reference Citation Analysis]
423 Oh D, Pyo JS, Son BK. Prognostic Roles of Inflammatory Markers in Pancreatic Cancer: Comparison between the Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio. Gastroenterol Res Pract 2018;2018:9745601. [PMID: 29977290 DOI: 10.1155/2018/9745601] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
424 Chiorean EG, Von Hoff DD, Tabernero J, El-Maraghi R, Wee Ma W, Reni M, Harris M, Whorf R, Liu H, Shiansong Li J, Manax V, Romano A, Lu B, Goldstein D. Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer. Br J Cancer. 2016;115:e13. [PMID: 27657342 DOI: 10.1038/bjc.2016.306] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
425 Digiacomo G, Volta F, Garajova I, Balsano R, Cavazzoni A. Biological Hallmarks and New Therapeutic Approaches for the Treatment of PDAC. Life (Basel) 2021;11:843. [PMID: 34440587 DOI: 10.3390/life11080843] [Reference Citation Analysis]
426 Michl P, Löhr M, Neoptolemos JP, Capurso G, Rebours V, Malats N, Ollivier M, Ricciardiello L. UEG position paper on pancreatic cancer. Bringing pancreatic cancer to the 21st century: Prevent, detect, and treat the disease earlier and better. United European Gastroenterol J 2021. [PMID: 34431604 DOI: 10.1002/ueg2.12123] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
427 Feisthammel J, Mössner J, Hoffmeister A. Palliative Endoscopic Treatment Options in Malignancies of the Biliopancreatic System. Viszeralmedizin 2014;30:238-43. [PMID: 26288596 DOI: 10.1159/000366145] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
428 Peretti U, Zanon S, Michele R. The personalized medicine for pancreatic ductal adenocarcinoma patients: The oncologist perspective. Endosc Ultrasound 2017;6:S66-8. [PMID: 29387692 DOI: 10.4103/eus.eus_62_17] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
429 Miller AL, Garcia PL, Gamblin TL, Vance RB, Yoon KJ. Development of gemcitabine-resistant patient-derived xenograft models of pancreatic ductal adenocarcinoma. Cancer Drug Resist 2020;3:572-85. [PMID: 33073205 DOI: 10.20517/cdr.2020.35] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
430 Shaib WL, Zakka K, Shahin AA, Yared F, Switchenko JM, Wu C, Akce M, Alese OB, Patel PR, Mcdonald M, El-Rayes BF. Radiation as a Single-Modality Treatment in Localized Pancreatic Cancer. Pancreas 2020;49:822-9. [PMID: 32541638 DOI: 10.1097/MPA.0000000000001584] [Reference Citation Analysis]
431 Jin L, Shi N, Ruan S, Hou B, Zou Y, Zou X, Jin H, Jian Z. The role of intraoperative radiation therapy in resectable pancreatic cancer: a systematic review and meta-analysis. Radiat Oncol 2020;15:76. [PMID: 32272945 DOI: 10.1186/s13014-020-01511-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
432 Yamada D, Kobayashi S, Takahashi H, Akita H, Yamada T, Asaoka T, Shimizu J, Takeda Y, Yokoyama S, Tsujie M, Tomokuni A, Tanemura M, Morimoto O, Murakami M, Kim Y, Nakahira S, Hama N, Sugimoto K, Hashimoto K, Doki Y, Eguchi H. Randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine and nanoparticle albumin-bound paclitaxel combination therapy as neoadjuvant chemotherapy for resectable/borderline resectable pancreatic ductal adenocarcinoma (PDAC-GS/GA-rP2, CSGO-HBP-015). Trials 2021;22:568. [PMID: 34446057 DOI: 10.1186/s13063-021-05541-w] [Reference Citation Analysis]
433 Joglekar S, Asghar A, Mott SL, Johnson BE, Button AM, Clark E, Mezhir JJ. Sarcopenia is an independent predictor of complications following pancreatectomy for adenocarcinoma. J Surg Oncol. 2015;111:771-775. [PMID: 25556324 DOI: 10.1002/jso.23862] [Cited by in Crossref: 155] [Cited by in F6Publishing: 136] [Article Influence: 22.1] [Reference Citation Analysis]
434 Kitayama H, Tsuji Y, Kondo T, Sugiyama J, Hirayama M, Yamamoto K, Kawarada Y, Oyamada Y, Hirano S. Conversion therapy for pancreatic cancer with peritoneal metastases using intravenous and intraperitoneal paclitaxel with S-1. Mol Clin Oncol 2016;5:779-82. [PMID: 28105356 DOI: 10.3892/mco.2016.1051] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
435 Abdel Hadi N, Reyes-Castellanos G, Carrier A. Targeting Redox Metabolism in Pancreatic Cancer. Int J Mol Sci 2021;22:1534. [PMID: 33546421 DOI: 10.3390/ijms22041534] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
436 Beatty GL, Shahda S, Beck T, Uppal N, Cohen SJ, Donehower R, Gabayan AE, Assad A, Switzky J, Zhen H, Von Hoff DD. A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus nab-Paclitaxel and Gemcitabine in Advanced Solid Tumors. Oncologist 2019;24:14-e10. [PMID: 30115734 DOI: 10.1634/theoncologist.2017-0665] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
437 Morrison AH, Byrne KT, Vonderheide RH. Immunotherapy and Prevention of Pancreatic Cancer. Trends Cancer 2018;4:418-28. [PMID: 29860986 DOI: 10.1016/j.trecan.2018.04.001] [Cited by in Crossref: 81] [Cited by in F6Publishing: 83] [Article Influence: 27.0] [Reference Citation Analysis]
438 Ohkawa S, Okusaka T, Isayama H, Fukutomi A, Yamaguchi K, Ikeda M, Funakoshi A, Nagase M, Hamamoto Y, Nakamori S, Tsuchiya Y, Baba H, Ishii H, Omuro Y, Sho M, Matsumoto S, Yamada N, Yanagimoto H, Unno M, Ichikawa Y, Takahashi S, Watanabe G, Wakabayashi G, Egawa N, Tsuda M, Hosotani R, Hamada C, Hyodo I. Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer. Br J Cancer 2015;112:1428-34. [PMID: 25880004 DOI: 10.1038/bjc.2015.103] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 5.0] [Reference Citation Analysis]
439 Lowder CY, Metkus J, Epstein J, Kozak GM, Lavu H, Yeo CJ, Winter JM. Clinical Implications of Extensive Lymph Node Metastases for Resected Pancreatic Cancer. Ann Surg Oncol 2018;25:4004-11. [PMID: 30225835 DOI: 10.1245/s10434-018-6763-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
440 Azzariti A, Brunetti O, Porcelli L, Graziano G, Iacobazzi RM, Signorile M, Scarpa A, Lorusso V, Silvestris N. Potential predictive role of chemotherapy-induced changes of soluble CD40 ligand in untreated advanced pancreatic ductal adenocarcinoma. Onco Targets Ther 2016;9:4681-6. [PMID: 27555786 DOI: 10.2147/OTT.S106496] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
441 Kobayashi Y, Maeda S, Hama N, Miyamoto A, Uemura M, Miyake M, Nishikawa K, Hirao M, Kato T, Sekimoto M, Mori K, Mano M, Nakamori S. Successful conversion surgery for unresectable pancreatic cancer with peritoneal metastases after neoadjuvant albumin-bound paclitaxel and gemcitabine chemotherapy: case report and literature review. Int Cancer Conf J 2018;7:20-5. [PMID: 31149507 DOI: 10.1007/s13691-017-0311-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
442 Hamada T, Khalaf N, Yuan C, Morales-Oyarvide V, Babic A, Nowak JA, Qian ZR, Ng K, Rubinson DA, Kraft P, Giovannucci EL, Stampfer MJ, Fuchs CS, Ogino S, Wolpin BM. Prediagnosis Use of Statins Associates With Increased Survival Times of Patients With Pancreatic Cancer. Clin Gastroenterol Hepatol. 2018;16:1300-1306.e3. [PMID: 29474971 DOI: 10.1016/j.cgh.2018.02.022] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
443 Farren MR, Mace TA, Geyer S, Mikhail S, Wu C, Ciombor K, Tahiri S, Ahn D, Noonan AM, Villalona-Calero M, Bekaii-Saab T, Lesinski GB. Systemic Immune Activity Predicts Overall Survival in Treatment-Naïve Patients with Metastatic Pancreatic Cancer. Clin Cancer Res 2016;22:2565-74. [PMID: 26719427 DOI: 10.1158/1078-0432.CCR-15-1732] [Cited by in Crossref: 44] [Cited by in F6Publishing: 31] [Article Influence: 7.3] [Reference Citation Analysis]
444 Maulat C, Canivet C, Touraine C, Gourgou S, Napoleon B, Palazzo L, Flori N, Piessen G, Guibert P, Truant S, Assenat E, Buscail L, Bournet B, Muscari F, The Bacap Consortium. A New Score to Predict the Resectability of Pancreatic Adenocarcinoma: The BACAP Score. Cancers (Basel) 2020;12:E783. [PMID: 32218346 DOI: 10.3390/cancers12040783] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
445 Yang SH, Lee JC, Guo JC, Kuo SH, Tien YW, Kuo TC, Cheng AL, Yeh KH. Association of MDM2 expression with shorter progression-free survival and overall survival in patients with advanced pancreatic cancer treated with gemcitabine-based chemotherapy. PLoS One 2017;12:e0180628. [PMID: 28678832 DOI: 10.1371/journal.pone.0180628] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
446 Kuroda T, Kumagi T, Yokota T, Azemoto N, Hasebe A, Seike H, Nishiyama M, Inada N, Shibata N, Miyata H, Kawamura T, Imai Y, Ueno-Toshimori A, Tanaka Y, Terao T, Imamura Y, Koizumi M, Yamanishi H, Ohno Y, Hiasa Y; Ehime Pancreato-Cholangiology (EPOCH) Study Group. Efficacy of chemotherapy in elderly patients with unresectable pancreatic cancer: a multicenter review of 895 patients. BMC Gastroenterol 2017;17:66. [PMID: 28532457 DOI: 10.1186/s12876-017-0623-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
447 Dai W, Qiu X, Lu C, Zou Z, Sha H, Kong W, Liu B, Du J. AGIG Chemo-Immunotherapy in Patients With Advanced Pancreatic Cancer: A Single-Arm, Single-Center, Phase 2 Study. Front Oncol 2021;11:693386. [PMID: 34722242 DOI: 10.3389/fonc.2021.693386] [Reference Citation Analysis]
448 Sachindra S, Hellberg T, Exner S, Prasad S, Beindorff N, Rogalla S, Kimura R, Gambhir SS, Wiedenmann B, Grötzinger C. SPECT/CT Imaging, Biodistribution and Radiation Dosimetry of a 177Lu-DOTA-Integrin αvβ6 Cystine Knot Peptide in a Pancreatic Cancer Xenograft Model. Front Oncol 2021;11:684713. [PMID: 34136410 DOI: 10.3389/fonc.2021.684713] [Reference Citation Analysis]
449 Damm M, Efremov L, Birnbach B, Terrero G, Kleeff J, Mikolajczyk R, Rosendahl J, Michl P, Krug S. Efficacy and Safety of Neoadjuvant Gemcitabine Plus Nab-Paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Cancer-A Systematic Review and Meta-Analysis. Cancers (Basel) 2021;13:4326. [PMID: 34503138 DOI: 10.3390/cancers13174326] [Reference Citation Analysis]
450 Ito H, Tajiri T, Hiraiwa SI, Sugiyama T, Ito A, Shinma Y, Kaneko M, Anzai K, Tsuda S, Ichikawa H, Nagata J, Kojima S, Watanabe N. A Case of Rare Cutaneous Metastasis from Advanced Pancreatic Cancer. Case Rep Oncol. 2020;13:49-54. [PMID: 32110219 DOI: 10.1159/000505322] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
451 Nakamura Y, Takimoto T, Kobayashi T, Tachibana K, Kasai T, Akira M, Arai T, Inoue Y. Drug-related pneumonitis with radiographic hypersensitivity pneumonitis pattern: Three case series. Respir Med Case Rep 2021;34:101498. [PMID: 34471597 DOI: 10.1016/j.rmcr.2021.101498] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
452 Torres C, Grippo PJ. Pancreatic cancer subtypes: a roadmap for precision medicine. Ann Med 2018;50:277-87. [PMID: 29537309 DOI: 10.1080/07853890.2018.1453168] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 7.7] [Reference Citation Analysis]
453 Sibaud V, Lebœuf NR, Roche H, Belum VR, Gladieff L, Deslandres M, Montastruc M, Eche A, Vigarios E, Dalenc F, Lacouture ME. Dermatological adverse events with taxane chemotherapy. Eur J Dermatol 2016;26:427-43. [PMID: 27550571 DOI: 10.1684/ejd.2016.2833] [Cited by in Crossref: 68] [Cited by in F6Publishing: 50] [Article Influence: 17.0] [Reference Citation Analysis]
454 Frappart PO, Hofmann TG. Pancreatic Ductal Adenocarcinoma (PDAC) Organoids: The Shining Light at the End of the Tunnel for Drug Response Prediction and Personalized Medicine. Cancers (Basel) 2020;12:E2750. [PMID: 32987786 DOI: 10.3390/cancers12102750] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
455 Lee KC, Maturo C, Perera CN, Luddy J, Rodriguez R, Shorr R. Translational assessment of mitochondrial dysfunction of pancreatic cancer from in vitro gene microarray and animal efficacy studies, to early clinical studies, via the novel tumor-specific anti-mitochondrial agent, CPI-613. Ann Transl Med 2014;2:91. [PMID: 25405166 DOI: 10.3978/j.issn.2305-5839.2014.05.08] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
456 Yoshida A, Takenaka M, Takashima K, Tanaka H, Okamoto A, Yamazaki T, Nakai A, Omoto S, Minaga K, Kamata K, Yamao K, Komeda Y, Nishida N, Kudo M. Usefulness of the Novel Snare-over-the-Guidewire Method for Transpapillary Plastic Stent Replacement (with Video). J Clin Med 2021;10:2858. [PMID: 34203200 DOI: 10.3390/jcm10132858] [Reference Citation Analysis]
457 Taieb J, Abdallah R. How I treat pancreatic cancer. ESMO Open 2020;4:e000818. [PMID: 32817138 DOI: 10.1136/esmoopen-2020-000818] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
458 Wandmacher AM, Letsch A, Sebens S. Challenges and Future Perspectives of Immunotherapy in Pancreatic Cancer. Cancers (Basel) 2021;13:4235. [PMID: 34439389 DOI: 10.3390/cancers13164235] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
459 Mian OY, Ram AN, Tuli R, Herman JM. Management options in locally advanced pancreatic cancer. Curr Oncol Rep 2014;16:388. [PMID: 24740136 DOI: 10.1007/s11912-014-0388-y] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
460 Inman KS, Francis AA, Murray NR. Complex role for the immune system in initiation and progression of pancreatic cancer. World J Gastroenterol 2014; 20(32): 11160-11181 [PMID: 25170202 DOI: 10.3748/wjg.v20.i32.11160] [Cited by in CrossRef: 73] [Cited by in F6Publishing: 78] [Article Influence: 10.4] [Reference Citation Analysis]
461 Henderson SE, Makhijani N, Mace TA. Pancreatic Cancer-Induced Cachexia and Relevant Mouse Models. Pancreas 2018;47:937-45. [PMID: 30113428 DOI: 10.1097/MPA.0000000000001124] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
462 Schlick K, Kiem D, Greil R. Recent Advances in Pancreatic Cancer: Novel Prognostic Biomarkers and Targeted Therapy-A Review of the Literature. Biomolecules 2021;11:1469. [PMID: 34680101 DOI: 10.3390/biom11101469] [Reference Citation Analysis]
463 Salgado M, Arévalo S, Hernando O, Martínez A, Yaya R, Hidalgo M. Management of unresectable, locally advanced pancreatic adenocarcinoma. Clin Transl Oncol 2018;20:113-8. [PMID: 28612202 DOI: 10.1007/s12094-017-1679-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
464 Williet N, Saint A, Pointet AL, Tougeron D, Pernot S, Pozet A, Bechade D, Trouilloud I, Lourenco N, Hautefeuille V, Locher C, Desrame J, Artru P, Thirot Bidault A, Le Roy B, Pezet D, Phelip JM, Taieb J. Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study. Therap Adv Gastroenterol 2019;12:1756284819878660. [PMID: 31598136 DOI: 10.1177/1756284819878660] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
465 Rochefort P, Lardy-Cleaud A, Sarabi M, Desseigne F, Cattey-Javouhey A, de la Fouchardière C. Long-Term Survivors in Metastatic Pancreatic Ductal Adenocarcinoma: A Retrospective and Matched Pair Analysis. Oncologist 2019;24:1543-8. [PMID: 31164454 DOI: 10.1634/theoncologist.2018-0786] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
466 Mancini BR, Stein S, Lloyd S, Rutter CE, James E, Chang BW, Lacy J, Johung KL. Chemoradiation after FOLFIRINOX for borderline resectable or locally advanced pancreatic cancer. J Gastrointest Oncol 2018;9:982-8. [PMID: 30603116 DOI: 10.21037/jgo.2018.04.03] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
467 Chiorean EG, Von Hoff DD, Reni M, Arena FP, Infante JR, Bathini VG, Wood TE, Mainwaring PN, Muldoon RT, Clingan PR, Kunzmann V, Ramanathan RK, Tabernero J, Goldstein D, McGovern D, Lu B, Ko A. CA19-9 decrease at 8 wk as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine vs gemcitabine alone in patients with metastatic pancreatic cancer. Ann Oncol. 2016;27:654-660. [PMID: 26802160 DOI: 10.1093/annonc/mdw006] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 9.6] [Reference Citation Analysis]
468 Borsoi C, Leonard F, Lee Y, Zaid M, Elganainy D, Alexander JF, Kai M, Liu YT, Kang Y, Liu X, Koay EJ, Ferrari M, Godin B, Yokoi K. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma. Cancer Lett 2017;403:296-304. [PMID: 28687352 DOI: 10.1016/j.canlet.2017.06.026] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
469 Lo Re G, Santeufemia DA, Foltran L, Bidoli E, Basso SM, Lumachi F. Prognostic factors of survival in patients treated with nab-paclitaxel plus gemcitabine regimen for advanced or metastatic pancreatic cancer: a single institutional experience. Oncotarget 2015;6:8255-60. [PMID: 25779664 DOI: 10.18632/oncotarget.3143] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
470 Moravec R, Divi R, Verma M. Detecting circulating tumor material and digital pathology imaging during pancreatic cancer progression. World J Gastrointest Oncol 2017; 9(6): 235-250 [PMID: 28656074 DOI: 10.4251/wjgo.v9.i6.235] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
471 Chen CY, Liang SH, Su YY, Chiang NJ, Wang HC, Chiu CF, Chen LT, Bai LY. Modified gemcitabine, S-1, and leucovorin combination for patients with newly diagnosed locally advanced or metastatic pancreatic adenocarcinoma: A multi-center retrospective study in Taiwan. PLoS One 2020;15:e0244487. [PMID: 33373398 DOI: 10.1371/journal.pone.0244487] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
472 Cook N, Basu B, Smith DM, Gopinathan A, Evans J, Steward WP, Palmer D, Propper D, Venugopal B, Hategan M, Anthoney DA, Hampson LV, Nebozhyn M, Tuveson D, Farmer-Hall H, Turner H, McLeod R, Halford S, Jodrell D. A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma. Br J Cancer 2018;118:793-801. [PMID: 29438372 DOI: 10.1038/bjc.2017.495] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 13.3] [Reference Citation Analysis]
473 Murphy KJ, Chambers CR, Herrmann D, Timpson P, Pereira BA. Dynamic Stromal Alterations Influence Tumor-Stroma Crosstalk to Promote Pancreatic Cancer and Treatment Resistance. Cancers (Basel) 2021;13:3481. [PMID: 34298706 DOI: 10.3390/cancers13143481] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
474 Hamada T, Yuan C, Bao Y, Zhang M, Khalaf N, Babic A, Morales-Oyarvide V, Cochrane BB, Gaziano JM, Giovannucci EL, Kraft P, Manson JE, Ng K, Nowak JA, Rohan TE, Sesso HD, Stampfer MJ, Amundadottir LT, Fuchs CS, De Vivo I, Ogino S, Wolpin BM. Prediagnostic Leukocyte Telomere Length and Pancreatic Cancer Survival. Cancer Epidemiol Biomarkers Prev 2019;28:1868-75. [PMID: 31427306 DOI: 10.1158/1055-9965.EPI-19-0577] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
475 Brouwer TP, Vahrmeijer AL, de Miranda NFCC. Immunotherapy for pancreatic cancer: chasing the light at the end of the tunnel. Cell Oncol (Dordr) 2021;44:261-78. [PMID: 33710604 DOI: 10.1007/s13402-021-00587-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
476 Alistar A, Morris BB, Desnoyer R, Klepin HD, Hosseinzadeh K, Clark C, Cameron A, Leyendecker J, D'Agostino R Jr, Topaloglu U, Boteju LW, Boteju AR, Shorr R, Zachar Z, Bingham PM, Ahmed T, Crane S, Shah R, Migliano JJ, Pardee TS, Miller L, Hawkins G, Jin G, Zhang W, Pasche B. Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial. Lancet Oncol 2017;18:770-8. [PMID: 28495639 DOI: 10.1016/S1470-2045(17)30314-5] [Cited by in Crossref: 91] [Cited by in F6Publishing: 66] [Article Influence: 22.8] [Reference Citation Analysis]
477 Brunetti O, Badalamenti G, De Summa S, Calabrese A, Argentiero A, Fucci L, Longo V, Galetta D, Perrotti PMS, Pinto R, Petriella D, Danza K, Tommasi S, Leonetti F, Silvestris N. Molecular Characterization of a Long-Term Survivor Double Metastatic Non-Small Cell Lung Cancer and Pancreatic Ductal Adenocarcinoma Treated with Gefitinib in Combination with Gemcitabine Plus Nab-Paclitaxel and mFOLFOX6 as First and Second Line Therapy. Cancers (Basel) 2019;11:E749. [PMID: 31146476 DOI: 10.3390/cancers11060749] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
478 Mitsuka Y, Yamazaki S, Yoshida N, Yan M, Higaki T, Takayama T. Time interval-based indication for liver resection of metastasis from pancreatic cancer. World J Surg Oncol 2020;18:294. [PMID: 33172482 DOI: 10.1186/s12957-020-02058-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
479 Andersson G, Lundgren S, Heby M, Nodin B, Elebro J, Jirström K. Clinical significance of stromal ER and PR expression in periampullary adenocarcinoma. Biomark Res 2019;7:26. [PMID: 31827798 DOI: 10.1186/s40364-019-0176-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
480 Zhao S, Devega R, Francois A, Kidane D. Human ALKBH6 Is Required for Maintenance of Genomic Stability and Promoting Cell Survival During Exposure of Alkylating Agents in Pancreatic Cancer. Front Genet 2021;12:635808. [PMID: 33897761 DOI: 10.3389/fgene.2021.635808] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
481 Dai WF, Beca J, Guo H, Isaranawatchai W, Schwartz D, Naipaul R, Arias J, Qiao Y, Gavura S, Redmond-Misner R, Ismail Z, Barbera L, Chan K. Are population-based patient-reported outcomes associated with overall survival in patients with advanced pancreatic cancer? Cancer Med 2020;9:215-24. [PMID: 31736256 DOI: 10.1002/cam4.2704] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
482 Skelton WP 4th, Parekh H, Starr JS, Trevino J, Cioffi J, Hughes S, George TJ Jr. Clinical Factors as a Component of the Personalized Treatment Approach to Advanced Pancreatic Cancer: a Systematic Literature Review. J Gastrointest Cancer 2018;49:1-8. [PMID: 29110227 DOI: 10.1007/s12029-017-0021-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
483 Mondal G, Almawash S, Chaudhary AK, Mahato RI. EGFR-Targeted Cationic Polymeric Mixed Micelles for Codelivery of Gemcitabine and miR-205 for Treating Advanced Pancreatic Cancer. Mol Pharm 2017;14:3121-33. [PMID: 28719220 DOI: 10.1021/acs.molpharmaceut.7b00355] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
484 Kokkali S, Tripodaki ES, Drizou M, Stefanou D, Magou E, Zylis D, Kapiris M, Nasi D, Georganta C, Ardavanis A. Biweekly Gemcitabine/Nab-Paclitaxel as First-line Treatment for Advanced Pancreatic Cancer. In Vivo 2018;32:653-7. [PMID: 29695574 DOI: 10.21873/invivo.11289] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
485 Swayden M, Iovanna J, Soubeyran P. Pancreatic cancer chemo-resistance is driven by tumor phenotype rather than tumor genotype. Heliyon 2018;4:e01055. [PMID: 30582059 DOI: 10.1016/j.heliyon.2018.e01055] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
486 Rosemurgy AS, Ross SB, Vitulli PL, Malek R, Li J, Agah R. Safety Study of Targeted and Localized Intra-Arterial Delivery of Gemcitabine in Patients with Locally Advanced Pancreatic Adenocarcinoma. J Pancreat Cancer 2017;3:58-65. [PMID: 30631844 DOI: 10.1089/pancan.2017.0011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
487 Loc WS, Smith JP, Matters G, Kester M, Adair JH. Novel strategies for managing pancreatic cancer. World J Gastroenterol 2014; 20(40): 14717-14725 [PMID: 25356034 DOI: 10.3748/wjg.v20.i40.14717] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
488 Rosenberg A, Mahalingam D. Immunotherapy in pancreatic adenocarcinoma-overcoming barriers to response. J Gastrointest Oncol. 2018;9:143-159. [PMID: 29564181 DOI: 10.21037/jgo.2018.01.13] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 8.7] [Reference Citation Analysis]
489 Reyes-Castellanos G, Masoud R, Carrier A. Mitochondrial Metabolism in PDAC: From Better Knowledge to New Targeting Strategies. Biomedicines 2020;8:E270. [PMID: 32756381 DOI: 10.3390/biomedicines8080270] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
490 Adamska A, Falasca M. ATP-binding cassette transporters in progression and clinical outcome of pancreatic cancer: What is the way forward? World J Gastroenterol 2018; 24(29): 3222-3238 [PMID: 30090003 DOI: 10.3748/wjg.v24.i29.3222] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 37] [Article Influence: 12.7] [Reference Citation Analysis]
491 Cooper E, Choi PJ, Denny WA, Jose J, Dragunow M, Park TI. The Use of Heptamethine Cyanine Dyes as Drug-Conjugate Systems in the Treatment of Primary and Metastatic Brain Tumors. Front Oncol 2021;11:654921. [PMID: 34141613 DOI: 10.3389/fonc.2021.654921] [Reference Citation Analysis]
492 Lee SW, Kim YM, Cho CH, Kim YT, Kim SM, Hur SY, Kim JH, Kim BG, Kim SC, Ryu HS, Kang SB. An Open-Label, Randomized, Parallel, Phase II Trial to Evaluate the Efficacy and Safety of a Cremophor-Free Polymeric Micelle Formulation of Paclitaxel as First-Line Treatment for Ovarian Cancer: A Korean Gynecologic Oncology Group Study (KGOG-3021). Cancer Res Treat 2018;50:195-203. [PMID: 28324920 DOI: 10.4143/crt.2016.376] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
493 Hagihara K, Kajimoto K, Osaga S, Nagai N, Shimosegawa E, Nakata H, Saito H, Nakano M, Takeuchi M, Kanki H, Kagitani-Shimono K, Kijima T. Promising Effect of a New Ketogenic Diet Regimen in Patients with Advanced Cancer. Nutrients 2020;12:E1473. [PMID: 32438645 DOI: 10.3390/nu12051473] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
494 Chao T, Furth EE, Vonderheide RH. CXCR2-Dependent Accumulation of Tumor-Associated Neutrophils Regulates T-cell Immunity in Pancreatic Ductal Adenocarcinoma. Cancer Immunol Res 2016;4:968-82. [PMID: 27737879 DOI: 10.1158/2326-6066.CIR-16-0188] [Cited by in Crossref: 99] [Cited by in F6Publishing: 80] [Article Influence: 19.8] [Reference Citation Analysis]
495 Enzler T, Bates S. Clinical Trials in Pancreatic Cancer: A Long Slog. Oncologist 2017;22:1424-6. [PMID: 28982802 DOI: 10.1634/theoncologist.2017-0453] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
496 Bailey RE, Surapaneni PK, Core J, Vidal LLC, LeGout J, Ritchie C, Frey G, McKinney JM, Sella D, Paz-Fumagalli R, Toskich B, Mody K. Safety and efficacy of locoregional therapy for metastatic pancreatic ductal adenocarcinoma to the liver: a single-center experience. J Gastrointest Oncol. 2019;10:688-694. [PMID: 31392049 DOI: 10.21037/jgo.2019.03.13] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
497 Uzunparmak B, Sahin IH. Pancreatic cancer microenvironment: a current dilemma. Clin Transl Med 2019;8:2. [PMID: 30645701 DOI: 10.1186/s40169-019-0221-1] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 18.5] [Reference Citation Analysis]
498 Puri A, Chang J, Tanner N, Lucente P, Desiongco J, Dragovich T, Naraev B, Kundranda M. Skeletal metastases in advanced pancreatic ductal adenocarcinoma: a retrospective analysis. J Gastrointest Oncol 2021;12:455-63. [PMID: 34012639 DOI: 10.21037/jgo-20-361] [Reference Citation Analysis]
499 Neuzillet C, Vergnault M, Bonnetain F, Hammel P. Rationale and design of the Adapted Physical Activity in advanced Pancreatic Cancer patients (APACaP) GERCOR (Groupe Coopérateur Multidisciplinaire en Oncologie) trial: study protocol for a randomized controlled trial. Trials 2015;16:454. [PMID: 26458923 DOI: 10.1186/s13063-015-0983-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
500 Nywening TM, Wang-Gillam A, Sanford DE, Belt BA, Panni RZ, Cusworth BM, Toriola AT, Nieman RK, Worley LA, Yano M, Fowler KJ, Lockhart AC, Suresh R, Tan BR, Lim KH, Fields RC, Strasberg SM, Hawkins WG, DeNardo DG, Goedegebuure SP, Linehan DC. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. Lancet Oncol. 2016;17:651-662. [PMID: 27055731 DOI: 10.1016/s1470-2045(16)00078-4] [Cited by in Crossref: 308] [Cited by in F6Publishing: 209] [Article Influence: 61.6] [Reference Citation Analysis]
501 Prieto-García E, Díaz-García CV, Agudo-López A, Pardo-Marqués V, García-Consuegra I, Asensio-Peña S, Alonso-Riaño M, Pérez C, Gómez C, Adeva J, Paz-Ares L, López-Martín JA, Agulló-Ortuño MT. Tumor-Stromal Interactions in a Co-Culture Model of Human Pancreatic Adenocarcinoma Cells and Fibroblasts and Their Connection with Tumor Spread. Biomedicines 2021;9:364. [PMID: 33807441 DOI: 10.3390/biomedicines9040364] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
502 Amrutkar M, Gladhaug IP. Pancreatic Cancer Chemoresistance to Gemcitabine. Cancers (Basel). 2017;9. [PMID: 29144412 DOI: 10.3390/cancers9110157] [Cited by in Crossref: 142] [Cited by in F6Publishing: 143] [Article Influence: 35.5] [Reference Citation Analysis]
503 Ueno M, Nakamori S, Sugimori K, Kanai M, Ikeda M, Ozaka M, Furukawa M, Okusaka T, Kawabe K, Furuse J, Komatsu Y, Ishii H, Sato A, Shimizu S, Chugh P, Tang R, Ioka T. nal-IRI+5-FU/LV versus 5-FU/LV in post-gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients. Cancer Med 2020;9:9396-408. [PMID: 33099898 DOI: 10.1002/cam4.3558] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
504 Iede K, Yamada T, Kato R, Ueda M, Tsuda Y, Nakashima S, Ohta K, Matsuyama J, Ikenaga M, Tominaga S. Efficacy of S-1 in second-line chemotherapy after nab-paclitaxel plus gemcitabine for patients with advanced pancreatic cancer. Cancer Rep (Hoboken) 2020;3:e1215. [PMID: 32672000 DOI: 10.1002/cnr2.1215] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
505 Miura T, Mitsunaga S, Ikeda M, Ohno I, Takahashi H, Suzuki H, Irisawa A, Kuwata T, Ochiai A. Characterization of low active ghrelin ratio in patients with advanced pancreatic cancer. Support Care Cancer 2018;26:3811-7. [PMID: 29777378 DOI: 10.1007/s00520-018-4248-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
506 Kim H, Samuel S, Lopez-Casas P, Grizzle W, Hidalgo M, Kovar J, Oelschlager D, Zinn K, Warram J, Buchsbaum D. SPARC-Independent Delivery of Nab-Paclitaxel without Depleting Tumor Stroma in Patient-Derived Pancreatic Cancer Xenografts. Mol Cancer Ther. 2016;15:680-688. [PMID: 26832793 DOI: 10.1158/1535-7163.mct-15-0764] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 5.6] [Reference Citation Analysis]
507 Perry LM, Bateni SB, Bold RJ, Hoch JS. Is Improved Survival in Early-Stage Pancreatic Cancer Worth the Extra Cost at High-Volume Centers? J Am Coll Surg 2021;233:90-8. [PMID: 33766724 DOI: 10.1016/j.jamcollsurg.2021.02.014] [Reference Citation Analysis]
508 Wong KM, Horton KJ, Coveler AL, Hingorani SR, Harris WP. Targeting the Tumor Stroma: the Biology and Clinical Development of Pegylated Recombinant Human Hyaluronidase (PEGPH20). Curr Oncol Rep. 2017;19:47. [PMID: 28589527 DOI: 10.1007/s11912-017-0608-3] [Cited by in Crossref: 61] [Cited by in F6Publishing: 64] [Article Influence: 20.3] [Reference Citation Analysis]
509 Mundry CS, Eberle KC, Singh PK, Hollingsworth MA, Mehla K. Local and systemic immunosuppression in pancreatic cancer: Targeting the stalwarts in tumor's arsenal. Biochim Biophys Acta Rev Cancer 2020;1874:188387. [PMID: 32579889 DOI: 10.1016/j.bbcan.2020.188387] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
510 Chung V, McDonough S, Philip PA, Cardin D, Wang-Gillam A, Hui L, Tejani MA, Seery TE, Dy IA, Al Baghdadi T, Hendifar AE, Doyle LA, Lowy AM, Guthrie KA, Blanke CD, Hochster HS. Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial. JAMA Oncol 2017;3:516-22. [PMID: 27978579 DOI: 10.1001/jamaoncol.2016.5383] [Cited by in Crossref: 78] [Cited by in F6Publishing: 75] [Article Influence: 19.5] [Reference Citation Analysis]
511 Kurimoto M, Kimura M, Usami E, Iwai M, Hirose T, Kawachi S, Yoshimura T. Comparing the cost-effectiveness of FOLFIRINOX, nab-paclitaxel plus gemcitabine, gemcitabine and S-1 for the treatment of metastatic pancreatic cancer. Mol Clin Oncol 2017;7:125-30. [PMID: 28685089 DOI: 10.3892/mco.2017.1278] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
512 Zechner D, Bürtin F, Albert AC, Zhang X, Kumstel S, Schönrogge M, Graffunder J, Shih HY, Müller S, Radecke T, Jaster R, Vollmar B. Intratumoral heterogeneity of the therapeutical response to gemcitabine and metformin. Oncotarget 2016;7:56395-407. [PMID: 27486761 DOI: 10.18632/oncotarget.10892] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
513 Williet N, Petrillo A, Roth G, Ghidini M, Petrova M, Forestier J, Lopez A, Thoor A, Weislinger L, De Vita F, Taieb J, Phelip JM. Gemcitabine/Nab-Paclitaxel versus FOLFIRINOX in Locally Advanced Pancreatic Cancer: A European Multicenter Study. Cancers (Basel) 2021;13:2797. [PMID: 34199796 DOI: 10.3390/cancers13112797] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
514 Kieler M, Unseld M, Bianconi D, Schindl M, Kornek GV, Scheithauer W, Prager GW. Impact of New Chemotherapy Regimens on the Treatment Landscape and Survival of Locally Advanced and Metastatic Pancreatic Cancer Patients. J Clin Med. 2020;9. [PMID: 32121198 DOI: 10.3390/jcm9030648] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
515 Golombek SK, May JN, Theek B, Appold L, Drude N, Kiessling F, Lammers T. Tumor targeting via EPR: Strategies to enhance patient responses. Adv Drug Deliv Rev 2018;130:17-38. [PMID: 30009886 DOI: 10.1016/j.addr.2018.07.007] [Cited by in Crossref: 437] [Cited by in F6Publishing: 405] [Article Influence: 145.7] [Reference Citation Analysis]
516 O'Reilly EM, Lee JW, Lowery MA, Capanu M, Stadler ZK, Moore MJ, Dhani N, Kindler HL, Estrella H, Maynard H, Golan T, Segal A, Salo-Mullen EE, Yu KH, Epstein AS, Segal M, Brenner R, Do RK, Chen AP, Tang LH, Kelsen DP. Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma. Cancer 2018;124:1374-82. [PMID: 29338080 DOI: 10.1002/cncr.31218] [Cited by in Crossref: 53] [Cited by in F6Publishing: 52] [Article Influence: 17.7] [Reference Citation Analysis]
517 Lo JH, Hao L, Muzumdar MD, Raghavan S, Kwon EJ, Pulver EM, Hsu F, Aguirre AJ, Wolpin BM, Fuchs CS, Hahn WC, Jacks T, Bhatia SN. iRGD-guided Tumor-penetrating Nanocomplexes for Therapeutic siRNA Delivery to Pancreatic Cancer. Mol Cancer Ther 2018;17:2377-88. [PMID: 30097486 DOI: 10.1158/1535-7163.MCT-17-1090] [Cited by in Crossref: 27] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
518 Zhu X, Straubinger RM, Jusko WJ. Mechanism-based mathematical modeling of combined gemcitabine and birinapant in pancreatic cancer cells. J Pharmacokinet Pharmacodyn 2015;42:477-96. [PMID: 26252969 DOI: 10.1007/s10928-015-9429-x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
519 O'Reilly EM, Cockrum P, Surinach A, Wu Z, Dillon A, Yu KH. Reducing nihilism in metastatic pancreatic ductal adenocarcinoma: Treatment, sequencing, and effects on survival outcomes. Cancer Med. 2020;9:8480-8490. [PMID: 32997898 DOI: 10.1002/cam4.3477] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
520 Lapin M, Tjensvoll K, Oltedal S, Javle M, Smaaland R, Gilje B, Nordgård O. Single-cell mRNA profiling reveals transcriptional heterogeneity among pancreatic circulating tumour cells. BMC Cancer 2017;17:390. [PMID: 28569190 DOI: 10.1186/s12885-017-3385-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
521 Lee K, Bang K, Yoo C, Hwang I, Jeong JH, Chang HM, Oh D, Song TJ, Park DH, Lee SS, Lee SK, Kim MH, Park JH, Kim KP, Ryoo BY. Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma. Cancer Res Treat. 2020;52:254-262. [PMID: 31291709 DOI: 10.4143/crt.2019.190] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
522 Niu J, Wang X, Qu J, Mager DE, Straubinger RM. Pharmacodynamic modeling of synergistic birinapant/paclitaxel interactions in pancreatic cancer cells. BMC Cancer 2020;20:1024. [PMID: 33097020 DOI: 10.1186/s12885-020-07398-9] [Reference Citation Analysis]
523 Luo W, Yang G, Qiu J, Luan J, Zhang Y, You L, Feng M, Zhao F, Liu Y, Cao Z, Zheng L, Zhang T, Zhao Y. Novel discoveries targeting gemcitabine-based chemoresistance and new therapies in pancreatic cancer: How far are we from the destination? Cancer Med 2019;8:6403-13. [PMID: 31475468 DOI: 10.1002/cam4.2384] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
524 Suzuki R, Asama H, Waragai Y, Takagi T, Hikichi T, Sugimoto M, Konno N, Watanabe K, Nakamura J, Kikuchi H, Sato Y, Marubashi S, Masamune A, Ohira H. Fibrosis-related miRNAs as serum biomarkers for pancreatic ductal adenocarcinoma. Oncotarget 2018;9:4451-60. [PMID: 29435115 DOI: 10.18632/oncotarget.23377] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
525 Ettrich TJ, Berger AW, Perkhofer L, Daum S, König A, Dickhut A, Wittel U, Wille K, Geissler M, Algül H, Gallmeier E, Atzpodien J, Kornmann M, Muche R, Prasnikar N, Tannapfel A, Reinacher-Schick A, Uhl W, Seufferlein T. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group. BMC Cancer 2018;18:1298. [PMID: 30594153 DOI: 10.1186/s12885-018-5183-y] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 8.7] [Reference Citation Analysis]
526 Abaza YM, Alemany C. Nanoparticle albumin-bound-Paclitaxel in the treatment of metastatic urethral adenocarcinoma: the significance of molecular profiling and targeted therapy. Case Rep Urol 2014;2014:489686. [PMID: 25202467 DOI: 10.1155/2014/489686] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
527 Quan MY, Guo Q, Liu J, Yang R, Bai J, Wang W, Cai Y, Han R, Lv YQ, Ding L, Billadeau DD, Lou Z, Bellusci S, Li X, Zhang JS. An FGFR/AKT/SOX2 Signaling Axis Controls Pancreatic Cancer Stemness. Front Cell Dev Biol 2020;8:287. [PMID: 32457900 DOI: 10.3389/fcell.2020.00287] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
528 Iizumi S, Kuchiba A, Okusaka T, Ikeda M, Sakamoto Y, Kondo S, Morizane C, Ueno H, Osame K, Mitsunaga S, Ohno I, Imaoka H, Hashimoto Y, Takahashi H, Sasaki M, Ohashi K. Impact of the Duration of Diabetes Mellitus on the Outcome of Metastatic Pancreatic Cancer Treated with Gemcitabine: A Retrospective Study. Intern Med. 2019;58:2435-2441. [PMID: 31178491 DOI: 10.2169/internalmedicine.2539-18] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
529 Gower A, Golestany B, Gong J, Singhi AD, Hendifar AE. Novel ALK Fusion, PPFIBP1-ALK, in Pancreatic Ductal Adenocarcinoma Responsive to Alectinib and Lorlatinib. JCO Precis Oncol 2020;4:PO. [PMID: 32923899 DOI: 10.1200/PO.19.00365] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
530 Johnson BA 3rd, Yarchoan M, Lee V, Laheru DA, Jaffee EM. Strategies for Increasing Pancreatic Tumor Immunogenicity. Clin Cancer Res. 2017;23:1656-1669. [PMID: 28373364 DOI: 10.1158/1078-0432.ccr-16-2318] [Cited by in Crossref: 68] [Cited by in F6Publishing: 45] [Article Influence: 22.7] [Reference Citation Analysis]
531 Lai IL, Chou CC, Lai PT, Fang CS, Shirley LA, Yan R, Mo X, Bloomston M, Kulp SK, Bekaii-Saab T. Targeting the Warburg effect with a novel glucose transporter inhibitor to overcome gemcitabine resistance in pancreatic cancer cells. Carcinogenesis. 2014;35:2203-2213. [PMID: 24879635 DOI: 10.1093/carcin/bgu124] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
532 Nakai Y, Isayama H, Sasaki T, Takahara N, Saito K, Ishigaki K, Hamada T, Mizuno S, Miyabayashi K, Yamamoto K, Mohri D, Kogure H, Yamamoto N, Ijichi H, Tateishi K, Tada M, Koike K. The inhibition of renin-angiotensin system in advanced pancreatic cancer: an exploratory analysis in 349 patients. J Cancer Res Clin Oncol 2015;141:933-9. [PMID: 25398651 DOI: 10.1007/s00432-014-1873-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
533 Ocal O, Pashkov V, Kollipara RK, Zolghadri Y, Cruz VH, Hale MA, Heath BR, Artyukhin AB, Christie AL, Tsoulfas P, Lorens JB, Swift GH, Brekken RA, Wilkie TM. A rapid in vivo screen for pancreatic ductal adenocarcinoma therapeutics. Dis Model Mech 2015;8:1201-11. [PMID: 26438693 DOI: 10.1242/dmm.020933] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
534 Maeda S, Ariake K, Iseki M, Ohtsuka H, Mizuma M, Nakagawa K, Morikawa T, Hayashi H, Motoi F, Kamei T, Naitoh T, Unno M. Prognostic indicators in pancreatic cancer patients undergoing total pancreatectomy. Surg Today 2020;50:490-8. [PMID: 31768656 DOI: 10.1007/s00595-019-01924-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
535 Suzuki N, Hazama S, Iguchi H, Uesugi K, Tanaka H, Hirakawa K, Aruga A, Hatori T, Ishizaki H, Umeda Y, Fujiwara T, Ikemoto T, Shimada M, Yoshimatsu K, Shimizu R, Hayashi H, Sakata K, Takenouchi H, Matsui H, Shindo Y, Iida M, Koki Y, Arima H, Furukawa H, Ueno T, Yoshino S, Nakamura Y, Oka M, Nagano H. Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS-PC study. Cancer Sci 2017;108:73-80. [PMID: 27783849 DOI: 10.1111/cas.13113] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 5.8] [Reference Citation Analysis]
536 Kiesewetter B, Raderer M, Prager GW, Fuereder T, Marosi C, Preusser M, Krainer M, Locker GJ, Brodowicz T, Zielinski CC. The European Society for Medical Oncology 'Magnitude of Clinical Benefit Scale' field-tested in infrequent tumour entities: an extended analysis of its feasibility at the Medical University of Vienna. ESMO Open 2017;2:e000166. [PMID: 28761758 DOI: 10.1136/esmoopen-2017-000166] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
537 Ying H, Dey P, Yao W, Kimmelman AC, Draetta GF, Maitra A, DePinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2016;30:355-385. [PMID: 26883357 DOI: 10.1101/gad.275776.115] [Cited by in Crossref: 241] [Cited by in F6Publishing: 226] [Article Influence: 48.2] [Reference Citation Analysis]
538 Martínez-Galán J, Rodriguez I, Caba O. Importance of BRCA mutation for the current treatment of pancreatic cancer beyond maintenance. World J Gastroenterol 2021; 27(39): 6515-6521 [DOI: 10.3748/wjg.v27.i39.6515] [Reference Citation Analysis]
539 Mancinelli G, Torres C, Krett N, Bauer J, Castellanos K, McKinney R, Dawson D, Guzman G, Hwang R, Grimaldo S, Grippo P, Jung B. Role of stromal activin A in human pancreatic cancer and metastasis in mice. Sci Rep 2021;11:7986. [PMID: 33846512 DOI: 10.1038/s41598-021-87213-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
540 Vivaldi C, Fornaro L, Cappelli C, Pecora I, Catanese S, Salani F, Cacciato Insilla A, Kauffmann E, Donati F, Pasquini G, Massa V, Napoli N, Lencioni M, Boraschi P, Campani D, Boggi U, Caramella D, Falcone A, Vasile E. Early Tumor Shrinkage and Depth of Response Evaluation in Metastatic Pancreatic Cancer Treated with First Line Chemotherapy: An Observational Retrospective Cohort Study. Cancers (Basel) 2019;11:E939. [PMID: 31277449 DOI: 10.3390/cancers11070939] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
541 Yamada S, Fujii T, Yamamoto T, Takami H, Yoshioka I, Yamaki S, Sonohara F, Shibuya K, Motoi F, Hirano S, Murakami Y, Inoue H, Hayashi M, Murotani K, Kitayama J, Ishikawa H, Kodera Y, Sekimoto M, Satoi S. Phase I/II study of adding intraperitoneal paclitaxel in patients with pancreatic cancer and peritoneal metastasis. Br J Surg 2020;107:1811-7. [PMID: 32638367 DOI: 10.1002/bjs.11792] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 12.0] [Reference Citation Analysis]
542 Polani F, Grierson PM, Lim KH. Stroma-targeting strategies in pancreatic cancer: Past lessons, challenges and prospects. World J Gastroenterol 2021; 27(18): 2105-2121 [PMID: 34025067 DOI: 10.3748/wjg.v27.i18.2105] [Reference Citation Analysis]
543 Tamburrino D, Partelli S, Crippa S, Manzoni A, Maurizi A, Falconi M. Selection criteria in resectable pancreatic cancer: A biological and morphological approach. World J Gastroenterol 2014; 20(32): 11210-11215 [PMID: 25170205 DOI: 10.3748/wjg.v20.i32.11210] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
544 Steckiewicz KP, Barcinska E, Sobczak K, Tomczyk E, Wojcik M, Inkielewicz-Stepniak I. Assessment of Anti-Tumor potential and safety of application of Glutathione stabilized Gold Nanoparticles conjugated with Chemotherapeutics. Int J Med Sci 2020;17:824-33. [PMID: 32218704 DOI: 10.7150/ijms.40827] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
545 Endo S, Kawaguchi S, Terada S, Shirane N. Hepatic Arterial Infusion Chemotherapy for Liver Metastases Following Standard Chemotherapy for Pancreatic Cancer. Intern Med 2021;60:223-9. [PMID: 32963157 DOI: 10.2169/internalmedicine.5449-20] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
546 Yamamoto S, Chishima T, Sugae S, Shibata Y, Yamada A. Breast cancer suspected to originate from familial hereditary tumors: A case report. Clin Case Rep 2020;8:648-52. [DOI: 10.1002/ccr3.2698] [Reference Citation Analysis]
547 de Jesus VHF, da Costa WL Jr, Claro LCL, Coimbra FJF, Dettino ALA, Riechelmann RP, Curado MP. Disparities in access to health care system as determinant of survival for patients with pancreatic cancer in the State of São Paulo, Brazil. Sci Rep 2021;11:6346. [PMID: 33737639 DOI: 10.1038/s41598-021-85759-5] [Reference Citation Analysis]
548 Hidalgo M, Amant F, Biankin AV, Budinská E, Byrne AT, Caldas C, Clarke RB, de Jong S, Jonkers J, Mælandsmo GM, Roman-Roman S, Seoane J, Trusolino L, Villanueva A. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov 2014;4:998-1013. [PMID: 25185190 DOI: 10.1158/2159-8290.CD-14-0001] [Cited by in Crossref: 863] [Cited by in F6Publishing: 552] [Article Influence: 123.3] [Reference Citation Analysis]
549 Schwartzberg LS, Arena FP, Bienvenu BJ, Kaplan EH, Camacho LH, Campos LT, Waymack JP, Tagliaferri MA, Chen MM, Li D. A Randomized, Open-Label, Safety and Exploratory Efficacy Study of Kanglaite Injection (KLTi) plus Gemcitabine versus Gemcitabine in Patients with Advanced Pancreatic Cancer. J Cancer 2017;8:1872-83. [PMID: 28819385 DOI: 10.7150/jca.15407] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
550 Tjensvoll K, Lapin M, Buhl T, Oltedal S, Steen-Ottosen Berry K, Gilje B, Søreide JA, Javle M, Nordgård O, Smaaland R. Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer. Mol Oncol 2016;10:635-43. [PMID: 26725968 DOI: 10.1016/j.molonc.2015.11.012] [Cited by in Crossref: 86] [Cited by in F6Publishing: 86] [Article Influence: 14.3] [Reference Citation Analysis]
551 Wang D, Zhang W, Qian D, Guan Y, Chen X, Zhang H, Wang J, Pang Q. Efficacy and safety of weekly nab-paclitaxel plus cisplatin with concurrent intensity-modulated radiotherapy in patients with inoperable, locally advanced esophageal cancer: a pilot trial. Onco Targets Ther 2018;11:6333-8. [PMID: 30319273 DOI: 10.2147/OTT.S168275] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
552 Poon C, He C, Liu D, Lu K, Lin W. Self-assembled nanoscale coordination polymers carrying oxaliplatin and gemcitabine for synergistic combination therapy of pancreatic cancer. J Control Release 2015;201:90-9. [PMID: 25620067 DOI: 10.1016/j.jconrel.2015.01.026] [Cited by in Crossref: 87] [Cited by in F6Publishing: 80] [Article Influence: 14.5] [Reference Citation Analysis]
553 Xu R, Yu X, Hao J, Wang L, Pan H, Han G, Xu J, Zhang Y, Yang S, Chen J, Ying J, Dai G, Li M, Begic D, Lu B, Shen L. Efficacy and safety of weekly nab-paclitaxel plus gemcitabine in Chinese patients with metastatic adenocarcinoma of the pancreas: a phase II study. BMC Cancer 2017;17:885. [PMID: 29273007 DOI: 10.1186/s12885-017-3887-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
554 Paniccia A, Merkow J, Edil BH, Zhu Y. Immunotherapy for pancreatic ductal adenocarcinoma: an overview of clinical trials. Chin J Cancer Res 2015;27:376-91. [PMID: 26361407 DOI: 10.3978/j.issn.1000-9604.2015.05.01] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
555 Jhaveri DT, Kim MS, Thompson ED, Huang L, Sharma R, Klein AP, Zheng L, Le DT, Laheru DA, Pandey A, Jaffee EM, Anders RA. Using Quantitative Seroproteomics to Identify Antibody Biomarkers in Pancreatic Cancer. Cancer Immunol Res 2016;4:225-33. [PMID: 26842750 DOI: 10.1158/2326-6066.CIR-15-0200-T] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 3.4] [Reference Citation Analysis]
556 Roeder F. Neoadjuvant radiotherapeutic strategies in pancreatic cancer. World J Gastrointest Oncol 2016; 8(2): 186-197 [PMID: 26909133 DOI: 10.4251/wjgo.v8.i2.186] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
557 Kutova OM, Guryev EL, Sokolova EA, Alzeibak R, Balalaeva IV. Targeted Delivery to Tumors: Multidirectional Strategies to Improve Treatment Efficiency. Cancers (Basel) 2019;11:E68. [PMID: 30634580 DOI: 10.3390/cancers11010068] [Cited by in Crossref: 42] [Cited by in F6Publishing: 32] [Article Influence: 21.0] [Reference Citation Analysis]
558 Wei H, Wang F, Wang Y, Li T, Xiu P, Zhong J, Sun X, Li J. Verteporfin suppresses cell survival, angiogenesis and vasculogenic mimicry of pancreatic ductal adenocarcinoma via disrupting the YAP-TEAD complex. Cancer Sci 2017;108:478-87. [PMID: 28002618 DOI: 10.1111/cas.13138] [Cited by in Crossref: 76] [Cited by in F6Publishing: 85] [Article Influence: 19.0] [Reference Citation Analysis]
559 Duan K, Jang GH, Grant RC, Wilson JM, Notta F, O'Kane GM, Knox JJ, Gallinger S, Fischer S. The value of GATA6 immunohistochemistry and computer-assisted diagnosis to predict clinical outcome in advanced pancreatic cancer. Sci Rep 2021;11:14951. [PMID: 34294813 DOI: 10.1038/s41598-021-94544-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
560 Wei AC, Ou FS, Shi Q, Carrero X, O'Reilly EM, Meyerhardt J, Wolff RA, Kindler HL, Evans DB, Deshpande V, Misdraji J, Tamm E, Sahani D, Moore M, Newman E, Merchant N, Berlin J, Goff LW, Pisters P, Posner MC. Perioperative Gemcitabine + Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial. Ann Surg Oncol 2019;26:4489-97. [PMID: 31418130 DOI: 10.1245/s10434-019-07685-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
561 Thota R, Maitra A, Berlin JD. Preclinical Rationale for the Phase III Trials in Metastatic Pancreatic Cancer: Is Wishful Thinking Clouding Successful Drug Development for Pancreatic Cancer? Pancreas 2017;46:143-50. [PMID: 28085753 DOI: 10.1097/MPA.0000000000000753] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
562 Lu Z, Weniger M, Jiang K, Boeck S, Zhang K, Bazhin A, Miao Y, Werner J, D'Haese JG. Therapies Targeting the Tumor Stroma and the VEGF/VEGFR Axis in Pancreatic Ductal Adenocarcinoma: a Systematic Review and Meta-Analysis. Target Oncol 2018;13:447-59. [PMID: 30062609 DOI: 10.1007/s11523-018-0578-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
563 Yuan C, Clish CB, Wu C, Mayers JR, Kraft P, Townsend MK, Zhang M, Tworoger SS, Bao Y, Qian ZR, Rubinson DA, Ng K, Giovannucci EL, Ogino S, Stampfer MJ, Gaziano JM, Ma J, Sesso HD, Anderson GL, Cochrane BB, Manson JE, Torrence ME, Kimmelman AC, Amundadottir LT, Vander Heiden MG, Fuchs CS, Wolpin BM. Circulating Metabolites and Survival Among Patients With Pancreatic Cancer. J Natl Cancer Inst 2016;108:djv409. [PMID: 26755275 DOI: 10.1093/jnci/djv409] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 4.4] [Reference Citation Analysis]
564 Lennon KM, Wakefield DL, Maddox AL, Brehove MS, Willner AN, Garcia-Mansfield K, Meechoovet B, Reiman R, Hutchins E, Miller MM, Goel A, Pirrotte P, Van Keuren-Jensen K, Jovanovic-Talisman T. Single molecule characterization of individual extracellular vesicles from pancreatic cancer. J Extracell Vesicles 2019;8:1685634. [PMID: 31741725 DOI: 10.1080/20013078.2019.1685634] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
565 Reni M, Balzano G, Zanon S, Passoni P, Nicoletti R, Arcidiacono PG, Pepe G, Doglioni C, Fugazza C, Ceraulo D, Falconi M, Gianni L. Phase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin (PAXG regimen) in patients with unresectable or borderline resectable pancreatic adenocarcinoma. Br J Cancer. 2016;115:290-296. [PMID: 27404453 DOI: 10.1038/bjc.2016.209] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
566 Walter K, Rodriguez-Aznar E, Ferreira MSV, Frappart PO, Dittrich T, Tiwary K, Meessen S, Lerma L, Daiss N, Schulte LA, Najafova Z, Arnold F, Usachov V, Azoitei N, Erkan M, Lechel A, Brümmendorf TH, Seufferlein T, Kleger A, Tabarés E, Günes C, Johnsen SA, Beier F, Sainz B Jr, Hermann PC. Telomerase and Pluripotency Factors Jointly Regulate Stemness in Pancreatic Cancer Stem Cells. Cancers (Basel) 2021;13:3145. [PMID: 34201898 DOI: 10.3390/cancers13133145] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
567 Zhang J, Zhang Y, Tang S, Liang H, Chen D, Jiang L, He Q, Huang Y, Wang X, Deng K, Jiang S, Zhou J, Xu J, Chen X, Liang W, He J. Evaluation bias in objective response rate and disease control rate between blinded independent central review and local assessment: a study-level pooled analysis of phase III randomized control trials in the past seven years. Ann Transl Med 2017;5:481. [PMID: 29299443 DOI: 10.21037/atm.2017.11.24] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
568 Jameson GS, Borazanci E, Babiker HM, Poplin E, Niewiarowska AA, Gordon MS, Barrett MT, Rosenthal A, Stoll-D'Astice A, Crowley J, Shemanski L, Korn RL, Ansaldo K, Lebron L, Ramanathan RK, Von Hoff DD. Response Rate Following Albumin-Bound Paclitaxel Plus Gemcitabine Plus Cisplatin Treatment Among Patients With Advanced Pancreatic Cancer: A Phase 1b/2 Pilot Clinical Trial. JAMA Oncol 2019. [PMID: 31580386 DOI: 10.1001/jamaoncol.2019.3394] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 9.5] [Reference Citation Analysis]
569 Nie RC, Zou XB, Yuan SQ, Chen YB, Chen S, Chen YM, Chen GM, Chen XJ, Luo TQ, Li SM, Duan JL, Wang Y, Li YF. Disease-free survival as a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: a meta-analysis of 20 randomized controlled trials. BMC Cancer 2020;20:421. [PMID: 32410591 DOI: 10.1186/s12885-020-06910-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
570 Bhattacharjee V, Zhou Y, Yen TJ. A synthetic lethal screen identifies the Vitamin D receptor as a novel gemcitabine sensitizer in pancreatic cancer cells. Cell Cycle 2014;13:3839-56. [PMID: 25558828 DOI: 10.4161/15384101.2014.967070] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
571 Abrams MJ, Rakszawski K, Vasekar M, Passero F, Abbas A, Jia Y, Saif MW. Recent advances in pancreatic cancer: updates and insights from the 2015 annual meeting of the American Society of Clinical Oncology. Therap Adv Gastroenterol 2016;9:141-51. [PMID: 26929776 DOI: 10.1177/1756283X15622601] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.4] [Reference Citation Analysis]
572 Lee JM, Lee HS, Hyun JJ, Choi HS, Kim ES, Keum B, Seo YS, Jeen YT, Chun HJ, Um SH, Kim CD. Prognostic value of inflammation-based markers in patients with pancreatic cancer administered gemcitabine and erlotinib. World J Gastrointest Oncol 2016; 8(7): 555-562 [PMID: 27559435 DOI: 10.4251/wjgo.v8.i7.555] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 28] [Article Influence: 5.2] [Reference Citation Analysis]
573 Vienot A, Chevalier H, Bolognini C, Gherga E, Klajer E, Meurisse A, Jary M, Kim S, d’Engremont C, Nguyen T, Calcagno F, Almotlak H, Fein F, Nasri M, Abdeljaoued S, Turpin A, Borg C, Vernerey D. FOLFOXIRI vs FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort study. World J Gastrointest Oncol 2020; 12(3): 332-346 [PMID: 32206183 DOI: 10.4251/wjgo.v12.i3.332] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
574 Kourie HR, Gharios J, Elkarak F, Antoun J, Ghosn M. Is metastatic pancreatic cancer an untargetable malignancy? World J Gastrointest Oncol 2016; 8(3): 297-304 [PMID: 26989465 DOI: 10.4251/wjgo.v8.i3.297] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
575 Kawaguchi K, Miyake K, Zhao M, Kiyuna T, Igarashi K, Miyake M, Higuchi T, Oshiro H, Bouvet M, Unno M, Hoffman RM. Tumor targeting Salmonella typhimurium A1-R in combination with gemcitabine (GEM) regresses partially GEM-resistant pancreatic cancer patient-derived orthotopic xenograft (PDOX) nude mouse models. Cell Cycle 2018;17:2019-26. [PMID: 29963961 DOI: 10.1080/15384101.2018.1480223] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
576 Costa RB, Benson A, Yaghmai V, Costa RLB, Zhou H, Behdad A, Kaplan JB, Sadim M, Talamantes S, Kalyan A. An Extremely Rapid Case of Pneumonitis with the Use of Nivolumab for Pancreatic Adenocarcinoma. Case Rep Oncol Med 2018;2018:6314392. [PMID: 29808141 DOI: 10.1155/2018/6314392] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
577 Yoshida K, Iwashita T, Uemura S, Maruta A, Okuno M, Ando N, Iwata K, Kawaguchi J, Mukai T, Shimizu M. A multicenter prospective phase II study of first-line modified FOLFIRINOX for unresectable advanced pancreatic cancer. Oncotarget. 2017;8:111346-111355. [PMID: 29340058 DOI: 10.18632/oncotarget.22795] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
578 Rosen MN, Goodwin RA, Vickers MM. BRCA mutated pancreatic cancer: A change is coming. World J Gastroenterol 2021; 27(17): 1943-1958 [PMID: 34007132 DOI: 10.3748/wjg.v27.i17.1943] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
579 Mita N, Iwashita T, Ichikawa H, Iwasa Y, Uemura S, Murase K, Shimizu M. Clinical Outcomes of Conversion Surgery after FOLFIRINOX in Patients with Unresectable Advanced Pancreatic Cancer: A Retrospective Cohort Study at a Single Center. J Clin Med 2021;10:2848. [PMID: 34199125 DOI: 10.3390/jcm10132848] [Reference Citation Analysis]
580 Resovi A, Bani MR, Porcu L, Anastasia A, Minoli L, Allavena P, Cappello P, Novelli F, Scarpa A, Morandi E, Falanga A, Torri V, Taraboletti G, Belotti D, Giavazzi R. Soluble stroma-related biomarkers of pancreatic cancer. EMBO Mol Med 2018;10:e8741. [PMID: 29941541 DOI: 10.15252/emmm.201708741] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 13.0] [Reference Citation Analysis]
581 Cherri S, Noventa S, Zaniboni A. Pancreatic adenocarcinoma: Beyond first line, where are we? World J Gastroenterol 2021; 27(17): 1847-1863 [PMID: 34007126 DOI: 10.3748/wjg.v27.i17.1847] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
582 Azar I, Virk G, Esfandiarifard S, Wazir A, Mehdi S. Treatment and survival rates of stage IV pancreatic cancer at VA hospitals: a nation-wide study. J Gastrointest Oncol 2019;10:703-11. [PMID: 31392051 DOI: 10.21037/jgo.2018.07.08] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
583 Narayanan JSS, Ray P, Hayashi T, Whisenant TC, Vicente D, Carson DA, Miller AM, Schoenberger SP, White RR. Irreversible Electroporation Combined with Checkpoint Blockade and TLR7 Stimulation Induces Antitumor Immunity in a Murine Pancreatic Cancer Model. Cancer Immunol Res 2019;7:1714-26. [PMID: 31409607 DOI: 10.1158/2326-6066.CIR-19-0101] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 12.0] [Reference Citation Analysis]
584 Giordano G, Pancione M, Olivieri N, Parcesepe P, Velocci M, Di Raimo T, Coppola L, Toffoli G, D’Andrea MR. Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions. World J Gastroenterol 2017; 23(32): 5875-5886 [PMID: 28932079 DOI: 10.3748/wjg.v23.i32.5875] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 35] [Article Influence: 10.3] [Reference Citation Analysis]
585 Isacoff WH, Reber HA, Bedford R, Hoos W, Rahib L, Upfill-Brown A, Donahue T, Hines OJ. Low-Dose Continuous 5-Fluorouracil Combined with Leucovorin, nab-Paclitaxel, Oxaliplatin, and Bevacizumab for Patients with Advanced Pancreatic Cancer: A Retrospective Analysis. Target Oncol 2018;13:461-8. [PMID: 29882102 DOI: 10.1007/s11523-018-0572-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
586 Wang JP, Wu CY, Yeh YC, Shyr YM, Wu YY, Kuo CY, Hung YP, Chen MH, Lee WP, Luo JC, Chao Y, Li CP. Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial. Oncotarget. 2015;6:18162-18173. [PMID: 26046796 DOI: 10.18632/oncotarget.4216] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 11.8] [Reference Citation Analysis]
587 Cong PF, Qu YC, Chen JP, Duan LL, Lin CJ, Zhu XL, Li-Ling J, Zhang MX. Growth inhibition and apoptosis induction by alternol in pancreatic carcinoma cells. World J Gastroenterol 2015; 21(15): 4526-4535 [PMID: 25914461 DOI: 10.3748/wjg.v21.i15.4526] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
588 Giampieri R, Piva F, Occhipinti G, Bittoni A, Righetti A, Pagliaretta S, Murrone A, Bianchi F, Amantini C, Giulietti M, Ricci G, Principato G, Santoni G, Berardi R, Cascinu S. Clinical impact of different exosomes' protein expression in pancreatic ductal carcinoma patients treated with standard first line palliative chemotherapy. PLoS One 2019;14:e0215990. [PMID: 31048929 DOI: 10.1371/journal.pone.0215990] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
589 Kim AY, Unger K, Wang H, Pishvaian MJ. Incorporating Yttrium-90 trans-arterial radioembolization (TARE) in the treatment of metastatic pancreatic adenocarcioma: a single center experience. BMC Cancer. 2016;16:492. [PMID: 27430276 DOI: 10.1186/s12885-016-2552-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 3.2] [Reference Citation Analysis]
590 Liberko M, Kolostova K, Szabo A, Gurlich R, Oliverius M, Soumarova R. Circulating Tumor Cells, Circulating Tumor DNA and Other Blood-based Prognostic Scores in Pancreatic Ductal Adenocarcinoma - Mini-Review. In Vivo 2021;35:31-9. [PMID: 33402447 DOI: 10.21873/invivo.12229] [Reference Citation Analysis]
591 Marsh Rde W, Talamonti MS, Katz MH, Herman JM. Pancreatic cancer and FOLFIRINOX: a new era and new questions. Cancer Med 2015;4:853-63. [PMID: 25693729 DOI: 10.1002/cam4.433] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 4.8] [Reference Citation Analysis]
592 Ahmad RS, Eubank TD, Lukomski S, Boone BA. Immune Cell Modulation of the Extracellular Matrix Contributes to the Pathogenesis of Pancreatic Cancer. Biomolecules 2021;11:901. [PMID: 34204306 DOI: 10.3390/biom11060901] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
593 Catenacci DV, Junttila MR, Karrison T, Bahary N, Horiba MN, Nattam SR, Marsh R, Wallace J, Kozloff M, Rajdev L, Cohen D, Wade J, Sleckman B, Lenz HJ, Stiff P, Kumar P, Xu P, Henderson L, Takebe N, Salgia R, Wang X, Stadler WM, de Sauvage FJ, Kindler HL. Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer. J Clin Oncol. 2015;33:4284-4292. [PMID: 26527777 DOI: 10.1200/jco.2015.62.8719] [Cited by in Crossref: 266] [Cited by in F6Publishing: 172] [Article Influence: 44.3] [Reference Citation Analysis]
594 Golan T, Khvalevsky EZ, Hubert A, Gabai RM, Hen N, Segal A, Domb A, Harari G, David EB, Raskin S, Goldes Y, Goldin E, Eliakim R, Lahav M, Kopleman Y, Dancour A, Shemi A, Galun E. RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients. Oncotarget. 2015;6:24560-24570. [PMID: 26009994 DOI: 10.18632/oncotarget.4183] [Cited by in Crossref: 139] [Cited by in F6Publishing: 134] [Article Influence: 27.8] [Reference Citation Analysis]
595 Kajihara M, Takakura K, Kanai T, Ito Z, Matsumoto Y, Shimodaira S, Okamoto M, Ohkusa T, Koido S. Advances in inducing adaptive immunity using cell-based cancer vaccines: Clinical applications in pancreatic cancer. World J Gastroenterol 2016; 22(18): 4446-4458 [PMID: 27182156 DOI: 10.3748/wjg.v22.i18.4446] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
596 Srinivasan M, Rajabi M, Mousa SA. Multifunctional Nanomaterials and Their Applications in Drug Delivery and Cancer Therapy. Nanomaterials (Basel) 2015;5:1690-703. [PMID: 28347089 DOI: 10.3390/nano5041690] [Cited by in Crossref: 69] [Cited by in F6Publishing: 47] [Article Influence: 11.5] [Reference Citation Analysis]
597 Jing W, Song N, Liu Y, Qu X, Hou K, Yang X, Che X. DNA methyltransferase 3a modulates chemosensitivity to gemcitabine and oxaliplatin via CHK1 and AKT in p53‑deficient pancreatic cancer cells. Mol Med Rep 2018;17:117-24. [PMID: 29115606 DOI: 10.3892/mmr.2017.7923] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
598 Ma WW, Xie H, Fetterly G, Pitzonka L, Whitworth A, LeVea C, Wilton J, Mantione K, Schihl S, Dy GK, Boland P, Iyer R, Tan W, Brady W, Straubinger RM, Adjei AA. A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients. Am J Clin Oncol 2019;42:184-9. [PMID: 30418178 DOI: 10.1097/COC.0000000000000492] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
599 Chiorean EG, Von Hoff DD, Tabernero J, El-Maraghi R, Ma WW, Reni M, Harris M, Whorf R, Liu H, Li JS. Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer. Br J Cancer. 2016;115:188-194. [PMID: 27351217 DOI: 10.1038/bjc.2016.185] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 8.2] [Reference Citation Analysis]
600 Chang PM, Cheng CT, Wu RC, Chung YH, Chiang KC, Yeh TS, Liu CY, Chen MH, Chen MH, Yeh CN. Nab-paclitaxel is effective against intrahepatic cholangiocarcinoma via disruption of desmoplastic stroma. Oncol Lett. 2018;16:566-572. [PMID: 29963132 DOI: 10.3892/ol.2018.8690] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
601 Tiriac H, Belleau P, Engle DD, Plenker D, Deschênes A, Somerville TDD, Froeling FEM, Burkhart RA, Denroche RE, Jang GH, Miyabayashi K, Young CM, Patel H, Ma M, LaComb JF, Palmaira RLD, Javed AA, Huynh JC, Johnson M, Arora K, Robine N, Shah M, Sanghvi R, Goetz AB, Lowder CY, Martello L, Driehuis E, LeComte N, Askan G, Iacobuzio-Donahue CA, Clevers H, Wood LD, Hruban RH, Thompson E, Aguirre AJ, Wolpin BM, Sasson A, Kim J, Wu M, Bucobo JC, Allen P, Sejpal DV, Nealon W, Sullivan JD, Winter JM, Gimotty PA, Grem JL, DiMaio DJ, Buscaglia JM, Grandgenett PM, Brody JR, Hollingsworth MA, O'Kane GM, Notta F, Kim E, Crawford JM, Devoe C, Ocean A, Wolfgang CL, Yu KH, Li E, Vakoc CR, Hubert B, Fischer SE, Wilson JM, Moffitt R, Knox J, Krasnitz A, Gallinger S, Tuveson DA. Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Cancer Discov 2018;8:1112-29. [PMID: 29853643 DOI: 10.1158/2159-8290.CD-18-0349] [Cited by in Crossref: 299] [Cited by in F6Publishing: 189] [Article Influence: 99.7] [Reference Citation Analysis]
602 Li D, Capanu M, Yu KH, Lowery MA, Kelsen DP, O'Reilly EM. Treatment, Outcomes, and Clinical Trial Participation in Elderly Patients With Metastatic Pancreas Adenocarcinoma. Clin Colorectal Cancer 2015;14:269-76.e1. [PMID: 26072442 DOI: 10.1016/j.clcc.2015.05.005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
603 Ulusakarya A, Karaboué A, Ciacio O, Pittau G, Haydar M, Biondani P, Gumus Y, Chebib A, Almohamad W, Innominato PF. A retrospective study of patient-tailored FOLFIRINOX as a first-line chemotherapy for patients with advanced biliary tract cancer. BMC Cancer 2020;20:515. [PMID: 32493242 DOI: 10.1186/s12885-020-07004-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
604 Hong JY, Cho HJ, Kim ST, Park YS, Shin SH, Han IW, Lee J, Heo JS, Park JO. Comprehensive molecular profiling to predict clinical outcomes in pancreatic cancer. Ther Adv Med Oncol 2021;13:17588359211038478. [PMID: 34471425 DOI: 10.1177/17588359211038478] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
605 Cho M, Wang-Gillam A, Myerson R, Gao F, Strasberg S, Picus J, Sorscher S, Fournier C, Nagaraj G, Parikh P, Suresh R, Linehan D, Tan BR. A phase II study of adjuvant gemcitabine plus docetaxel followed by concurrent chemoradation in resected pancreaticobiliary carcinoma. HPB (Oxford) 2015;17:587-93. [PMID: 25800066 DOI: 10.1111/hpb.12413] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
606 Hu W, Zhang Z. A phase II clinical study of using nab-paclitaxel as second-line chemotherapy for Chinese patients with advanced non-small cell lung cancer. Med Oncol. 2015;32:498. [PMID: 25944796 DOI: 10.1007/s12032-015-0498-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
607 Shukla SK, Purohit V, Mehla K, Gunda V, Chaika NV, Vernucci E, King RJ, Abrego J, Goode GD, Dasgupta A, Illies AL, Gebregiworgis T, Dai B, Augustine JJ, Murthy D, Attri KS, Mashadova O, Grandgenett PM, Powers R, Ly QP, Lazenby AJ, Grem JL, Yu F, Matés JM, Asara JM, Kim JW, Hankins JH, Weekes C, Hollingsworth MA, Serkova NJ, Sasson AR, Fleming JB, Oliveto JM, Lyssiotis CA, Cantley LC, Berim L, Singh PK. MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer. Cancer Cell 2017;32:71-87.e7. [PMID: 28697344 DOI: 10.1016/j.ccell.2017.06.004] [Cited by in Crossref: 163] [Cited by in F6Publishing: 172] [Article Influence: 40.8] [Reference Citation Analysis]
608 Guzmán EA, Xu Q, Pitts TP, Mitsuhashi KO, Baker C, Linley PA, Oestreicher J, Tendyke K, Winder PL, Suh EM, Wright AE. Leiodermatolide, a novel marine natural product, has potent cytotoxic and antimitotic activity against cancer cells, appears to affect microtubule dynamics, and exhibits antitumor activity. Int J Cancer 2016;139:2116-26. [PMID: 27376928 DOI: 10.1002/ijc.30253] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 4.4] [Reference Citation Analysis]
609 Lellouche L, Palmieri LJ, Dermine S, Brezault C, Chaussade S, Coriat R. Systemic therapy in metastatic pancreatic adenocarcinoma: current practice and perspectives. Ther Adv Med Oncol 2021;13:17588359211018539. [PMID: 34285720 DOI: 10.1177/17588359211018539] [Reference Citation Analysis]
610 Huerta M, Roselló S, Sabater L, Ferrer A, Tarazona N, Roda D, Gambardella V, Alfaro-Cervelló C, Garcés-Albir M, Cervantes A, Ibarrola-Villava M. Circulating Tumor DNA Detection by Digital-Droplet PCR in Pancreatic Ductal Adenocarcinoma: A Systematic Review. Cancers (Basel) 2021;13:994. [PMID: 33673558 DOI: 10.3390/cancers13050994] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
611 Kim J, Jo YH, Jang M, Nguyen NNY, Yun HR, Ko SH, Shin Y, Lee JS, Kang I, Ha J, Choi TG, Kim SS. PAC-5 Gene Expression Signature for Predicting Prognosis of Patients with Pancreatic Adenocarcinoma. Cancers (Basel) 2019;11:E1749. [PMID: 31703415 DOI: 10.3390/cancers11111749] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
612 Perri G, Prakash L, Qiao W, Varadhachary GR, Wolff R, Fogelman D, Overman M, Pant S, Javle M, Koay EJ, Herman J, Kim M, Ikoma N, Tzeng CW, Lee JE, Katz MHG. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. JAMA Surg. 2020;155:832-839. [PMID: 32667641 DOI: 10.1001/jamasurg.2020.2286] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 26.0] [Reference Citation Analysis]
613 Noonan AM, Farren MR, Geyer SM, Huang Y, Tahiri S, Ahn D, Mikhail S, Ciombor KK, Pant S, Aparo S. Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma. Mol Ther. 2016;24:1150-1158. [PMID: 27039845 DOI: 10.1038/mt.2016.66] [Cited by in Crossref: 64] [Cited by in F6Publishing: 64] [Article Influence: 12.8] [Reference Citation Analysis]
614 Hersh EM, Del Vecchio M, Brown MP, Kefford R, Loquai C, Testori A, Bhatia S, Gutzmer R, Conry R, Haydon A, Robert C, Ernst S, Homsi J, Grob JJ, Kendra K, Agarwala SS, Li M, Clawson A, Brachmann C, Karnoub M, Elias I, Renschler MF, Hauschild A. A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma. Ann Oncol 2015;26:2267-74. [PMID: 26410620 DOI: 10.1093/annonc/mdv324] [Cited by in Crossref: 43] [Cited by in F6Publishing: 34] [Article Influence: 7.2] [Reference Citation Analysis]
615 Soliman HH. nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors. Onco Targets Ther 2017;10:101-12. [PMID: 28053544 DOI: 10.2147/OTT.S122974] [Cited by in Crossref: 35] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
616 Takahara N, Isayama H, Nakai Y, Ishigami H, Satoi S, Mizuno S, Kogure H, Matsubara S, Yamamoto N, Yamaguchi H, Tada M, Kitayama J, Watanabe T, Koike K. Intravenous and intraperitoneal paclitaxel with S-1 for treatment of refractory pancreatic cancer with malignant ascites. Invest New Drugs 2016;34:636-42. [PMID: 27339809 DOI: 10.1007/s10637-016-0369-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.6] [Reference Citation Analysis]
617 Martín AM, Hidalgo M, Alvarez R, Arrazubi V, Martínez-Galán J, Salgado M, Macarulla T, Carrato A. From First Line to Sequential Treatment in the Management of Metastatic Pancreatic Cancer. J Cancer 2018;9:1978-88. [PMID: 29896283 DOI: 10.7150/jca.23716] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
618 Lees C, Weerasinghe S, Lamond N, Younis T, Ramjeesingh R. Palliative care consultation and aggressive care at end of life in unresectable pancreatic cancer. Curr Oncol 2019;26:28-36. [PMID: 30853795 DOI: 10.3747/co.26.4389] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
619 He C, Huang X, Zhang Y, Lin X, Li S. T-cell activation and immune memory enhancement induced by irreversible electroporation in pancreatic cancer. Clin Transl Med 2020;10:e39. [PMID: 32508058 DOI: 10.1002/ctm2.39] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
620 Sinn M, Denkert C, Striefler JK, Pelzer U, Stieler JM, Bahra M, Lohneis P, Dörken B, Oettle H, Riess H. α-Smooth muscle actin expression and desmoplastic stromal reaction in pancreatic cancer: results from the CONKO-001 study. Br J Cancer. 2014;111:1917-1923. [PMID: 25314063 DOI: 10.1038/bjc.2014.495] [Cited by in Crossref: 74] [Cited by in F6Publishing: 75] [Article Influence: 10.6] [Reference Citation Analysis]
621 Yin H, Chen N, Guo R, Wang H, Li W, Wang G, Cui J, Jin H, Hu JF. Antitumor potential of a synthetic interferon-alpha/PLGF-2 positive charge peptide hybrid molecule in pancreatic cancer cells. Sci Rep 2015;5:16975. [PMID: 26584517 DOI: 10.1038/srep16975] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
622 Kunzmann V, Ramanathan RK, Goldstein D, Liu H, Ferrara S, Lu B, Renschler MF, Von Hoff DD. Tumor Reduction in Primary and Metastatic Pancreatic Cancer Lesions With nab-Paclitaxel and Gemcitabine: An Exploratory Analysis From a Phase 3 Study. Pancreas. 2017;46:203-208. [PMID: 27841795 DOI: 10.1097/mpa.0000000000000742] [Cited by in Crossref: 18] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
623 Kakwere H, Ingham ES, Tumbale SK, Ferrara KW. Gemcitabine-retinoid prodrug loaded nanoparticles display in vitro antitumor efficacy towards drug-resilient human PANC-1 pancreatic cancer cells. Mater Sci Eng C Mater Biol Appl 2020;117:111251. [PMID: 32919625 DOI: 10.1016/j.msec.2020.111251] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
624 Peng X, Chen L, Jiao Y, Wang Y, Hao Z, Zhan X. Application of natural killer cells in pancreatic cancer. Oncol Lett 2021;22:647. [PMID: 34386069 DOI: 10.3892/ol.2021.12908] [Reference Citation Analysis]
625 Zhang L, Tao L, Guo L, Zhan J, Yuan C, Ma Z, Jiang B, Xiu D. G-CSF associates with neurogenesis and predicts prognosis and sensitivity to chemotherapy in pancreatic ductal adenocarcinoma. Cancer Manag Res 2018;10:2767-75. [PMID: 30147373 DOI: 10.2147/CMAR.S165226] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
626 Sielaff CM, Mousa SA. Status and future directions in the management of pancreatic cancer: potential impact of nanotechnology. J Cancer Res Clin Oncol 2018;144:1205-17. [PMID: 29721665 DOI: 10.1007/s00432-018-2651-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
627 Choueiry F, Torok M, Shakya R, Agrawal K, Deems A, Benner B, Hinton A, Shaffer J, Blaser BW, Noonan AM, Williams TM, Dillhoff M, Conwell DL, Hart PA, Cruz-Monserrate Z, Bai XF, Carson WE 3rd, Mace TA. CD200 promotes immunosuppression in the pancreatic tumor microenvironment. J Immunother Cancer 2020;8:e000189. [PMID: 32581043 DOI: 10.1136/jitc-2019-000189] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
628 Rogers JE, Mizrahi JD, Xiao L, Mohindroo C, Shroff RT, Wolff R, Varadhachary GR, Javle MM, Overman M, Fogelman DR, Raghav KPS, Pant S, McAllister F. Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma. Cancer Med 2020;9:5406-15. [PMID: 32519420 DOI: 10.1002/cam4.3229] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
629 Murakami T, Hiroshima Y, Matsuyama R, Homma Y, Hoffman RM, Endo I. Role of the tumor microenvironment in pancreatic cancer. Ann Gastroenterol Surg 2019;3:130-7. [PMID: 30923782 DOI: 10.1002/ags3.12225] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 20.0] [Reference Citation Analysis]
630 Pokataev I, Fedyanin M, Polyanskaya E, Popova A, Agafonova J, Menshikova S, Tryakin A, Rumyantsev A, Tjulandin S. Efficacy of platinum-based chemotherapy and prognosis of patients with pancreatic cancer with homologous recombination deficiency: comparative analysis of published clinical studies. ESMO Open 2020;5:e000578. [PMID: 33551067 DOI: 10.1136/esmoopen-2019-000578] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
631 Okusaka T, Miyakawa H, Fujii H, Nakamori S, Satoh T, Hamamoto Y, Ito T, Maguchi H, Matsumoto S, Ueno H, Ioka T, Boku N, Egawa S, Hatori T, Furuse J, Mizumoto K, Ohkawa S, Yamaguchi T, Yamao K, Funakoshi A, Chen JS, Cheng AL, Sato A, Ohashi Y, Tanaka M; GEST group. Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer. J Cancer Res Clin Oncol 2017;143:1053-9. [PMID: 28210843 DOI: 10.1007/s00432-017-2349-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
632 Ishii H, Yamashita N, Ueno M, Ohkawa S, Saito AM, Sekimoto M. A randomised controlled trial of gemcitabine hydrochloride plus S-1 combination therapy versus gemcitabine hydrochloride therapy alone in pancreatic cancer patients aged ≥75 years: a study protocol for an open-label randomised feasibility study. BMJ Open Gastroenterol 2018;5:e000187. [PMID: 29527313 DOI: 10.1136/bmjgast-2017-000187] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
633 Abendroth A, Noureddine R, Abramczyk M, Paul A, Gerken G, Schmid KW, Markus P, Schumacher B, Wiesweg M, Köhler J, Markus M, Mende B, Dechêne A, Schuler M, Kasper S. Long-term outcome of patients with advanced pancreatic cancer treated with sequential chemotherapies before the era of modern combination therapy protocols. J Cancer Res Clin Oncol 2019;145:445-55. [PMID: 30430229 DOI: 10.1007/s00432-018-2789-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
634 Arias-Pinilla GA, Dalgleish AG, Mudan S, Bagwan I, Walker AJ, Modjtahedi H. Development of novel monoclonal antibodies against CD109 overexpressed in human pancreatic cancer. Oncotarget 2018;9:19994-20007. [PMID: 29731998 DOI: 10.18632/oncotarget.25017] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
635 Chan E, Arlinghaus LR, Cardin DB, Goff L, Berlin JD, Parikh A, Abramson RG, Yankeelov TE, Hiebert S, Merchant N. Phase I trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer. Radiother Oncol. 2016;119:312-318. [PMID: 27106554 DOI: 10.1016/j.radonc.2016.04.013] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
636 Matsuda Y, Inoue Y, Hiratsuka M, Kawakatsu S, Arai T, Matsueda K, Saiura A, Takazawa Y. Encapsulating fibrosis following neoadjuvant chemotherapy is correlated with outcomes in patients with pancreatic cancer. PLoS One 2019;14:e0222155. [PMID: 31491010 DOI: 10.1371/journal.pone.0222155] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
637 Sun J, Russell CC, Scarlett CJ, McCluskey A. Small molecule inhibitors in pancreatic cancer. RSC Med Chem 2020;11:164-83. [PMID: 33479626 DOI: 10.1039/c9md00447e] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 7.0] [Reference Citation Analysis]
638 Catalano M, Aprile G, Ramello M, Conca R, Petrioli R, Roviello G. Association between Low-Grade Chemotherapy-Induced Peripheral Neuropathy (CINP) and Survival in Patients with Metastatic Adenocarcinoma of the Pancreas. J Clin Med 2021;10:1846. [PMID: 33922821 DOI: 10.3390/jcm10091846] [Reference Citation Analysis]
639 Ko AH, Murphy PB, Peyton JD, Shipley DL, Al-Hazzouri A, Rodriguez FA, Womack MS 4th, Xiong HQ, Waterhouse DM, Tempero MA, Guo S, Lane CM, Earwood C, DeBusk LM, Bendell JC. A Randomized, Double-Blinded, Phase II Trial of Gemcitabine and Nab-Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial. Oncologist 2017;22:1427-e129. [PMID: 28935773 DOI: 10.1634/theoncologist.2017-0066] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
640 Fujii H, Koda M, Sadaka S, Ohata K, Kato-Hayashi H, Iihara H, Kobayashi R, Ishihara T, Uemura S, Iwashita T, Hayashi H, Sugiyama T, Shimizu M, Suzuki A. Anorexia, pain and peripheral neuropathy are associated with a decrease in quality of life in patients with advanced pancreatic cancer receiving outpatient chemotherapy - a retrospective observational study. J Pharm Health Care Sci 2021;7:27. [PMID: 34334136 DOI: 10.1186/s40780-021-00210-1] [Reference Citation Analysis]
641 Askan G, Sahin IH, Chou JF, Yavas A, Capanu M, Iacobuzio-Donahue CA, Basturk O, O'Reilly EM. Pancreatic cancer stem cells may define tumor stroma characteristics and recurrence patterns in pancreatic ductal adenocarcinoma. BMC Cancer 2021;21:385. [PMID: 33836674 DOI: 10.1186/s12885-021-08123-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
642 Chiu JW, Wong H, Leung R, Pang R, Cheung TT, Fan ST, Poon R, Yau T. Advanced pancreatic cancer: flourishing novel approaches in the era of biological therapy. Oncologist 2014;19:937-50. [PMID: 25117068 DOI: 10.1634/theoncologist.2012-0131] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
643 Koong AJ, Toesca DAS, von Eyben R, Pollom EL, Chang DT. Reirradiation with stereotactic body radiation therapy after prior conventional fractionation radiation for locally recurrent pancreatic adenocarcinoma. Adv Radiat Oncol 2017;2:27-36. [PMID: 28740913 DOI: 10.1016/j.adro.2017.01.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
644 Zhong A, Cheng CS, Kai J, Lu R, Guo L. Clinical Significance of Glucose to Lymphocyte Ratio (GLR) as a Prognostic Marker for Patients With Pancreatic Cancer. Front Oncol 2020;10:520330. [PMID: 33117673 DOI: 10.3389/fonc.2020.520330] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
645 Woo W, Carey ET, Choi M. Spotlight on liposomal irinotecan for metastatic pancreatic cancer: patient selection and perspectives. Onco Targets Ther 2019;12:1455-63. [PMID: 30863113 DOI: 10.2147/OTT.S167590] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
646 Villanueva MT. Pancreatic cancer: standing on the shoulders of mice, making an iMPACT on pancreatic cancer. Nat Rev Clin Oncol 2013;10:665. [PMID: 24189469 DOI: 10.1038/nrclinonc.2013.209] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
647 Wang S, Zheng Y, Yang F, Zhu L, Zhu XQ, Wang ZF, Wu XL, Zhou CH, Yan JY, Hu BY, Kong B, Fu DL, Bruns C, Zhao Y, Qin LX, Dong QZ. The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives. Signal Transduct Target Ther 2021;6:249. [PMID: 34219130 DOI: 10.1038/s41392-021-00659-4] [Reference Citation Analysis]
648 Karakhanova S, Ryschich E, Mosl B, Harig S, Jäger D, Schmidt J, Hartwig W, Werner J, Bazhin AV. Prognostic and predictive value of immunological parameters for chemoradioimmunotherapy in patients with pancreatic adenocarcinoma. Br J Cancer 2015;112:1027-36. [PMID: 25742476 DOI: 10.1038/bjc.2015.72] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 4.8] [Reference Citation Analysis]
649 Valsecchi ME, Díaz-Cantón E, de la Vega M, Littman SJ. Recent treatment advances and novel therapies in pancreas cancer: a review. J Gastrointest Cancer 2014;45:190-201. [PMID: 24343588 DOI: 10.1007/s12029-013-9561-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
650 Wang X, Hu L, Yang X, Chen F, Xu H, Yu H, Song Z, Fei J, Zhong Z. Clinical prognostic value of circulating tumor cells in the treatment of pancreatic cancer with gemcitabine chemotherapy. Exp Ther Med 2021;22:1140. [PMID: 34504586 DOI: 10.3892/etm.2021.10574] [Reference Citation Analysis]
651 Cuneo KC, Morgan MA, Sahai V, Schipper MJ, Parsels LA, Parsels JD, Devasia T, Al-Hawaray M, Cho CS, Nathan H, Maybaum J, Zalupski MM, Lawrence TS. Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer. J Clin Oncol 2019;37:2643-50. [PMID: 31398082 DOI: 10.1200/JCO.19.00730] [Cited by in Crossref: 50] [Cited by in F6Publishing: 31] [Article Influence: 25.0] [Reference Citation Analysis]
652 Kordes M, Yu J, Malgerud O, Gustafsson Liljefors M, Löhr J-. Survival Benefits of Chemotherapy for Patients with Advanced Pancreatic Cancer in A Clinical Real-World Cohort. Cancers (Basel) 2019;11:E1326. [PMID: 31500236 DOI: 10.3390/cancers11091326] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
653 Yanagimoto H, Satoi S, Yamamoto T, Yamaki S, Hirooka S, Kotsuka M, Ryota H, Ishida M, Matsui Y, Sekimoto M. Benefits of Conversion Surgery after Multimodal Treatment for Unresectable Pancreatic Ductal Adenocarcinoma. Cancers (Basel) 2020;12:E1428. [PMID: 32486418 DOI: 10.3390/cancers12061428] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
654 Primavesi F, Stättner S, Schlick K, Kiesslich T, Mayr C, Klieser E, Urbas R, Neureiter D. Pancreatic cancer in young adults: changes, challenges, and solutions. Onco Targets Ther 2019;12:3387-400. [PMID: 31118690 DOI: 10.2147/OTT.S176700] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
655 Torgeson A, Tao R, Garrido-Laguna I, Willen B, Dursteler A, Lloyd S. Large database utilization in health outcomes research in pancreatic cancer: an update. J Gastrointest Oncol 2018;9:996-1004. [PMID: 30603118 DOI: 10.21037/jgo.2018.05.15] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
656 Jordan EJ, Lowery MA, Basturk O, Allen PJ, Yu KH, Tabar V, Beal K, Reidy DL, Yamada Y, Janjigian Y, Abou-Alfa GK, O'Reilly EM. Brain Metastases in Pancreatic Ductal Adenocarcinoma: Assessment of Molecular Genotype-Phenotype Features-An Entity With an Increasing Incidence? Clin Colorectal Cancer 2018;17:e315-21. [PMID: 29496399 DOI: 10.1016/j.clcc.2018.01.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
657 Mita N, Iwashita T, Uemura S, Yoshida K, Iwasa Y, Ando N, Iwata K, Okuno M, Mukai T, Shimizu M. Second-Line Gemcitabine Plus Nab-Paclitaxel for Patients with Unresectable Advanced Pancreatic Cancer after First-Line FOLFIRINOX Failure. J Clin Med 2019;8:E761. [PMID: 31146420 DOI: 10.3390/jcm8060761] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
658 Okusaka T, Furuse J. Recent advances in chemotherapy for pancreatic cancer: evidence from Japan and recommendations in guidelines. J Gastroenterol. 2020;55:369-382. [PMID: 31997007 DOI: 10.1007/s00535-020-01666-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
659 Kaliberov SA, Kaliberova LN, Buchsbaum DJ, Curiel DT. Experimental virotherapy of chemoresistant pancreatic carcinoma using infectivity-enhanced fiber-mosaic oncolytic adenovirus. Cancer Gene Ther 2014;21:264-74. [PMID: 24903014 DOI: 10.1038/cgt.2014.26] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
660 Dhupal M, Chowdhury D. Phytochemical-Based Nanomedicine for Advanced Cancer Theranostics: Perspectives on Clinical Trials to Clinical Use. Int J Nanomedicine 2020;15:9125-57. [PMID: 33244231 DOI: 10.2147/IJN.S259628] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
661 Xiao X, Chen W, Wei ZW, Chu WW, Lu XF, Li B, Chen H, Meng SJ, Hao TF, Wei JT, He YL, Zhang CH. The Anti-Tumor Effect of Nab-Paclitaxel Proven by Patient-Derived Organoids. Onco Targets Ther 2020;13:6017-25. [PMID: 32612367 DOI: 10.2147/OTT.S237431] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
662 Zhang J, Khanna S, Jiang Q, Alewine C, Miettinen M, Pastan I, Hassan R. Efficacy of Anti-mesothelin Immunotoxin RG7787 plus Nab-Paclitaxel against Mesothelioma Patient-Deri